

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 August 2002 (22.08.2002)

PCT

(10) International Publication Number  
WO 02/064598 A1

(51) International Patent Classification<sup>7</sup>: C07D 495/04,  
A61K 31/505, A61P 29/00, 35/00

Research & Development, 2800 Plymouth Road, Ann Arbor, MI 48105 (US).

(21) International Application Number: PCT/IB02/00204

(74) Agents: LUMB, J., Trevor et al.; Pfizer Inc., 201 Tabor Road, Morris Plains, NJ 07950 (US).

(22) International Filing Date: 18 January 2002 (18.01.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/268,756 14 February 2001 (14.02.2001) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except US*):  
WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): HARTER, William, Glen [US/US]; Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). LI, Jie, Jack [CN/US]; Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). ORTWINE, Daniel, Fred [US/US]; Pfizer Global Research & Development, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). SHULER, Kevin, Ray [US/US]; Pfizer Global Research & Development, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). YUE, Wen-Song [US/US]; Pfizer Global

**Published:**

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: THIENO<sup>2</sup>,3-D PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS

(57) Abstract: Selective MMP-13 inhibitors are fused pyrimidinones of the formula or a pharmaceutically acceptable salt thereof, wherein: W, together with the carbon atoms to which it is attached, form a 5-membered ring diradical Y is O, S, SO, SO<sub>2</sub>, NR<sup>5</sup>, or CH<sub>2</sub>, ?A is -C- or -S-; B is O or NR<sup>5</sup>; or A and B are taken together to form -C≡C-; R<sup>1</sup>, R<sup>4</sup>, and R<sup>5</sup> are hydrogen, alkyl, alkenyl, alkynyl, (CH<sub>2</sub>)<sub>n</sub> aryl, (CH<sub>2</sub>)<sub>n</sub> cycloalkyl, C<sub>1</sub> C<sub>6</sub> alkanoyl, or (CH<sub>2</sub>)<sub>n</sub> heteroaryl; R<sup>2</sup> and R<sup>3</sup> are hydrogen, alkyl, alkenyl, alkynyl CN, NO<sub>2</sub>, NR<sup>4</sup>R<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub> cycloalkyl, (CH<sub>2</sub>)<sub>n</sub> aryl, or (CH<sub>2</sub>)<sub>n</sub> heteroaryl; R<sup>2</sup> may further be halo; n is an integer of from 0 to 5; and R<sup>4</sup> and R<sup>5</sup> when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing O, S, or N, and substituted or unsubstituted; with the proviso that R<sup>1</sup> and R<sup>3</sup> are not both selected from hydrogen and C<sub>1</sub>-C<sub>6</sub> alkyl.

USSN: 10/634,713; Filed: 08-05-2003;  
Art Unit: 1614; Docket: PC25298A;  
Inventor: Picard

WO 02/064598 A1

-1-

THIENO`2,3-DIPYRIMIDINDIONE DERIVATIVES AS MATRIX  
METALLOPROTEINASE INHIBITORS

FIELD OF THE INVENTION

5 This invention relates to fused bicyclic pyrimidinones that inhibit matrix metalloproteinase enzymes and thus are useful for treating diseases resulting from tissue breakdown, such as heart disease, multiple sclerosis, arthritis, atherosclerosis, and osteoporosis.

BACKGROUND OF THE INVENTION

10 Matrix metalloproteinases (sometimes referred to as MMPs) are naturally-occurring enzymes found in most mammals. Over-expression and activation of MMPs or an imbalance between MMPs and inhibitors of MMPs, have been suggested as factors in the pathogenesis of diseases characterized by the breakdown of extracellular matrix or connective tissues.

15 Stromelysin-1 and gelatinase A are members of the matrix metalloproteinases (MMP) family. Other members include fibroblast collagenase (MMP-1), neutrophil collagenase (MMP-8), gelatinase B (92 kDa gelatinase) (MMP-9), stromelysin-2 (MMP-10), stromelysin-3 (MMP-11), matrilysin (MMP-7), collagenase 3 (MMP-13), TNF-alpha converting enzyme (TACE), and other newly discovered membrane-associated matrix metalloproteinases (Sato H, Takino T., Okada Y., Cao J., Shinagawa A., Yamamoto E., and Seiki M., *Nature*, 20 1994;370:61-65). These enzymes have been implicated with a number of diseases which result from breakdown of connective tissue, including such diseases as rheumatoid arthritis, osteoarthritis, osteoporosis, periodontitis, multiple sclerosis, gingivitis, corneal epidermal and gastric ulceration, atherosclerosis, neointimal proliferation which leads to restenosis and ischemic heart failure, stroke, renal disease, macular degeneration, and tumor metastasis. A method for preventing and 25 treating these and other diseases is now recognized to be by inhibiting metalloproteinase enzymes, thereby curtailing and/or eliminating the breakdown of connective tissues that results in the disease states.

-2-

The catalytic zinc in matrix metalloproteinases is typically the focal point for inhibitor design. The modification of substrates by introducing zinc chelating groups has generated potent inhibitors such as peptide hydroxamates and thiol-containing peptides. Peptide hydroxamates and the natural endogenous inhibitors of MMPs (TIMPs) have been used successfully to treat animal models of cancer and inflammation. MMP inhibitors have also been used to prevent and treat congestive heart failure and other cardiovascular diseases, United States Patent No. 5,948,780.

A major limitation on the use of currently known MMP inhibitors is their lack of specificity for any particular enzyme. Recent data has established that specific MMP enzymes are associated with some diseases, with no effect on others. The MMPs are generally categorized based on their substrate specificity, and indeed the collagenase subfamily of MMP-1, MMP-8, and MMP-13 selectively cleave native interstitial collagens, and thus are associated only with diseases linked to such interstitial collagen tissue. This is evidenced by the recent discovery that MMP-13 alone is overexpressed in breast carcinoma, while MMP-1 alone is overexpressed in papillary carcinoma (see Chen et al., *J. Am. Chem. Soc.*, 2000;122:9648-9654).


There appears to be few selective inhibitors of MMP-13 reported. A compound named WAY-170523 has been reported by Chen et al., *supra.*, 2000, and a few other compounds are reported in PCT International patent application publication Number WO 01/63244 A1, as allegedly selective inhibitors of MMP-13. Further, United States Patent Number 6,088,243 discloses inhibitors of MMP-13. However, no selective or nonselective inhibitor of MMP-13 has been approved and marketed for the treatment of any disease in any mammal. Accordingly, the need continues to find new low molecular weight compounds that are potent and selective MMP inhibitors, and that have an acceptable therapeutic index of toxicity/potency to make them amenable for use clinically in the prevention and treatment of the associated disease states. An object of this invention is to provide a group of selective MMP-13 inhibitor compounds characterized as being fused bicyclic pyrimidinones.

-3-

## SUMMARY OF THE INVENTION

This invention provides bicyclic pyrimidinones that are inhibitors of matrix metalloproteinase enzymes, and especially MMP-13. The invention is more particularly directed to compounds defined by Formula I

5




I

or a pharmaceutically acceptable salt thereof;

wherein:

W, together with the carbon atoms to which it is attached, form a 5-membered ring diradical



10

A is  $\begin{array}{c} \text{O} \\ \parallel \\ -\text{C}- \end{array}$  or  $\begin{array}{c} (\text{O})_{0-2} \\ \parallel \\ -\text{S}- \end{array}$ ;

B is O or NR<sup>5</sup>; or

15

A and B are taken together to form  $-\text{C}\equiv\text{C}-$ ;

X is O, S, SO, SO<sub>2</sub>, NR<sup>5</sup>, or CH<sub>2</sub>;



-4-

each Y independently is O or S;

$R^1$ ,  $R^4$ , and  $R^5$  independently are hydrogen,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $(CH_2)_n$  cycloalkyl,  $(CH_2)_n$  heterocyclic,  $C_1$ - $C_6$  alkanoyl,  $(CH_2)_n$  aryl, or  $(CH_2)_n$  heteroaryl;

5  $R^2$  and  $R^3$  independently are hydrogen,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl, CN,  $NO_2$ ,  $NR^4R^5$ ,  $(CH_2)_n$  cycloalkyl,  $(CH_2)_n$  aryl, or  $(CH_2)_n$  heteroaryl;  $CONR^4R^5$ , or  $COR^6$ ;


$R^2$  may further be halo;

n is an integer of from 0 to 5;

10  $R^4$  and  $R^5$  when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing O, S, or N, and substituted or unsubstituted;

with the proviso that  $R^1$  and  $R^3$  are not both selected from: hydrogen and  $C_1$ - $C_6$  alkyl.

15 Preferred compounds are thieno[2,3-*d*]pyrimidinones of Formula II



II


wherein A, B,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ , and Y are as defined above.

More preferred are compounds of Formula II wherein -A-B- is  $-C\equiv C-$ ,

20  $\begin{array}{c} O \\ || \\ -C-O- \end{array}$ , or  $\begin{array}{c} O \\ || \\ -C-N(R^5)- \end{array}$ , wherein  $R^5$  is as defined above for Formula I.

Especially preferred invention compounds have Formula III

-5-




III

wherein A, B, R<sup>1</sup>, R<sup>2</sup>, and R<sup>4</sup> are as defined above, and R<sup>3</sup> is (CH<sub>2</sub>)<sub>n</sub> aryl, (CH<sub>2</sub>)<sub>n</sub> cycloalkyl, or (CH<sub>2</sub>)<sub>n</sub> heteroaryl.

Still more preferred are compounds of Formula III, wherein R<sup>3</sup> is (CH<sub>2</sub>)<sub>n</sub> aryl, (CH<sub>2</sub>)<sub>n</sub> cycloalkyl, or (CH<sub>2</sub>)<sub>n</sub> heteroaryl, and -A-B- is -C≡C-.


Another preferred group of pyrimidinone MMP-inhibitors have Formula IV



IV

wherein A, B, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> are as defined above.

Still another preferred group of pyrimidinone compounds provided by this invention have Formula V




V


wherein A, B, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, and R<sup>5</sup> are as defined above.

Also preferred are compounds of Formula VI-IX:


-6-




VI



VII




VIII



IX

5 wherein A, B, X, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> are as defined above.

Another embodiment of the invention is a compound of Formula X



X

or a pharmaceutically acceptable salt thereof, wherein R<sup>1</sup>-R<sup>4</sup>, A, B, and X are as defined above.

-7-

In a preferred embodiment,  $R^4$  in the above formulas is hydrogen, methyl, or trifluoromethyl. More preferred,  $R^4$  is methyl or trifluoromethyl.

In a preferred embodiment,  $R^1$  in the above formulas is  $(CH_2)_n$  cycloalkyl,  $(CH_2)_n$  aryl,  $(CH_2)_n$  heterocyclic, or  $(CH_2)_n$  heteroaryl, wherein  $n$  is as defined above for Formula I.

In another preferred embodiment,  $R^2$  in the above Formulas is hydrogen or fluoro.

In another preferred embodiment,  $n$  in the above Formulas is 1.

Another preferred group of compounds are those of the above formulas

where A is  $\begin{array}{c} O \\ || \\ -C- \end{array}$  and B is  $-O-$ .

Still more preferred in the above Formulas is a combination of any two or more preferred embodiments selected from:

A-B is  $\begin{array}{cc} O & O \\ || & || \end{array}$   $-C\equiv C-$ ,  $-C-O-$ , or  $-C-N(R^5)-$ , wherein  $R^5$  is as defined above for Formula I;  $R^1$  and  $R^3$  independently are  $(CH_2)_n$  cycloalkyl,  $(CH_2)_n$  aryl,  $(CH_2)_n$

heterocyclic, or  $(CH_2)_n$  heteroaryl, wherein  $n$  is as defined above for


Formula I;

$R^2$  is hydrogen or fluoro;

$R^4$  is methyl or trifluoromethyl; and

$n$  is 1.

Another embodiment of the invention is a compound of Formula XI




XI

or a pharmaceutically acceptable salt thereof,  
wherein:

W, together with the carbon atoms to which it is attached, form a 5-membered ring diradical

-8-



each Y independently is O or S;

X is S, O, or NR<sup>5</sup>;

R<sup>1</sup>, R<sup>4</sup>, and R<sup>5</sup> independently are hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl,

5 C<sub>2</sub>-C<sub>6</sub> alkynyl, (CH<sub>2</sub>)<sub>n</sub> cycloalkyl, (CH<sub>2</sub>)<sub>n</sub> heterocyclic, C<sub>1</sub>-C<sub>6</sub> alkanoyl, (CH<sub>2</sub>)<sub>n</sub> aryl, or (CH<sub>2</sub>)<sub>n</sub> heteroaryl;

R<sup>2</sup> is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, CN, NO<sub>2</sub>, NR<sup>4</sup>R<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub> cycloalkyl, (CH<sub>2</sub>)<sub>n</sub> aryl, or (CH<sub>2</sub>)<sub>n</sub> heteroaryl;

10 R<sup>3</sup> is hydrogen, halo, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, CN, NO<sub>2</sub>, NR<sup>4</sup>R<sup>5</sup>, (CH<sub>2</sub>)<sub>q</sub> cycloalkyl, (CH<sub>2</sub>)<sub>q</sub> aryl, or (CH<sub>2</sub>)<sub>q</sub> heteroaryl;

n is 0, 1, or 2;

q is 2, 3, or 4; and

R<sup>4</sup> and R<sup>5</sup> when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing O, S, or N, and substituted or unsubstituted;

15 with the proviso that R<sup>1</sup> and R<sup>3</sup> are not both selected from: hydrogen and C<sub>1</sub>-C<sub>6</sub> alkyl.


Preferred is the compound of Formula XI, or a pharmaceutically acceptable salt thereof, wherein Y is O and X is S.

20 Also preferred is the compound of Formula XI, or a pharmaceutically acceptable salt thereof, wherein Y is O and X is O.


Also preferred is the compound of Formula XI, or a pharmaceutically acceptable salt thereof, wherein Y is O and X is NR<sup>5</sup>, wherein R<sup>5</sup> is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, (CH<sub>2</sub>)<sub>n</sub> cycloalkyl, (CH<sub>2</sub>)<sub>n</sub> heterocyclic, C<sub>1</sub>-C<sub>6</sub> alkanoyl, (CH<sub>2</sub>)<sub>n</sub> aryl, or (CH<sub>2</sub>)<sub>n</sub> heteroaryl.

25 The compounds of this invention typically will be named according to the following numbering system

-9-



The compound of the formula



will be named 3-ethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid.

Especially preferred compounds provided by this invention are:

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester; and

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester.

More preferred is a compound selected from:

3-(4-Pyridyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(4-Pyridyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (4-pyridyl) ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (4-pyridyl) ester;

3-(4-Pyridyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (4-pyridyl) ester;

3-(4-Pyridyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (4-pyridyl) ester;

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid piperoyl ester;



-10-

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid piperoyl ester;

3-Piperoyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid piperoyl ester;

5 3-Piperoyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid piperoyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-furo[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-1*H*-pyrrolo[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-Benzyl-1,7-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-1*H*-pyrrolo[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-Benzyl-1,7-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-1*H*-pyrrolo[2,3-*d*]pyrimidine-6-carboxylic acid benzofuran-6-ylmethyl ester;

15 3-Benzyl-1-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-1*H*-pyrrolo[2,3-*d*]pyrimidine-6-carboxylic acid benzofuran-6-ylmethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-furo[2,3-*d*]pyrimidine-6-carboxylic acid benzofuran-6-ylmethyl ester;

20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzofuran-6-ylmethyl ester;

3-Benzyl-1,7-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-1*H*-pyrrolo[2,3-*d*]pyrimidine-6-carboxylic acid benzothiophene-6-ylmethyl ester;

3-Benzyl-1-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-1*H*-pyrrolo[2,3-*d*]pyrimidine-6-carboxylic acid benzothiophene-6-ylmethyl ester;

25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-furo[2,3-*d*]pyrimidine-6-carboxylic acid benzothiophene-6-ylmethyl ester; and

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzothiophene-6-ylmethyl ester.

Still further preferred compounds are the following:

30 3-(3-Methoxy-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(4-Chloro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

-11-

- 3-(4-Cyano-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 3-(4-Fluoro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 5 3-(3-Chloro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 1-Methyl-3-(2-methyl-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 1-Methyl-3-(4-methyl-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 10 3-(4-Carboxy-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 1-Methyl-2,4-dioxo-3-(3-trifluoromethyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 15 3-Biphenyl-4-ylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 1-Methyl-2,4-dioxo-3-(2-trifluoromethyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 3-(3-Cyano-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 20 3-(2-Cyano-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 1-Methyl-2,4-dioxo-3-(4-trifluoromethyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 25 3-[2-Hydroxy-3-(naphthalen-1-yloxy)-propyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 3-(3-Chloro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 1-Methyl-3-naphthalen-1-ylmethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 30 3-(6-Chloro-benzo[1,3]dioxol-5-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

-12-

1-Methyl-2,4-dioxo-3-(4-oxo-4-thiophen-2-yl-butyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-pyridin-4-ylmethyl-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

5 1-Methyl-2,4-dioxo-3-(4-*m*-tolylloxy-butyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(3,5-Dimethyl-isoxazol-4-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

10 3-Dioxo-1,3-dihydro-isoindol-2-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-Dihydro-benzo[1,4]dioxin-2-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-pyridin-2-ylmethyl-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

15 3-[2-(2,5-Dimethoxy-phenyl)-2-oxo-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-Benzoyloxymethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

20 1-Methyl-2,4-dioxo-3-(4-*m*-tolylloxy-butyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-(2-phenylmethanesulfonyl-ethyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(4-Amino-6-phenylamino-[1,3,5]triazin-2-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

25 3-[4-(4-Fluoro-phenyl)-4-oxo-butyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-[4-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-butyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

30 1-Methyl-2,4-dioxo-3-(4-phenoxy-butyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-(4-oxo-4-phenyl-butyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

-13-

1-Methyl-2,4-dioxo-3-(2-phenoxy-ethyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-{3-[4-(3-Chloro-phenyl)-piperazin-1-yl]-propyl}-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

5 3-[1-Bromo-2-(1H-indol-3-yl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(2-Benzenesulfinyl-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

10 3-[3-(3-Fluoro-phenylcarbamoyl)-propyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-[2-(2-trifluoromethyl-phenylcarbamoyl)-ethyl]-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-[2-(4-Methoxy-phenyl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

15 3-[2-(4-Chloro-2-nitro-phenoxy)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-3-(5-nitro-furan-2-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

20 3-(1-Benzyl-1*H*-imidazol-2-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-[3-(Benzyl-methyl-amino)-propyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(Bis-trifluoromethyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

25 3-[3-(2-Bromo-4-methyl-phenoxy)-propyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-Benzenesulfonylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

30 3-[2-(4-Chloro-benzenesulfonyl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-Benzo[1,3]dioxol-5-ylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

-14-

3-(3-Iodo-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-(4-trifluoromethoxy-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

5 3-(4-Acetoxy-butyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(4-Methanesulfonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

10 1-Methyl-2,4-dioxo-3-(4-[1,2,3]thiadiazol-4-yl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(5-Methoxycarbonyl-furan-2-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(2-Carboxy-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

15 1-Methyl-2,4-dioxo-3-(3-pyrrol-1-yl-propyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(3-Carboxy-propyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

20 3-(2-Cyano-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(3-Ethoxycarbonyl-furan-2-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(3-Amino-propyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

25 3-(3-Cyano-propyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(2-Hydroxy-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

30 3-(2-Carboxy-hexyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-(2,2,2-trifluoro-ethyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

-15-

1-Methyl-2,4-dioxo-3-(2,2,2-trifluoro-ethyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxyl carboxylic acid benzyl ester;

Iodomethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

5 3-(2-Fluoro-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

Methyl-2,4-dioxo-3-(tetrahydro-furan-2-ylmethyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

10 3-[1-(4-Carboxy-phenyl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(Hex-5-enyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(2-Ethyl-butyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

15 1-Methyl-2,4-dioxo-3-(2,2,2-trifluoro-ethyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxyl pyrimidine acid benzyl ester;

3-(Diethoxy-phosphorylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

20 3-But-2-ynyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

Bromo-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid;

1-Methyl-2,4-dioxo-3-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

25 1-Methyl-2,4-dioxo-3-propyl-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(2-Acetoxy-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid;

30 3-Butyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-Isobutyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;



-16-

3-Ethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(3-Bromo-propyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

5 3-Cyclohexylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(2-Ethylamino-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

10 3-Cyclobutylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-((R)-3-Hydroxy-2-methyl-propyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(4-Hydroxy-butyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

15 3-(2-Ethoxy-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-Isobutyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

20 3-(2-Chloro-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-3-(3-methyl-but-2-enyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-Allyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

25 3-(2,2-Dimethoxy-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-3-oxiranylmethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

30 1-Methyl-2,4-dioxo-3-propyl-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-Benzo[1,2,5]oxadiazol-5-ylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

-17-

3-(3-Hydroxy-2,2-dimethyl-propyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(2-Carboxy-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

5 3-Propyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-(4-sulfamoyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

10 1-Methyl-3-(4-methylsulfamoyl-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(4-Dimethylsulfamoyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(4-Methanesulfonylamino-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

15 3-[4-(Methanesulfonyl-methyl-amino)-benzyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(4-Acetylamino-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

20 3-[4-(Acetyl-methyl-amino)-benzyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(4-Dimethylamino-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-3-(4-methylamino-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

25 3-(4-Carbamoyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(4-Dimethylcarbamoyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

30 3-(4-Carboxy-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(4-Methoxycarbonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

-18-

3-{4-[Bis-(2-hydroxy-ethyl)-amino]-benzyl}-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(3,5-Dimethoxy-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

5 3-(4-*tert*-Butyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-(4-trifluoromethoxy-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

10 3-(4-Methanesulfonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

2,4-Dioxo-3-[1,3,4]thiadiazol-2-ylmethyl-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-Isloxazol-3-ylmethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

15 3-Oxazol-2-ylmethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

2,4-Dioxo-3-thiazol-2-ylmethyl-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

20 3-(1*H*-Imidazol-2-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(1-Methyl-1*H*-imidazol-2-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(1-Methyl-1*H*-pyrrol-2-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

25 2,4-Dioxo-3-(1*H*-pyrrol-2-ylmethyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

2,4-Dioxo-3-(1*H*-pyrrol-2-ylmethyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

30 2,4-Dioxo-3-thiophen-2-ylmethyl-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

2,4-Dioxo-3-[1,2,3,4]tetrazin-5-ylmethyl-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

-19-

- 2,4-Dioxo-3-[1,2,4,5]tetrazin-3-ylmethyl-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 3-(1-Methyl-piperidin-4-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 5 2,4-Dioxo-3-pyrimidin-2-ylmethyl-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 2,4-Dioxo-3-(2*H*-pyran-2-ylmethyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 3-(1*H*-Imidazo[4,5-*b*]pyridin-2-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 10 3-(1*H*-Benzoimidazol-2-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 3-Benzo[*b*]thiophen-2-ylmethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 15 2,4-Dioxo-3-quinolin-2-ylmethyl-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 3-(2*H*-Chromen-2-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 3-(1*H*-Benzoimidazol-2-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 20 3-(1-Methyl-1*H*-benzoimidazol-2-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 3-(1*H*-Indol-2-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid furan-3-ylmethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1-ethyl-propyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1,1-dioxo-tetrahydro-1*H*-thiophen-3-yl ester;
- 30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-hydroxy-benzyl ester;

-20-

- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1-oxy-pyridin-4-ylmethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid but-3-enyl ester;
- 5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-diethylamino-propyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1-cyano-1-phenyl-methyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-amino-benzyl ester;
- 10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1-oxy-pyridin-3-ylmethyl ester;
- 15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-ethoxy-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid thiophen-2-ylmethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2,6-dichloro-benzyl ester;
- 20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid dimethylamino-methyl-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2,2-diphenyl-ethyl ester;
- 25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-pyridin-2-yl-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-ethanesulfonyl-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid diethylamino-methyl-ethyl ester;
- 30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid dimethylamino-methyl-propyl ester;

-21-

- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-(2-chloro-phenoxy)-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-(2-ethoxy-ethoxy)-ethyl ester;
- 5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-hydroxy-benzyl ester;
- 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-morpholin-4-yl-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-ethyl ester;
- 10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1-methyl-piperidin-4-yl ester;
- 15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-(4-hydroxy-phenyl)-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-cyano-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid hexyl ester;
- 20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-fluoro-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-hydroxy-6-methyl-pyridin-2-ylmethyl ester;
- 25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-benzyloxy-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-methoxy-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-methoxy-benzyl ester;
- 30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2,2,2-trifluoro-ethyl ester;



-22-

- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2,2,2-trichloro-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid pyridin-3-ylmethyl ester;
- 5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid pyridin-4-;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-pyridin-3-yl-propyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid;
- 10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-phenoxy-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1,3-dimethyl-butyl ester;
- 15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-methyl-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1-phenyl-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1-benzyl-piperidin-4-yl ester;
- 20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid propyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid methyl ester;
- 25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-trifluoromethyl-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-*p*-tolyl-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-trifluoromethyl-benzyl ester;
- 30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid tetrahydro-furan-2-ylmethyl ester;

-23-

- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid octahydro-inden-5-yl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-amino-benzyl ester;
- 5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-aziridin-1-yl-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methyl-but-2-enyl ester;
- 10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid trifluoro-trifluoromethyl-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid phenethyl ester;
- 15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-methoxy-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid biphenyl-4-ylmethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-chloro-6-fluoro-benzyl ester;
- 20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid tetrahydro-pyran-4-yl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-ethyl-oxetan-3-ylmethyl ester;
- 25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid butyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-(2-hydroxy-phenyl)-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-(4-fluoro-phenyl)-ethyl ester;
- 30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid cyclopropylmethyl ester;

-24-

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-ethyl-benzyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (S)-1-phenyl-ethyl ester;

5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2,6-difluoro-benzyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid cyclobutyl methyl ester;

10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-pyridin-4-yl-ethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-hydroxy-cyclopentyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1-pentafluorophenyl-ethyl ester;

15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-benzyloxycarbonylamino-ethyl ester; and

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid ethyl ester.

Another preferred group of compounds are those of the above formulas

20



wherein A is -C- and B is NR<sup>5</sup>, wherein R<sup>5</sup> is as defined above.

More preferred is a compound selected from:

25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (2-pyridin-4-yl-ethyl)-amide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (2-morpholin-4-yl-ethyl)-amide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-methyl-benzylamide;

30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid *sec*-butylamide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid cyclopentylamide;

- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid cyclopropylamide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid cyanomethyl-amide;
- 5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid cyclohexylamide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methyl-benzylamide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (3-ethoxy-propyl)-amide;
- 10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-chloro-benzylamide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-methyl-benzylamide;
- 15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (2,2-diphenyl-ethyl)-amide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (pyridin-3-ylmethyl)-amide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid cyclopropylmethyl-amide;
- 20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (1-ethyl-pyrrolidin-2-ylmethyl)-amide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (pyridin-2-ylmethyl)-amide;
- 25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid [2-(3,4-dimethoxy-phenyl)-ethyl]-amide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (furan-2-ylmethyl)-amide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-fluoro-benzylamide;
- 30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (2-bromo-ethyl)-amide;

-26-

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-sulfamoyl-benzylamide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid phenethyl-amide;

10 (S)-2-{[1-(3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidin-6-yl)-methanoyl]-amino}-propionic acid;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (1-phenyl-ethyl)-amide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-methoxy-benzylamide;

15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzylamide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-bromo-benzylamide;

20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid [2-(4-sulfamoyl-phenyl)-ethyl]-amide;

2-{[1-(3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidin-6-yl)-methanoyl]-amino}-3-phenyl-propionic acid methyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (3-imidazol-1-yl-propyl)-amide;

25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid [2-(2-methoxy-phenyl)-ethyl]-amide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-trifluoromethyl-benzylamide;

30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-amino-benzylamide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide; and

-27-

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid ((*R*)-2-hydroxy-1-methyl-ethyl)-amide.

Also more preferred is a compound selected from:

- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzofuran-5-ylmethyl ester;
- (3-{[1-(3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidin-6-yl)-methanoyl]-amino}-propyl)-carbamic acid *tert*-butyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzofuran-2-ylmethyl ester;
- 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid thiophen-3-ylmethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3*H*-[1,2,3]oxathiazol-5-ylmethyl ester;
- 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3*H*-[1,2,3]oxathiazol-5-ylmethyl ester;
- 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid [1,4,2]dioxazol-3-ylmethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid [1,4,2]dioxazol-3-ylmethyl ester;
- 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid furazan-3-ylmethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid furazan-3-ylmethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid [1,2,4]oxadiazol-5-ylmethyl ester;
- 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid [1,2,4]oxadiazol-5-ylmethyl ester;
- 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3*H*-[1,2,3]triazol-4-ylmethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3*H*-[1,2,3]triazol-4-ylmethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2*H*-[1,2,4]triazol-3-ylmethyl ester;



-28-

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2*H*-[1,2,4]triazol-3-ylmethyl ester;

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid isoxazol-5-ylmethyl ester;

5        3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid isoxazol-5-ylmethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid oxazol-2-ylmethyl ester;

10       3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid oxazol-2-ylmethyl ester;

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid isothiazol-5-ylmethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid isothiazol-5-ylmethyl ester;

15       3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid thiazol-2-ylmethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid thiazol-2-ylmethyl ester;

20       3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1*H*-imidazol-2-ylmethyl ester;

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2*H*-imidazol-2-ylmethyl ester;

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1*H*-pyrazol-3-ylmethyl ester;

25       3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2*H*-pyrazol-3-ylmethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1*H*-pyrrol-2-ylmethyl ester;

30       3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2*H*-pyrrol-2-ylmethyl ester;

3-Furazan-3-ylmethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

-29-

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2*H*-chromen-2-ylmethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2*H*-thiochromen-2-ylmethyl ester;

5 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2*H*-thiochromen-2-ylmethyl ester;

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid [1,3,4]thiadiazol-2-ylmethyl ester;

10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid [1,3,4]thiadiazol-2-ylmethyl ester;

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1*H*-benzoimidazol-5-ylmethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1*H*-benzoimidazol-5-ylmethyl ester;

15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1*H*-benzoimidazol-2-ylmethyl ester;

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1*H*-benzoimidazol-2-ylmethyl ester;

20 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1*H*-indol-2-ylmethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1*H*-indol-2-ylmethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1*H*-indol-5-ylmethyl ester;

25 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1*H*-indol-5-ylmethyl ester;

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2,3-dihydro-benzofuran-5-ylmethyl ester; and

30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2,3-dihydro-benzofuran-5-ylmethyl ester.

Also more preferred is a compound selected from:

4-{6-[3-(4-Methoxy-phenyl)-prop-1-ynyl]-1-methyl-2,4-dioxo-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidine-3-ylmethyl}-benzoic acid;

-30-

3-(4-Methanesulfonyl-benzyl)-6-[3-(4-methoxy-phenyl)-prop-1-ynyl]-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

4-{6-[3-(3-Methoxy-phenyl)-prop-1-ynyl]-1-methyl-2,4-dioxo-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidine-3-ylmehtyl}-benzoic acid;

5 3-(4-Methanesulfonyl-benzyl)-6-[3-(3-methoxy-phenyl)-prop-1-ynyl]-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

4-[1-Methyl-2,4-dioxo-6-(3-pyridine-4-yl-prop-1-ynyl)-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidine-3-ylmehtyl]-benzoic acid;

10 3-(4-Methanesulfonyl-benzyl)-1-6-(3-pyridin-4-yl-prop-1-ynyl)-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

4-[1-Methyl-2,4-dioxo-6-(3-pyridine-3-yl-prop-1-ynyl)-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidine-3-ylmehtyl]-benzoic acid;

3-(4-Methanesulfonyl-benzyl)-1-6-(3-pyridin-3-yl-prop-1-ynyl)-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

15 4-{6-[3-(4-Fluoro-phenyl)-prop-1-ynyl]-1-methyl-2,4-dioxo-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidine-3-ylmehtyl}-benzoic acid

6-[3-(4-Fluoro-phenyl)-prop-1-ynyl]-3-(4-methanesulfonyl-benzyl)-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

20 4-{6-[3-(3-Fluoro-phenyl)-prop-1-ynyl]-1-methyl-2,4-dioxo-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidine-3-ylmehtyl}-benzoic acid;

6-[3-(3-Fluoro-phenyl)-prop-1-ynyl]-3-(4-methanesulfonyl-benzyl)-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

4-{6-[3-(4-Chloro-phenyl)-prop-1-ynyl]-1-methyl-2,4-dioxo-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidine-3-ylmehtyl}-benzoic acid;

25 6-[3-(4-Chloro-phenyl)-prop-1-ynyl]-3-(4-methanesulfonyl-benzyl)-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

4-{6-[3-(3-Chloro-phenyl)-prop-1-ynyl]-1-methyl-2,4-dioxo-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidine-3-ylmehtyl}-benzoic acid;

30 6-[3-(3-Chloro-phenyl)-prop-1-ynyl]-3-(4-methanesulfonyl-benzyl)-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

4-{6-[3-(4-Bromo-phenyl)-prop-1-ynyl]-1-methyl-2,4-dioxo-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidine-3-ylmehtyl}-benzoic acid;

-31-

6-[3-(4-Bromo-phenyl)-prop-1-ynyl]-3-(4-methanesulfonyl-benzyl)-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

4-{6-[3-(3-Bromo-phenyl)-prop-1-ynyl]-1-methyl-2,4-dioxo-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidine-3-ylmethyl}-benzoic acid;

5 6-[3-(3-Bromo-phenyl)-prop-1-ynyl]-3-(4-methanesulfonyl-benzyl)-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

4-{1-Methyl-6-[3-(4-nitro-phenyl)-prop-1-ynyl]-2,4-dioxo-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidine-3-ylmethyl}-benzoic acid;

10 3-(4-Methanesulfonyl-benzyl)-1-methyl-6-[3-(4-nitro-phenyl)-prop-1-ynyl]-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

4-{6-[3-(2-Methoxy-pyridin-4-yl)-prop-1-ynyl]-1-methyl-2,4-dioxo-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidine-3-ylmethyl}-benzoic acid;

3-(4-Methanesulfonyl-benzyl)-6-[3-(2-methoxy-pyridin-4-yl)-prop-1-ynyl]-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

15 4-{1-Methyl-6-[3-(4-methylsulfanyl-phenyl)-prop-1-ynyl]-2,4-dioxo-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidine-3-ylmethyl}-benzoic acid;

3-(4-Methanesulfonyl-benzyl)-1-methyl-6-[3-(4-methylsulfanyl-phenyl)-prop-1-ynyl]-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

20 4-{1-Methyl-6-[3-(3-methylsulfanyl-phenyl)-prop-1-ynyl]-2,4-dioxo-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidine-3-ylmethyl}-benzoic acid;

3-(4-Methanesulfonyl-benzyl)-1-methyl-6-[3-(3-methylsulfanyl-phenyl)-prop-1-ynyl]-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

4-[1-Methyl-2,4-dioxo-6-(3-*p*-tolyl-prop-1-ynyl)-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidin-3-ylmethyl]benzoic acid;

25 3-(4-Methanesulfonyl-benzyl)-1-methyl-6-(3-*p*-tolyl-prop-1-ynyl)-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

4-[1-Methyl-2,4-dioxo-6-(3-*m*-tolyl-prop-1-ynyl)-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidin-3-ylmethyl]benzoic acid;

30 3-(4-Methanesulfonyl-benzyl)-1-methyl-6-(3-*m*-tolyl-prop-1-ynyl)-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

3-Benzyl-6-[3-(4-methoxy-phenyl)-prop-1-ynyl]-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

-32-

3-Benzyl-6-[3-(3-methoxy-phenyl)-prop-1-ynyl]-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

3-Benzyl-1-methyl-6-(3-pyridin-4-yl-prop-1-ynyl)-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

5 3-Benzyl-1-methyl-6-(3-pyridin-3-yl-prop-1-ynyl)-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

3-Benzyl-6-[3-(4-fluoro-phenyl)-prop-1-ynyl]-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

10 3-Benzyl-6-[3-(3-fluoro-phenyl)-prop-1-ynyl]-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

3-Benzyl-6-[3-(4-chloro-phenyl)-prop-1-ynyl]-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

3-Benzyl-6-[3-(3-chloro-phenyl)-prop-1-ynyl]-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

15 3-Benzyl-6-[3-(4-bromo-phenyl)-prop-1-ynyl]-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

3-Benzyl-6-[3-(3-bromo-phenyl)-prop-1-ynyl]-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

20 3-Benzyl-6-[3-(2-methoxy-pyridin-4-yl)-prop-1-ynyl]-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

3-Benzyl-1-methyl-6-[3-(4-methylsulfanyl-phenyl)-prop-1-ynyl]-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

3-Benzyl-1-methyl-6-[3-(3-methylsulfanyl-phenyl)-prop-1-ynyl]-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

25 3-Benzyl-1-methyl-6-(3-*p*-tolyl-prop-1-ynyl)-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

3-Benzyl-1-methyl-6-(3-*m*-tolyl-prop-1-ynyl)-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

30 3-(3-Fluoro-benzyl)-6-[3-(4-methoxy-phenyl)-prop-1-ynyl]-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

3-(3-Fluoro-benzyl)-6-[3-(3-methoxy-phenyl)-prop-1-ynyl]-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

-33-

3-(3-Fluoro-benzyl)-1-methyl-6-(3-pyridine-4-yl-prop-1-ynyl)-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

3-(3-Fluoro-benzyl)-1-methyl-6-(3-pyridine-3-yl-prop-1-ynyl)-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

5 3-(3-Fluoro-benzyl)-6-[3-(4-fluoro-phenyl)-prop-1-ynyl]-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

3-(3-Fluoro-benzyl)-6-[3-(3-fluoro-phenyl)-prop-1-ynyl]-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

10 6-[3-(4-Chloro-phenyl)-prop-1-ynyl]-3-(3-fluoro-benzyl)-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

6-[3-(3-Chloro-phenyl)-prop-1-ynyl]-3-(3-fluoro-benzyl)-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

6-[3-(4-Bromo-phenyl)-prop-1-ynyl]-3-(3-fluoro-benzyl)-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

15 6-[3-(3-Bromo-phenyl)-prop-1-ynyl]-3-(3-fluoro-benzyl)-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

3-(3-Fluoro-benzyl)-6-[3-(2-methoxy-pyridin-4-yl)-prop-1-ynyl]-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

20 3-(3-Fluoro-benzyl)-1-methyl-6-[3-(4-methylsulfanyl-phenyl)-prop-1-ynyl]-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

3-(3-Fluoro-benzyl)-1-methyl-6-[3-(3-methylsulfanyl-phenyl)-prop-1-ynyl]-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

3-(3-Fluoro-benzyl)-1-methyl-6-(3-*p*-tolyl-prop-1-ynyl)-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione; and

25 3-(3-Fluoro-benzyl)-1-methyl-6-(3-*m*-tolyl-prop-1-ynyl)-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione.

Also more preferred is a compound selected from:

3-(3-Methoxycarbonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

30 3-(3-Methoxycarbonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-Benzofuran-5-ylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

-34-

- 1-Methyl-3-(4-methyl-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 3-(4-Acetylamino-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 5 1-Methyl-2,4-dioxo-3-(4-vinyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 1-Methyl-2,4-dioxo-3-(4-sulfamoyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 3-(4-Bromo-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid pyridin-4-ylmethyl ester;
- 10 1-Methyl-2,4-dioxo-3-phenethyl-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 1-Methyl-2,4-dioxo-3-[4-(2H-tetrazol-5-yl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 15 3-(4-Fluoro-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid pyridin-4-ylmethyl ester;
- 3-(4-*tert*-Butyloxycarbonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 3-(4-*tert*-Butyloxycarbonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid;
- 20 4-[6-(4-Fluoro-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-benzoic acid;
- 4-[6-(4-Dimethylamino-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-benzoic acid, compound with trifluoro-acetic acid;
- 25 4-[6-(2-Ethoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-3-ylmethyl]-benzoic acid;
- 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid;
- 30 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 1-Methyl-2,4-dioxo-3-[4-(1H-tetrazol-5-yl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;



-35-

1-Methyl-3-[4-(morpholine-4-sulfonyl)-benzyl]-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

1-Methyl-3-[4-(morpholine-4-carbonyl)-benzyl]-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

5 3-But-2-ynyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

1-Methyl-2,4-dioxo-3-[3-(1*H*-tetrazol-5-yl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

10 3-(4-Cyano-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

{4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-phenyl}-acetic acid;

3-[2-(2,4-Dichloro-benzenesulfonyl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

15 3-(4-Methanesulfonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

1-Methyl-2,4-dioxo-3-(4-sulfamoyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;

1-Methyl-3-(4-methylsulfamoyl-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

3-(4-Isopropylsulfamoyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

25 1-Methyl-2,4-dioxo-3-[4-(pyrrolidine-1-sulfonyl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;  
and

1-Methyl-3-[4-(4-methyl-piperidine-1-sulfonyl)-benzyl]-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide.

30 Also more preferred is a compound selected from:

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzofuran-2-ylmethyl ester;

-36-

3-(4-Bromo-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid pyridin-4-ylmethyl ester;

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzyl ester;

5 4-{1-Methyl-2,4-dioxo-6-[(pyridin-4-ylmethyl)-carbamoyl]-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl}-benzoic acid, compound with trifluoroacetic acid;

4-[6-(4-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid;

10 4-[6-(3,4-Dimethoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid *tert*-butyl ester;

4-[6-(3,4-Dimethoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid;

15 4-[6-(4-Bromo-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid;

4-[6-(4-Bromo-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid *tert*-butyl ester;

4-[6-(3,5-Bis-trifluoromethyl-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid;

20 4-[6-(4-Chloro-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid;

4-[1-Methyl-2,4-dioxo-6-(4-sulfamoyl-benzylcarbamoyl)-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid;

25 3-(4-Fluoro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

3-(4-Iodo-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

3-(4-Dimethylsulfamoyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

30 3-(3-Methoxy-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

3-(4-Cyano-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

-37-

- 3-(4-Acetylamino-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 5-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-furan-2-carboxylic acid ethyl ester;
- 5 3-(4-Cyano-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzyl ester;
- 1-Methyl-2,4-dioxo-3-[4-(5-thioxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;
- 10 4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid 2-dimethylamino-ethyl ester;
- 3-Cyclohexylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;
- 3-Cyclohexylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;
- 15 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid furan-3-ylmethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid pentafluorophenylmethyl ester;
- 20 3-Benzyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;
- 3-Benzyl-1-cyclopropylmethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (pyridin-4-ylmethyl)-amide;
- 25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-bromo-benzyl ester;
- 4-[6-(3-Difluoromethoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid;
- 30 4-[6-(3-Difluoromethoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid tert-butyl ester;
- 4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid;

- 4-[6-(4-Methanesulfonyl-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid tert-butyl ester;
- 4-[6-(4-Methanesulfonyl-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid;
- 5 4-[1-Methyl-2,4-dioxo-6-(2-pyridin-4-yl-ethylcarbamoyl)-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid;
- 1-Methyl-2,4-dioxo-3-(4-trifluoromethoxy-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid methyl ester;
- 10 3-(2,3-Dihydro-benzofuran-6-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 1-Methyl-3-(2-methyl-thiazol-5-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 15 1-Methyl-2,4-dioxo-3-[4-(1H-tetrazol-5-yl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-fluoro-benzylamide;
- 3-Benzyl-2-methoxy-4-oxo-3,4-dihydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;
- 4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid 2,2-dimethyl-propionyloxymethyl ester;
- 20 4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-cyclohexanecarboxylic acid;
- 4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-cyclohexanecarboxylic acid methyl ester;
- 25 1-{4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-phenyl}-cyclopropanecarboxylic acid methyl ester;
- 1-{4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-phenyl}-cyclopropanecarboxylic acid tert-butyl ester;
- 30 1-{4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-phenyl}-cyclopropanecarboxylic acid;

-39-

2-{4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-phenoxy}-2-methyl-propionic acid tert-butyl ester;

5 2-{4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-phenoxy}-2-methyl-propionic acid;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-furo[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-(3-Methoxy-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-Biphenyl-4-ylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

15 3-(4-Methanesulfonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-(4-Methanesulfonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-3-(4-methyl-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

20 1-Methyl-2,4-dioxo-3-phenethyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-(4-Amino-6-phenylamino-1,3,5-triazin-2-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

25 1-Methyl-2,4-dioxo-3-(4-trifluoromethyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-(6-Cyano-hexyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-[2-(2,5-Dimethoxy-phenyl)-2-oxo-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

30 3-(3-Iodo-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-(3-trifluoromethyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

-40-

3-(2,4-Bis-trifluoromethyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-[2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

5 3-[2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-(2-Carboxy-allyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

10 3-(2-Carboxy-allyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-(3-Amino-propyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-(1,3-Dioxo-1,3-dihydro-isoindol-2-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

15 3-(4-Fluoro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-3-oxiranylmethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

20 1-Methyl-3-((S)-2-methyl-butyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-(4-phenoxy-butyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-(2-Cyano-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

25 1-Methyl-2,4-dioxo-3-(3-phenoxy-propyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-Hex-5-enyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

30 1-Methyl-2,4-dioxo-3-pyridin-3-ylmethyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-[2-Hydroxy-3-(naphthalen-1-yloxy)-propyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;



-41-

1,3-Dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-Cyclobutylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

5 3-Allyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-prop-2-ynyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

10 3-But-2-ynyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-(2-phenoxy-ethyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-(2-phenoxy-ethyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

15 3-((R)-3-Hydroxy-2-methyl-propyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-Isobutyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

20 3-(6-Chloro-pyridin-3-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-(2-Benzenesulfonylmethyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-3-naphthalen-1-ylmethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

25 1-Methyl-2,4-dioxo-3-(2-trifluoromethyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-(3-Chloro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

30 3-(4-Methoxycarbonyl-butyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-Ethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;



-42-

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-fluoro-benzyl ester;

3-[2-(4-Chloro-benzenesulfonyl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

5 3-(2-Acetoxy-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-phenoxy-ethyl ester;

10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzylamide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2,6-dichloro-benzyl ester;

15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid butyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2,3-dihydro-1,4-benzodioxin-2-ylmethyl ester;

20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-diethylamino-1-methyl-ethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-fluoro-benzyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-isopropyl-benzyl ester;

25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-p-tolyl-ethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-trifluoromethyl-benzyl ester;

30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid cyclobutylmethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2,6-difluoro-benzyl ester;

-43-

- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-(2-hydroxy-phenyl)-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-(2-hydroxy-phenyl)-ethyl ester;
- 5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 1-methyl-piperidin-4-yl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 1-methyl-piperidin-4-yl ester;
- 10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid pyridin-3-ylmethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-pyridin-3-yl-propyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-dimethylamino-1-methyl-ethyl ester;
- 15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid tetrahydro-pyran-4-yl ester;
- 20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2,2,2-trifluoro-1-trifluoromethyl-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-trifluoromethyl-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-benzyloxy-ethyl ester;
- 25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2,2,2-trichloro-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid phenethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-ethyl-oxetan-3-ylmethyl ester;
- 30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-morpholin-4-yl-ethyl ester;

- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-pyrrolidin-1-yl-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-pyrrolidin-1-yl-ethyl ester;
- 5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-(2-ethoxy-ethoxy)-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid tetrahydro-pyran-2-ylmethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-nitro-benzyl ester;
- 10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid pentyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-phenyl-propyl ester;
- 15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-phenoxy-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3,5-dimethoxy-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methyl-butyl ester;
- 20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-chloro-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 1-ethyl-piperidin-3-yl ester;
- 25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-benzyloxy-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid isobutyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-(4-methoxy-phenyl)-propyl ester;
- 30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-chloro-6-fluoro-benzyl ester;

- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (S)-(tetrahydro-furan-3-yl) ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzyl ester;
- 5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-pyridin-2-yl-propyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-piperidin-2-yl-ethyl ester;
- 10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 5-bromo-2-methoxy-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid cycloheptylmethyl ester;
- 15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 1,2,3,4-tetrahydro-naphthalen-1-yl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (S)-1-pyrrolidin-2-ylmethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-chloro-benzyl ester;
- 20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 1,3-benzodioxol-5-ylmethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methylsulfanyl-benzyl ester;
- 25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methylsulfanyl-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3,4-dichloro-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3,3-diphenyl-propyl ester;
- 30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-pyridin-2-yl-ethyl ester;

-46-

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid furan-3-ylmethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid but-3-enyl ester;

5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-cyano-ethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-ethoxy-ethyl ester;

10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid cyano-phenyl-methyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-trifluoromethyl-benzylamide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methyl-benzylamide;

15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid phenethyl-amide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid cyclopropylamide;

20 1-Methyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

1-Methyl-2,4-dioxo-3-(4-sulfamoyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

1-Methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

25 1-Methyl-2,4-dioxo-3-(3-oxo-3-phenyl-propyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

3-[4-(N-Hydroxycarbamimidoyl)-benzyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

30 1-Methyl-2,4-dioxo-3-[4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

-47-

1-Methyl-2,4-dioxo-3-[4-(5-thioxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

4-(5-Isopropyl-2H-pyrazol-3-yl)-pyridine;

5 3-Cyanomethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

(E)-4-[6-(4-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-yl]-but-2-enoic acid methyl ester;

10 (E)-4-[6-(4-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-yl]-but-2-enoic acid;

3-(2-Benzenesulfonyl-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

2-Methoxy-4-[6-(4-methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid methyl ester;

15 3-(2-Methoxymethyl-1,1,3-trioxo-2,3-dihydro-1H-1<sup>6</sup>-1,2-benzisothiazol-6-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

1-Methyl-3-oct-2-ynyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

20 3-[2-(4-Chloro-benzenesulfonylamino)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

3-[2-(4-Bromo-phenoxy)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

25 3-[2-(4-Bromo-phenoxy)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

3-[2-(4-Fluoro-phenoxy)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

3-[2-(4-Chloro-benzenesulfonyl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

30 3-[2-(4-Fluoro-phenoxy)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;



-48-

1-Methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;

3-Cyclohexylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

5 4-[6-(4-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-2-methyl-benzoic acid methyl ester;

4-[6-(4-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid methyl ester;

10 2-Methoxy-4-[6-(3-methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid methyl ester;

4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-2-methyl-benzoic acid methyl ester;

1-Methyl-2,4-dioxo-3-(3-oxo-3-phenyl-propyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

15 3-[2-(4-Chloro-phenoxy)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

1-Methyl-2,4-dioxo-3-[2-(3-trifluoromethyl-benzenesulfonyl)-ethyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

20 1-Methyl-2,4-dioxo-3-[2-(3-trifluoromethyl-benzenesulfonyl)-ethyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

3-[2-(4-Chloro-benzenesulfonyl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

25 and

3-(2-Amino-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide.

Also more preferred is a compound selected from:

30 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid;

4-(6-Carbamoyl-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl)-2-methyl-benzoic acid;



4-(6-Carbamoyl-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl)-2-methyl-benzoic acid methyl ester;

4-[6-(3-Hydroxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-2-methyl-benzoic acid;

5 4-(6-Carbamoyl-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl)-2-hydroxy-benzoic acid;

3-(2-Amino-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide; and

4-(2,5-Di-pyridin-4-yl-thiophen-3-yl)-benzaldehyde.

10 Also more preferred is a compound selected from:

1-Methyl-2,4-dioxo-3-(1-phenyl-ethyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

1-Methyl-2,4-dioxo-3-(3-oxo-3-phenyl-propyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

15 3-((S)-3,7-Dimethyl-oct-6-enyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

3-(2-Ethyl-hexyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

20 3-(5-Cyano-pentyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

3-(E)-But-2-enyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

1-Methyl-3-(2-naphthalen-1-yl-ethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

25 1-Methyl-2,4-dioxo-3-(E)-pent-2-enyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

1-Methyl-2,4-dioxo-3-(2-phenylsulfanyl-ethyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

30 3-sec-Butyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

1-Methyl-3-(2-methyl-allyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

3-(1-Ethyl-propyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

1-Methyl-2,4-dioxo-3-pent-2-ynyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

5 3-(2-Benzenesulfonyl-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

1-Methyl-3-(3-methyl-but-2-enyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

10 3-[2-(4-Fluoro-benzenesulfonyl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

1-Methyl-2,4-dioxo-3-[2-(toluene-4-sulfonyl)-ethyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

3-[3-(4-Fluoro-phenyl)-3-oxo-propyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

15 3-[3-(4-Chloro-phenyl)-3-oxo-propyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

3-(2-Benzoylamino-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

20 3-[2-(4-Bromo-phenoxy)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

3-Benzofurazan-5-ylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

1-Methyl-2,4-dioxo-3-(2-phenoxy-ethyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

25 {5-[6-(4-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-isoxazol-3-yl}-carbamic acid methyl ester;

3-Benzyloxycarbonylamino-5-[6-(4-methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-yl]-4-oxo-pentanoic acid tert-butyl ester;

30 3-[2-(4-Chloro-phenylsulfanyl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

1-Methyl-2,4-dioxo-3-(1-phenyl-ethyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

- 1-Methyl-2,4-dioxo-3-(E)-pent-2-enyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 3-(2-Ethyl-hexyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 5 1-Methyl-2,4-dioxo-3-(2-phenylmethanesulfonyl-ethyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 3-(5-Cyano-pentyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 3-(E)-But-2-enyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 10 1-Methyl-3-(2-naphthalen-1-yl-ethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 1-Methyl-2,4-dioxo-3-(E)-pent-2-enyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 15 1-Methyl-2,4-dioxo-3-(2-phenylsulfonyl-ethyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 3-sec-Butyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 1-Methyl-3-(2-methyl-allyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 20 3-(1-Ethyl-propyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 1-Methyl-2,4-dioxo-3-pent-2-ynyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 25 1-Methyl-3-(3-methyl-but-2-enyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 1-Methyl-2,4-dioxo-3-[2-(toluene-4-sulfonyl)-ethyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 3-(2-Benzoylamino-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 30 3-[2-(4-Bromo-phenoxy)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

3-Benzofurazan-5-ylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

1-Methyl-2,4-dioxo-3-(2-phenoxy-ethyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

5 {5-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-isoxazol-3-yl}-carbamic acid methyl ester;  
and

3-Benzylloxycarbonylamino-5-[6-(3-methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-yl]-4-oxo-pentanoic acid tert-butyl ester.

Also more preferred is a compound selected from:

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid methyl ester;

15 3-(4-Bromo-benzyl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-(4-Fluoro-benzyl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid pyridin-4-ylmethyl ester;

20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzo[b]thiophen-2-ylmethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 1-methyl-1H-indol-5-ylmethyl ester;

25 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid thiophen-3-ylmethyl ester;

3-1,3-Benzodioxol-5-ylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-pyridin-4-ylmethyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

30 3-(4-*tert*-Butyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-(3,4-Dichloro-benzyl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

-53-

1-Methyl-2,4-dioxo-3-(4-trifluoromethoxy-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-3-naphthalen-2-ylmethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

5 3-(4-Cyano-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzofuran-5-ylmethyl ester;

10 3-(3,5-Dimethoxy-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-(3,5-Dinitro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid; and

3-(4-Carboxy-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-ethoxy-benzyl ester.

Also more preferred is a compound selected from:

20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid [2-(3,4-dimethoxy-phenyl)-ethyl]-amide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-amino-benzylamide;

25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (biphenyl-2-ylmethyl)-amide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3,4-dimethoxy-benzylamide;

30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (2-pyridin-4-yl-ethyl)-amide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-difluoromethoxy-benzylamide;

- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid [2-(3-ethoxy-phenyl)-ethyl]-amide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-chloro-4-fluoro-benzylamide;
- 5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2,4-dichloro-benzylamide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (2-phenyl-propyl)-amide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3,4,5-trimethoxy-benzylamide;
- 10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-chloro-benzylamide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3,5-dimethoxy-benzylamide;
- 15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2,3-dimethoxy-benzylamide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-trifluoromethyl-benzylamide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-methoxy-benzylamide;
- 20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-methyl-benzylamide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (4-phenyl-butyl)-amide;
- 25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (pyridin-3-ylmethyl)-amide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid ((S)-2,2-dimethyl-4-phenyl-1,3-dioxinan-5-yl)-amide;
- 30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid [2-(3-methoxy-phenyl)-ethyl]-amide;



-55-

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (thiophen-2-ylmethyl)-amide;

5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-chloro-benzylamide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (5-methyl-furan-2-ylmethyl)-amide;

10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (2,2-diphenyl-ethyl)-amide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid [2-(2-methoxy-phenyl)-ethyl]-amide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid [2-(3-trifluoromethyl-phenyl)-ethyl]-amide;

15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-bromo-benzylamide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-amide;

20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3,5-dichloro-benzylamide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid indan-1-ylamide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (furan-2-ylmethyl)-amide;

25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid [2-(4-methoxy-phenyl)-ethyl]-amide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2,4-dimethoxy-benzylamide;

30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-chloro-benzylamide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (1-phenyl-ethyl)-amide;



3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3,4-dichloro-benzylamide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-fluoro-3-trifluoromethyl-benzylamide;

5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (2-pyridin-2-yl-ethyl)-amide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid [2-(2,4-dimethyl-phenyl)-ethyl]-amide;

10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid [2-(2,4-dichloro-phenyl)-ethyl]-amide;

1,3-Dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

3-Cyanomethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

3-(4-Cyclopropylsulfamoyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

20 1-Methyl-3-(6-nitro-pyridin-3-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

1-Methyl-3-(6-nitro-pyridin-3-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

25 1-Methyl-3-(6-nitro-pyridin-3-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;

3-Cyclohexylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;

30 3-{2-[(1H-Benzimidazole-5-carbonyl)-amino]-ethyl}-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

1-Methyl-2,4-dioxo-3-[2-(3-piperidin-1-yl-propionylamino)-ethyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

1-Methyl-2,4-dioxo-3-{2-[(6-pyrazol-1-yl-pyridine-3-carbonyl)-amino]-ethyl}-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

5 3-[2-(4-Diethylamino-benzoylamino)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

3-{2-[(6-Chloro-pyridine-3-carbonyl)-amino]-ethyl}-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

10 1-Methyl-2,4-dioxo-3-{2-[(1H-pyrrole-2-carbonyl)-amino]-ethyl}-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

3-[2-(2-Dimethylamino-acetylamino)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

1-Methyl-2,4-dioxo-3-{2-[(pyrazine-2-carbonyl)-amino]-ethyl}-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

15 1-Methyl-3-[2-(2-methyl-2-methylamino-propionylamino)-ethyl]-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

1-Methyl-2,4-dioxo-3-{2-[(pyrrolidine-2-carbonyl)-amino]-ethyl}-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

20 1-Methyl-2,4-dioxo-3-{2-[3-(5-phenyl-1H-pyrrol-2-yl)-propionylamino]-ethyl}-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

25 1-Methyl-2,4-dioxo-3-{2-[2-(pyridin-4-ylsulfanyl)-acetylamino]-ethyl}-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

3-(6-Amino-pyridin-3-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

1-Methyl-2,4-dioxo-3-(3-phenyl-prop-2-ynyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

30 3-(6-Amino-pyridin-3-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

3-(6-Amino-pyridin-3-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (pyridin-4-ylmethyl)-amide;

-58-

1-Methyl-2,4-dioxo-3-[2-(pyridin-2-ylamino)-ethyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

1-Methyl-2,4-dioxo-3-[2-(pyrimidin-2-ylamino)-ethyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide; and

5 1-Methyl-2,4-dioxo-3-[2-(pyrimidin-2-ylamino)-ethyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide.

A further embodiment of this invention is use of a compound of Formula I, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease mediated by an MMP-13 enzyme.

10 Also preferred is use of a compound of Formulas II, III, VI, VII, or XI, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease mediated by an MMP-13 enzyme.

Preferred is use of a compound of Formula I, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of  
15 cancer.

Also preferred is use of a compound of Formula I, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of rheumatoid arthritis.

Also preferred is use of a compound of Formula I, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of  
20 osteoarthritis.

A further embodiment of this invention is a pharmaceutical composition, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, admixed with a carrier, excipient, or diluent. Preferred compositions  
25 comprise compounds of Formulas II, III, VI, VII, or XI.

Another embodiment of this invention is a method for inhibiting MMP-13, in an animal, comprising administering to the animal an MMP-13 inhibiting amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.


30 A further embodiment is a method for treating a disease mediated by MMP-13 enzymes, comprising administering to a patient suffering from such disease a effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.

-59-

A preferred method of treatment according to this invention is treatment of a disease selected from cancer, especially breast carcinoma, and inflammation and heart failure. Other diseases to be treated according to this invention include arthritis, both osteoarthritis and rheumatoid arthritis.

5 Other preferred methods of treating a disease comprise administering a compound of Formulas II, III, VI, VII, or XI, or a pharmaceutically acceptable salt thereof.


Another embodiment of the present invention is a process for preparing a compound of Formula I



or a pharmaceutically acceptable salt thereof;


wherein:

W, together with the carbon atoms to which it is attached, form a 5-membered ring diradical



15

-60-



B is O or NR<sup>5</sup>; or

5 A and B are taken together to form -C≡C-;

X is O, S, SO, SO<sub>2</sub>, NR<sup>5</sup>, or CH<sub>2</sub>;

each Y independently is O or S;

R<sup>1</sup>, R<sup>4</sup>, and R<sup>5</sup> independently are hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl; C<sub>2</sub>-C<sub>6</sub> alkenyl,

C<sub>2</sub>-C<sub>6</sub> alkynyl, (CH<sub>2</sub>)<sub>n</sub> cycloalkyl, (CH<sub>2</sub>)<sub>n</sub> heterocyclic, C<sub>1</sub>-C<sub>6</sub> alkanoyl,

10 (CH<sub>2</sub>)<sub>n</sub> aryl, or (CH<sub>2</sub>)<sub>n</sub> heteroaryl;

R<sup>2</sup> and R<sup>3</sup> independently are hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl,

C<sub>2</sub>-C<sub>6</sub> alkynyl, CN, NO<sub>2</sub>, NR<sup>4</sup>R<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub> cycloalkyl, (CH<sub>2</sub>)<sub>n</sub> aryl, or

(CH<sub>2</sub>)<sub>n</sub> heteroaryl;

R<sup>2</sup> may further be halo;

15 n is an integer of from 0 to 5; and

R<sup>4</sup> and R<sup>5</sup> when taken together with the nitrogen to which they are attached


complete a 3- to 8-membered ring containing carbon atoms and optionally containing O, S, or N, and substituted or unsubstituted;

with the proviso that R<sup>1</sup> and R<sup>3</sup> are not both selected from: hydrogen and C<sub>1</sub>-C<sub>6</sub>

20 alkyl,

the process comprising the step of:

contacting a compound of Formula (A)




(A)

wherein Y, R<sup>1</sup>, and R<sup>4</sup> are as defined above; and

25 W<sup>1</sup>, together with the carbon atoms to which it is attached, form a 5-membered ring diradical

-61-



$R^2$  and X are as defined above; and

L is a group K or Q, wherein

K is halo,  $B(OH)_2$ ,  $Sn(C_1-C_6 \text{ alkyl})_3$ , or  $OS(O)_2CF_3$ , and

5 Q is  $CO_2H$ ,  $CO_2M$ ,  $C(=O)\text{-halo}$ ,  $C(=O)\text{-OR}^7$ ,  $C(=O)NR^8R^9$ ,  $C(=O)\text{-C(halo)}_3$ , or  $C\equiv N$ ,

wherein  $R^7$  is pentafluorophenyl,  $C(=O)R^4$ , wherein  $R^4$  is as defined above, or  $S(O)_2R^4$ , wherein  $R^4$  is as defined above;

10  $R^8$  and  $R^9$  are taken together with the nitrogen atom to which they are attached to form imidazol-1-yl, phthalimid-1-yl, benzotriazol-1-yl, or tetrazol-1-yl; and

M is an alkali earth metal cation or alkaline earth metal cation; with a solvent and, when L is the group Q, a compound of Formula (B)



15 wherein  $R^3$  is as defined above and D is HO,  $HN(R^5)$ , MO, or  $MN(R^5)$ ;

wherein  $R^5$  and M are as defined above;

optionally in the presence of from 1 to 3 agents selected from:

a coupling agent, a tertiary organic amine, an acid catalyst, a base catalyst, an acid halide, and an acid anhydride; or

20 the process comprising the step of:

-62-

contacting a compound of Formula (A)  
as defined above with a solvent and, when  
L is the group K, a compound of Formula (C)



5 wherein  $R^3$  is as defined above and

G is hydrogen or halo;

optionally in the presence of a coupling catalyst.

Preferred is the invention process wherein Y is O and X is S; or

10 Also preferred is the invention process wherein A is  $-C-$ , B is O or  $NR^5$ , Y is O, and X is S; or

Also preferred is the invention process wherein A and B are taken together to form  $-C\equiv C$ , Y is O, and X is S; or

15 Also preferred is the invention process wherein  $R^1$  and  $R^3$  independently are  $(CH_2)_n$  aryl, or  $(CH_2)_n$  heteroaryl, wherein n is an integer of from 0 to 5; or

Also preferred is the invention process wherein n is 1.

Also preferred is any one of the above invention process embodiments wherein L is  $CO_2H$ ,  $CO_2M$ ,  $C(=O)$ -halo, wherein M is an alkalai earth metal cation or an alkaline earth metal cation; or

20 Also preferred is any one of the above invention process embodiments wherein L is halo; or

Also preferred is any one of the above invention process embodiments wherein G is H.

## 25 DETAILED DESCRIPTION OF THE INVENTION

The compounds provided by this invention are those defined by Formula I. In Formula I,  $R^1$ - $R^4$  include "C<sub>1</sub>-C<sub>6</sub> alkyl" groups. These are straight and branched carbon chains having from 1 to 6 carbon atoms. Examples of such alkyl groups include methyl, ethyl, isopropyl, *tert*-butyl, neopentyl, and n-hexyl. The alkyl groups can be substituted if desired, for instance, with groups such as

30



aryl-O-, wherein aryl is as defined below, heteroaryl-O-, wherein heteroaryl is as defined below, hydroxy, amino, alkyl, and dialkylamino, halo, trifluoromethyl, carboxy, nitro, and cyano. Typical substituted alkyl groups thus are aminomethyl, 2-nitroethyl, 4-cyanobutyl, 2,3-dichloropentyl, and 3-hydroxy-5-carboxyhexyl.

5           Examples of  $\text{NR}^4\text{R}^5$  groups include amino, methylamino, di-isopropylamino, acetyl amino, propionyl amino, 3-aminopropyl amino, 3-ethylaminobutyl amino, 3-di-n-propylamino-propyl amino, 4-diethylaminobutyl amino, and 3-carboxypropionyl amino.  $\text{R}^4$  and  $\text{R}^5$  can be taken together with the nitrogen to which they are attached to form a ring having 3 to 7 carbon atoms and  
10       1, 2, or 3 heteroatoms selected from the group consisting of nitrogen, substituted nitrogen, oxygen, and sulfur. Examples of such cyclic  $\text{NR}^4\text{R}^5$  groups include pyrrolidinyl, piperazinyl, 4-methylpiperazinyl, 4-benzylpiperazinyl, pyridinyl, piperidinyl, pyrazinal, morpholinyl, and the like.

          "Halo" includes fluoro, chloro, bromo, and iodo.

15           "Alkenyl" means straight and branched hydrocarbon radicals having from 2 to 6 carbon atoms and one double bond and includes ethenyl, 3-buten-1-yl, 2-ethenylbutyl, 3-hexen-1-yl, and the like.

          "Alkynyl" means straight and branched hydrocarbon radicals having from 2 to 6 carbon atoms and one triple bond and includes ethynyl, 3-butyne-1-yl, propynyl, 2-butyne-1-yl, 3-pentyne-1-yl, and the like.  
20

          "Carbocycle" or "Cycloalkyl" mean a monocyclic or polycyclic hydrocarbyl group such as cyclopropyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclobutyl, adamantyl, norpinanyl, decalinyl, norbornyl, cyclohexyl, and cyclopentyl. Such groups can be substituted with groups such as hydroxy, keto, and the like. Also included are rings in which 1 to 3 heteroatoms replace carbons.  
25       Such groups are termed "heterocycle" or "heterocyclic" or "heterocyclyl," which mean a cycloalkyl group also bearing at least one heteroatom selected from O, S, or  $\text{NR}_2$ , examples being oxiranyl, pyrrolidinyl, piperidyl, tetrahydropyran, and morpholine.

30           "Alkoxy" refers to the alkyl groups mentioned above bound through oxygen, examples of which include methoxy, ethoxy, isopropoxy, tert-butoxy, and

-64-

the like. In addition, alkoxy refers to polyethers such as  $-O-(CH_2)_2-O-OH_3$ , and the like.

"Alkanoyl" groups are alkyl linked through a carbonyl, ie,  $C_1-C_5-C(O)-$ . Such groups include formyl, acetyl, propionyl, butyryl, and isobutyryl.

5 "Acyl" means an alkyl or aryl (Ar) group bonded through a carbonyl group, i.e.,  $R-C(O)-$ . For example, acyl includes a  $C_1-C_6$  alkanoyl, including substituted alkanoyl, wherein the alkyl portion can be substituted by  $NR^4R^5$  or a carboxylic or heterocyclic group. Typical acyl groups include acetyl, benzoyl, and the like.

10 The alkyl, alkenyl, alkoxy, and alkynyl groups described above are optionally substituted, preferably by 1 to 3 groups selected from  $NR^4R^5$ , phenyl, substituted phenyl, thio  $C_1-C_6$  alkyl,  $C_1-C_6$  alkoxy, hydroxy, carboxy, aryl-O-, wherein aryl is as defined below, heteroaryl-O-, wherein heteroaryl is as defined below,  $C_1-C_6$  alkoxy carbonyl, halo, nitrile, cycloalkyl, and a 5- or 6-membered  
15 carbocyclic ring or heterocyclic ring having 1 or 2 heteroatoms selected from nitrogen, substituted nitrogen, oxygen, and sulfur. "Substituted nitrogen" means nitrogen bearing  $C_1-C_6$  alkyl or  $(CH_2)_nPh$  where n is 1, 2, or 3. Perhalo and polyhalo substitution is also embraced. Oxo ( $=O$ ) substitution of a  $CH_2$  carbon group to provide a carbonyl ( $C=O$ ) is also embraced.

20 Examples of substituted alkyl groups include 2-aminoethyl, pentachloroethyl, trifluoromethyl, 2-diethylaminoethyl, 2-dimethylaminopropyl, ethoxycarbonylmethyl, 3-phenylbutyl, methanysulfanylmethyl, methoxymethyl, 3-hydroxypentyl, 2-carboxybutyl, 4-chlorobutyl, 3-cyclopropylpropyl, pentafluoroethyl, 3-morpholinopropyl, piperazinylmethyl, and  
25 2-(4-methylpiperazinyl)ethyl.

Examples of substituted alkynyl groups include 2-methoxyethynyl, 2-ethylsulfanyethynyl, 4-(1-piperazinyl)-3-(butynyl), 3-phenyl-5-hexynyl, 3-diethylamino-3-butynyl, 4-chloro-3-butynyl, 4-cyclobutyl-4-hexenyl, and the like.

-65-

Typical substituted alkoxy groups include aminomethoxy, trifluoromethoxy, 2-diethylaminoethoxy, 2-ethoxycarbonylethoxy, 3-hydroxypropoxy, 6-carboxhexyloxy, and the like.

Further, examples of substituted alkyl, alkenyl, and alkynyl groups include  
5 dimethylaminomethyl, carboxymethyl, 4-dimethylamino-3-buten-1-yl, 5-ethylmethylamino-3-pentyn-1-yl, 4-morpholinobutyl, 4-tetrahydropyridinylbutyl, 3-imidazolidin-1-ylpropyl, 4-tetrahydrothiazol-3-yl-butyl, phenylmethyl, 3-chlorophenylmethyl, and the like.

The terms "Ar" and "aryl" refer to unsubstituted and substituted aromatic  
10 groups. Heteroaryl groups have from 4 to 10 ring atoms which are carbon atoms, and from 1 to 4 of which are independently selected from the group consisting of O, S, and N. Preferred heteroaryl groups have 1 or 2 heteroatoms in a 5- or 6-membered aromatic ring. Mono and bicyclic aromatic ring systems are included in the definition of aryl and heteroaryl. Typical aryl and heteroaryl groups include  
15 phenyl, 3-chlorophenyl, 2,6-dibromophenyl, pyridyl, 3-methylpyridyl, benzothienyl, 2,4,6-tribromophenyl, 4-ethylbenzothienyl, furanyl, 3,4-diethylfuranyl, naphthyl, 4,7-dichloronaphthyl, morpholinyl, indolyl, benzotriazolyl, indazolyl, pyrrole, pyrazole, imidazole, thiazole, and the like.

Preferred Ar groups are phenyl and phenyl substituted by 1, 2, or 3 groups  
20 independently selected from the group consisting of alkyl, alkoxy, thio, thioalkyl, 1H-tetrazol-5-yl, halo, hydroxy, -COOR<sup>6</sup>, trifluoromethyl, nitro, amino of the formula -NR<sup>4</sup>R<sup>5</sup>, and T(CH<sub>2</sub>)<sub>m</sub>QR<sup>4</sup> or T(CH<sub>2</sub>)<sub>m</sub>CO<sub>2</sub>R<sup>4</sup> wherein m is 1 to 6, T is O, S, NR<sup>4</sup>, N(O)R<sup>4</sup>, NR<sup>4</sup>R<sup>5</sup>Y, or CR<sup>4</sup>R<sup>5</sup>, Q is O, S, NR<sup>5</sup>, N(O)R<sup>5</sup>, or NR<sup>4</sup>R<sup>5</sup>Y wherein R<sup>4</sup> and R<sup>5</sup> are as described above, and R<sup>6</sup> is hydrogen, alkyl, or substituted alkyl, for example, methyl, trichloroethyl, diphenylmethyl, and the  
25 like. The alkyl and alkoxy groups can be substituted as defined above. For example, typical groups are carboxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl, hydroxyalkoxy, and alkoxyalkyl. Typical substituted aryl groups include 2,6-dichlorophenyl, 3-methoxyphenyl, 4-trifluoromethylphenyl, 4-styrylphenyl, 3-amino-4-nitrophenyl, 3,5-dihydroxyphenyl, and the like.  
30

-66-

Most preferred aryl is phenyl, 4- or 3-methoxy-phenyl, 4-fluorophenyl, and 3-fluorophenyl, and each of 3,4-disubstituted phenyls wherein the substituents are methoxy and fluoro.

Most preferred heteroaryl is pyridin-4-yl or 2-methoxypyridin-4-yl.

5        The phrase "tertiary organic amine" means a trisubstituted nitrogen group wherein the 3 substituents are independently selected from C<sub>1</sub>-C<sub>12</sub> alkyl, C<sub>3</sub>-C<sub>12</sub> cycloalkyl, benzyl, or wherein two of the substituents are taken together with the nitrogen atom to which they are attached to form a 5- or 6-membered, monocyclic heterocycle containing one nitrogen atom and carbon atoms, and the  
10       third substituent is selected from C<sub>1</sub>-C<sub>12</sub> alkyl and benzyl, or wherein the three substituents are taken together with the nitrogen atom to which they are attached to form a 7- to 12-membered bicyclic heterocycle containing 1 or 2 nitrogen atoms and carbon atoms, and optionally a C=N double bond when 2 nitrogen atoms are present. Illustrative examples of tertiary organic amine include  
15       triethylamine, diisopropylethylamine, benzyl diethylamino, dicyclohexylmethylamine, 1,8-diazabicyclo[5.4.0]undec-7-ene ("DBU"), 1,4-diazabicyclo[2.2.2]-octane ("TED"), and 1,5-diazabicyclo[4.3.0]non-5-ene.

      The term "coupling agent" includes any reagent, or any combination of two, three, or four reagents, conventionally used to promote coupling of a  
20       carboxylic acid, or a pharmaceutically acceptable salt thereof, with an alcohol or an amine to yield a carboxylic ester or carboxylic amide, respectively. The coupling agents are described in *Reagents for Organic Synthesis* by Fieser and Fieser, New York: John Wiley & Sons, Inc., 2000; *Comprehensive Organic Transformations* by Richard C. Larock, New York: VCH Publishers, Inc., 1989;  
25       the series *Compendium of Organic Synthetic Methods* by Wiley-Interscience, 1989; and the text *Advanced Organic Chemistry*, 5<sup>th</sup> edition, by Jerry March, New York: Wiley-Interscience, 2001. Illustrative examples of coupling agents include N,N'-carbonyldiimidazole ("CDI"), N, N'-dicyclohexylcarbodiimide ("DCC"), triphenylphosphine with diethylazodicarboxylate, bis(2-oxo-  
30       3-oxazolidinyl)phosphinic chloride ("BOP-Cl"), POCl<sub>3</sub>, Ti(Cl)<sub>4</sub>, and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride ("EDAC").

The phrase "acid catalyst" means any protic or Lewis acid that is conventionally used to catalyze coupling of a carboxylic acid, or a pharmaceutically acceptable salt thereof, a nitrile, carboxylic ester, carboxylic amide, carboxylic acid halide, or carboxylic acid anhydride with an alcohol or an amine to yield a carboxylic ester or carboxylic amide, respectively. The acid catalysts are described in Fieser and Fieser, *supra.*, 2000; Larock RC, *supra.*, 1989; Wiley-Interscience, *supra.*, 1989; and March J, *supra.*, 2001. Illustrative examples include anhydrous hydrogen chloride, hydrochloric acid, hydrogen bromide in acetic acid, zinc chloride, titanium tetrachloride, acetic acid, trifluoroacetic acid, phenol, sulfuric acid, methanesulfonic acid, magnesium sulfate, Amberlyst-15 resin, silica gel, and the like.

It should be appreciated that a nitrile may be contacted with an alcohol or an amine in the presence of an acid catalyst, and the resulting intermediate imidate or amidine, respectfully, may be contacted with water to yield the carboxylic ester or carboxylic amide, respectively.

The phrase "base catalyst" means any base that is conventionally used to catalyze coupling of a carboxylic acid, or a pharmaceutically acceptable salt thereof, carboxylic ester, carboxylic amide, carboxylic acid halide, or carboxylic acid anhydride with an alcohol or an amine to yield a carboxylic ester or carboxylic amide, respectively. The base catalysts are described in Fieser and Fieser, *supra.*, 2000; Larock RC, *supra.*, 1989; Wiley-Interscience, *supra.*, 1989; and March J, *supra.*, 2001. Illustrative examples include sodium hydroxide, sodium hydride, potassium *tert*-butoxide, a tertiary organic amine, titanium tetraisopropoxide, sodium methoxide, sodium acetate, sodium bicarbonate, potassium carbonate, basic alumina, and the like.

The phrase "acid halide" means any carboxylic acid halide or sulfonic acid halide that is conventionally used to catalyze coupling of a carboxylic acid, or a pharmaceutically acceptable salt thereof, with an alcohol or an amine to yield a carboxylic ester or carboxylic amide, respectively. The acid halides are described in Fieser and Fieser, *supra.*, 2000; Larock RC, *supra.*, 1989; Wiley-Interscience, *supra.*, 1989; and March J, *supra.*, 2001. Illustrative examples include acetyl chloride, trifluoromethanesulfonyl chloride, 2,2-dimethylacetyl bromide, *para*-toluenesulfonyl chloride, pentafluoro-benzoyl chloride, and the like.

-68-

The phrase "acid anhydride" means any carboxylic acid anhydride or sulfonic acid anhydride that is conventionally used to catalyze coupling of a carboxylic acid, or a pharmaceutically acceptable salt thereof, with an alcohol or an amine to yield a carboxylic ester or carboxylic amide, respectively. The acid anhydrides are described in Fieser and Fieser, *supra.*, 2000; Larock RC, *supra.*, 1989; Wiley-Interscience, *supra.*, 1989; and March J, *supra.*, 2001. Illustrative examples include acetic anhydride, trifluoroacetic anhydride, trifluoromethanesulfonic acid anhydride, pentafluoro-benzoic anhydride, mixed anhydrides like trifluoroacetyloxycarbonylmethyl, and the like.

The term "halide" includes fluoride, chloride, bromide, and iodide.

The phrase "coupling catalyst" means any metal catalyst, preferably a transition metal catalyst, that is conventionally used to catalyze coupling of an aryl halide, aryl trifluoromethanesulfonate, heteroaryl halide, or heteroaryl trifluoromethanesulfonate, or activated derivatives thereof, including arylboronic acids, heteroarylboronic acids, aryl stannanes, heteroarylstannanes, aryl magnesium halides, heteroaryl magnesium halides, aryl lithiums, or heteroaryl lithiums, with an terminal alkyne to yield an arylalkyne or heteroarylalkyne. The coupling catalysts are described in Fieser and Fieser, *supra.*, 2000; Larock RC, *supra.*, 1989; Wiley-Interscience, *supra.*, 1989; and March J, *supra.*, 2001. Illustrative examples of coupling catalysts include tetrakis(triphenylphosphine)-palladium (0), palladium (II) chloride, palladium (II) acetate, iron (III) chloride, Heck reaction catalysts, Suzuki reaction catalysts, Stille reaction catalysts, and the like.

The group  $\text{—}\overset{\text{(O)}}{\underset{\text{||}}{\text{S}}}\text{—}^{0-2}$  means  $\text{—S—}$ ,  $\text{—}\overset{\text{O}}{\underset{\text{||}}{\text{S}}}\text{—}$ , or  $\text{—}\overset{\text{O}}{\underset{\text{||}}{\text{S}}}\text{—}\overset{\text{O}}{\underset{\text{||}}{\text{S}}}\text{—}$ .

The phrase "pharmaceutical composition" means a composition suitable for administration in medical or veterinary use.

The term "admixed" and the phrase "in admixture" are synonymous and mean in a state of being in a homogeneous or heterogeneous mixture. Preferred is a homogeneous mixture.

The term "patient" means a mammal. Preferred patients are humans, cats, dogs, cows, horses, pigs, and sheep.



-69-

The term "animal" means a mammal, as defined above. Preferred animals include humans, cats, dogs, horses, pigs, sheep, cows, monkeys, rats, mice, guinea pigs, and rabbits.

5       The phrase "anticancer effective amount" means an amount of invention compound, or a pharmaceutically acceptable salt thereof, sufficient to inhibit, halt, or cause regression of the cancer being treated in a particular patient or patient population. For example in a human or other mammal, an anticancer effective amount can be determined experimentally in a laboratory or clinical setting, or may be the amount required by the guidelines of the United States Food and Drug  
10       Administration, or equivalent foreign agency, for the particular cancer and patient being treated.

15       The phrase "antiarthritic effective amount" means an amount of invention compound, or a pharmaceutically acceptable salt thereof, sufficient to inhibit, halt, or cause regression of the arthritis being treated in a particular patient or patient population. For example in a human or other mammal, an antiarthritic effective amount can be determined experimentally in a laboratory or clinical setting, or may be the amount required by the guidelines of the United States Food and Drug Administration, or equivalent foreign agency, for the particular arthritis and patient being treated.

20       The phrase "MMP-13 inhibiting amount" means an amount of invention compound, or a pharmaceutically acceptable salt thereof, sufficient to inhibit an enzyme matrix metalloproteinase-13, including a truncated form thereof, including a catalytic domain thereof, in a particular animal or animal population. For example in a human or other mammal, an MMP-13 inhibiting amount can be  
25       determined experimentally in a laboratory or clinical setting, or may be the amount required by the guidelines of the United States Food and Drug Administration, or equivalent foreign agency, for the particular MMP-13 enzyme and patient being treated.

30       It should be appreciated that determination of proper dosage forms, dosage amounts, and routes of administration, is within the level of ordinary skill in the pharmaceutical and medical arts, and is described below.

      The phrases "effective amount" and "therapeutically effective amount" are synonymous and mean an amount of a compound of the present invention, a



-70-

pharmaceutically acceptable salt thereof, or a solvate thereof, sufficient to effect an improvement of the condition being treated when administered to a patient suffering from a disease that is mediated by MMP-13 and optionally from 0 to 12 additional MMP enzymes.

5           The term "IC<sub>50</sub>" means the concentration of test compound required to inhibit activity of a biological target, such as a receptor or enzyme, by 50%.

It should be appreciated that the matrix metalloproteinases include the following enzymes:

10           MMP-1, also known as interstitial collagenase, collagenase-1, or fibroblast-type collagenase;  
MMP-2, also known as gelatinase A or 72 kDa Type IV collagenase;  
MMP-3, also known as stromelysin or stromelysin-1;  
MMP-7, also known as matrilysin or PUMP-1;  
MMP-8, also known as collagenase-2, neutrophil collagenase, or  
15           polymorphonuclear-type ("PMN-type") collagenase;  
MMP-9, also known as gelatinase B or 92 kDa Type IV collagenase;  
MMP-10, also known as stromelysin-2;  
MMP-11, also known as stromelysin-3;  
MMP-12, also known as metalloelastase;  
20           MMP-13, also known as collagenase-3;  
MMP-14, also known as membrane-type ("MT") 1-MMP or MT1-MMP;  
MMP-15, also known as MT2-MMP;  
MMP-16, also known as MT3-MMP;  
MMP-17, also known as MT4-MMP;  
25           MMP-18; and  
MMP-19.

Other MMPs include MMP-26, also known as matrilysin-2.

30           One aspect of the present invention is novel compounds that are selective inhibitors of the enzyme MMP-13. A selective inhibitor of MMP-13, as used in the present invention, is a compound that is  $\geq 5$  times more potent *in vitro* versus MMP-13 than versus at least one other matrix metalloproteinase enzyme such as, for example, MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, or MMP-14,

-71-

or versus tumor necrosis factor alpha convertase ("TACE"). A preferred aspect of the present invention is novel compounds that are selective inhibitors of MMP-13 versus MMP-1. Other aspects of the present invention are compounds that are  $\geq 10$ ,  $\geq 20$ ,  $\geq 50$ ,  $\geq 100$ , or  $\geq 1000$  times more potent *in vitro* versus MMP-13 than  
5 versus at least one other MMP enzyme or TACE.

Still other aspects of the present invention are compounds of Formula I, or a pharmaceutically acceptable salt thereof, that are selective inhibitors of MMP-13 versus 2, 3, 4, 5, 6, or 7 other MMP enzymes, or versus TACE and 1, 2, 3, 4, 5, 6, or 7 other MMP enzymes.

10 Some of the compounds in the present invention may exist as stereoisomers, including enantiomers, diastereomers, and geometric isomers. Geometric isomers include compounds of the present invention that have alkenyl groups, which may exist as *entgegen* or *zusammen* conformations, in which case all geometric forms thereof, both *entgegen* and *zusammen*, *cis* and *trans*, and  
15 mixtures thereof, are within the scope of the present invention. Some compounds of the present invention have cycloalkyl groups, which may be substituted at more than one carbon atom, in which case all geometric forms thereof, both *cis* and *trans*, and mixtures thereof, are within the scope of the present invention. All of these forms, including (R), (S), epimers, diastereomers, *cis*, *trans*, *syn*, *anti*, (E),  
20 (Z), and mixtures thereof, are contemplated in the invention compounds of Formulas I to XI.

The compounds to be used in the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms, including hydrated forms, are equivalent to unsolvated forms and are  
25 intended to be encompassed within the scope of the present invention.

The compounds of Formulas I through XI are capable of further forming both pharmaceutically acceptable salts, including but not limited to acid addition and/or base salts. This invention also provides pharmaceutical compositions comprising a compound of Formula I together with a pharmaceutically acceptable  
30 carrier, diluent, or excipient therefor. All of these forms can be used in the method of the present invention.

Pharmaceutically acceptable acid addition salts of the compounds of Formula I include salts derived from inorganic acids such as hydrochloric, nitric,

phosphoric, sulfuric, hydrobromic, hydriodic, phosphorus, and the like, as well as the salts derived from organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanolic acids, hydroxy alkanolic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such salts thus  
5 include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate,  
10 toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like. Also contemplated are the salts of amino acids such as arginate, gluconate, galacturonate, and the like; see, for example, Berge et al., "Pharmaceutical Salts," *J. of Pharmaceutical Science*, 1977;66:1-19.

The acid addition salts of the basic compounds are prepared by contacting  
15 the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner. The free base form may be regenerated by contacting the salt form with a base and isolating the free base in the conventional manner. The free base forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are  
20 equivalent to their respective free base for purposes of the present invention.

Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metal hydroxides, or of organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N'-dibenzylethylenediamine,  
25 chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine, and procaine; see, for example, Berge et al., supra., 1977.

The base addition salts of acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the  
30 salt form with an acid and isolating the free acid in a conventional manner. The free acid forms differ from their respective salt forms somewhat in certain

-73-

physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention.

The compounds of the present invention can be formulated and administered in a wide variety of oral and parenteral dosage forms, including transdermal and rectal administration. All that is required is that an MMP inhibitor be administered to a mammal suffering from a disease in an effective amount, which is that amount required to cause an improvement in the disease and/or the symptoms associated with such disease. It will be recognized to those skilled in the art that the following dosage forms may comprise as the active component, either a compound of Formula I or a corresponding pharmaceutically acceptable salt or solvate of a compound of Formula I.

A compound of Formula I, or a pharmaceutically acceptable salt thereof, may be prepared by one of ordinary skill in the art of organic chemistry by procedures found in the chemical literature such as, for example, Fieser and Fieser, *supra.*, 2000; Larock RC, *supra.*, 1989; Wiley-Interscience, *supra.*, 1989; March J, *supra.*, 2001; or the *Handbook of Heterocyclic Chemistry* by Alan R. Katritzky, London: Pergamon Press Ltd., 1985, to name a few. Alternatively, a skilled artisan may find methods useful for preparing the invention compounds in the chemical literature by searching widely available databases such as, for example, those available from the *Chemical Abstracts Service*, Columbus, Ohio, or *MDL Information Systems GmbH* (formerly *Beilstein Information Systems GmbH*), Frankfurt, Germany.

Preparations of the compounds of the present invention may use starting materials, reagents, solvents, and catalysts that may be purchased from commercial sources or they may be readily prepared by adapting procedures in the references or resources cited above. Commercial sources of starting materials, reagents, solvents, and catalysts useful in preparing invention compounds include, for example, *The Aldrich Chemical Company*, and other subsidiaries of Sigma-Aldrich Corporation, St. Louis, Missouri, *BACHEM*, BACHEM A.G., Switzerland, or *Lancaster Synthesis Ltd.*, United Kingdom.


Fieser and Fieser, *supra.*, 2000; Larock RC, *supra.*, 1989; Wiley-Interscience, *supra.*, 1989; March J, *supra.*, 2001; and Katritzky AR, *supra.*, 1985, are hereby incorporated by reference.

-74-

The invention compounds are prepared by methods well known to those skilled in the art of organic chemistry. The compounds of Formula I are prepared utilizing commercially available starting materials, or reactants that are readily prepared by standard organic synthetic techniques. A typical synthesis of the invention compounds of Formula I is shown in Scheme 1 below. The first step in Scheme 1 comprises reacting a chlorouracil analog with 2-mercapto acetate ester, The reaction generally is carried out in a solvent such as an alkanol, for example ethanol, and in the presence of a base such as sodium carbonate. The reaction is usually substantially complete after about 2 to 6 hours when carried out at an elevated temperature of about 40°C to about 80°C. The product, an alkylthio substituted tetrahydro pyrimidine, can be isolated and purified if desired, or can be used directly in the next step. The next step is a cyclization reaction (Vilsmeier reaction). The alkylthio substituted tetrahydro pyrimidine is reacted with POCl<sub>3</sub> in a polar solvent such as dimethylformamide or dimethylsulfoxide to effect cyclization to the corresponding tetrahydro-thieno[2,3-*d*]pyrimidine-2,4-dione. The thienopyrimidinone can be further modified by standard procedures, for example alkylation at the 1-position by reaction with an alkylating agent R<sup>4</sup>L, where L is a leaving group such as chloro or bromo, and R<sup>4</sup> is as defined above. Ester groups can be hydrolyzed by reaction with a base such as sodium hydroxide, and carboxylic groups can be esterified by standard procedures such as reaction with an alcohol R<sup>3</sup>OH in the presence of an acid such as hydrochloric acid, or in the presence of a coupling reagent such as DCC (dicyclohexylcarbodiimide) and CMC (1-cyclohexyl-3-(2-morpholinoethyl)carbodiimide metho-p-toluenesulfonate). Carboxylic acid groups can be converted to amides by standard methods, for example by first reaction with oxalyl chloride to form an acid chloride, and then reaction of the acid chloride with an amine of the formula HNR<sup>4</sup>R<sup>5</sup>.

-75-

Scheme 1



Scheme 2 illustrates the synthesis of compounds of Formula 1 starting from a benzyl alkanoylacetate, which reacts with a cyanoacetic acid ester; in the


-76-

presence of powdered sulfur (when X is S) and a base such as morpholine to give an amino substituted heterocycle. This condensation typically is carried out by combining the reactants in a solvent such as methanol or ethanol, and generally is complete within about 2 to 10 hours when carried out at an elevated temperature of about 40°C to 60°C. The 5-benzyloxycarbonyl-2-amino-substituted heterocycle (e.g., thiophene when X is S, furan when X is O, and pyrrole when X is NH) is next reacted with an isocyanate ( $R^1NCO$ ) to effect cyclization to form the pyrimidinone ring. This cyclization reaction is carried out by mixing the reactants in a solvent such as dioxane in the presence of a strong base such as sodium hydride. The cyclization is generally complete within about 8 to 24 hours when carried out at a temperature of about 24°C to 60°C. The product, a compound of Formula I wherein  $R^4$  is H, can be alkylated or arylated by reaction with an alkyl or aryl halide ( $R^4L$ , where L is a leaving group such as chloro or bromo). The invention compound can be further modified by standard methods, for instance by hydrolyzing the ester; forming group  $R^3$  to give the corresponding acid (where  $R^3 = H$ ), and then re-esterifying or amidating by reaction with an amine in the presence of a coupling agent such as DCC or CMC.



-77-


Scheme 2



5 Scheme 3 illustrates reaction of a 4-alkoxycarbonyl-5-amino thiozole (where X is S) with an isocyanate in the presence of a strong base such as sodium hydride to form the 6-member pyrimidinone ring. The unsubstituted ring nitrogen can be alkylated or arylated by standard reactions, for example by reactions with a alkylating agent  $\text{R}^4\text{L}$ , where L is a leaving group such as halo.


-78-

Scheme 3



-79-


Scheme 4



The corresponding sulfoxide and sulfone analogs can be prepared in the same fashion.

5


Scheme 5



The corresponding ester and amide analogs can be prepared in the same fashion.


-80-

Scheme 6



The corresponding ester and amide analogs can be prepared in the same fashion.


Scheme 7



The corresponding ester and amide analogs can be prepared in the same fashion.

-81-


Scheme 8



The corresponding ester and amide analogs can be prepared in the same fashion.

The alkynes can be prepared in a conventional manner as illustrated in Scheme 9. In Scheme 9, an aryl iodide (or, optionally, an aryl bromide, aryl chloride, or aryl trifluoromethanesulfonate) is coupled to a terminal alkyne in the presence of a palladium catalyst, cuprous (I) iodide, and a base such as a tertiary amine base.

Scheme 9




wherein  $R$  and  $R'$  independently are hydrogen or from 1 to 3 substituents as defined above for substituted phenyl.

The following detailed examples further illustrate the synthesis of typical invention compounds of Formula I. The examples are representative only, and are not to be construed as limiting the invention in any respect.

-82-

## Preparation 1




(1-Benzyl-2,6-dioxo-1,2,3,6-tetrahydro-pyrimidin-4-ylsulfanyl)-acetic acid ethyl ester

5 To 250 mL of ethanol in a round bottom flask was added 3-benzyl-6-chloro-1*H*-pyrimidine-2,4-dione (11.55 g, 48.94 mmol); sodium carbonate (5.19 g, 48.94 mmol), and mercapto-acetic acid ethyl ester (6.47 g, 53.83 mmol). The mixture is stirred at reflux for 5 hours. The reaction solution is filtered, and the filtrate is chromatographed on a silica gel column, eluting with 4:1 Hexane/  
10 Ethyl Acetate (400 mL) followed by 1000 mL of 4:1 Dichloromethane/Ethyl Acetate. Removing the solvents by vacuum yielded 10.5 g of white powder identified as the titled product (67%). <sup>1</sup>H NMR (DMSO),  $\delta$  1.16 (t, *J* = 7.1 Hz, 3H), 4.06 (s, 2H), 4.12 (q, *J* = 7.1 Hz, 2H), 4.88 (s, 2H), 5.54 (s, 1H), 7.22-7.30 (m, 5H), 11.71 (broad s, 1H). MS (APCI-), *m/z* 321 (*M*<sup>+</sup>).

15

## Preparation 2



3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid ethyl ester


To a solution of (1-benzyl-2,6-dioxo-1,2,3,6-tetrahydro-pyrimidin-4-ylsulfanyl)-acetic acid ethyl ester from Preparation 1 (6.37 g, 19.8 mmol) in anhydrous DMF (60 mL) was added POCl<sub>3</sub> (9.11 g, 59.5 mmol) dropwise. The  
20 reaction is then stirred at room temperature overnight, and then heated to 70°C for 30 minutes. The reaction is cooled to room temperature and poured into 600 mL of

-83-

stirring ice water. The product is filtered and washed with water to yield 6.2 g (95%) very light yellow powder as the titled compound.  $^1\text{H}$  NMR (DMSO),  $\delta$  1.27 (t,  $J = 7.1$  Hz, 3H), 4.26 (q,  $J = 7.1$  Hz, 2H), 5.00 (s, 2H), 7.19-7.29 (m, 5H), 7.76 (s, 1H), 12.6 (broad s, 1H). MS (APCI-),  $m/z$  331 ( $\text{M}^+$ ).

5

## Preparation 3




3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid

To a solution of 3-benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid ethyl ester from Preparation 2 (2.9 g, 8.79 mmol) in a solution of 90% THF:10% water (v/v) was added lithium hydroxide (3.69 g, 87.9 mmol). The solution is refluxed for 2 hours. The solvent was removed by vacuum, and the residual was diluted with water (100 mL). HCl was added until the solution has a pH of 1. The solution was extracted with ethyl acetate (3  $\times$  100 mL). The combined organic layer was concentrated to yield 2.62 g of white powder as product (96%).  $^1\text{H}$  NMR (DMSO),  $\delta$  4.99 (s, 2H), 7.19-7.29 (m, 5H), 7.68 (s, 1H). MS (APCI-),  $m/z$  331 ( $\text{M}^+$ ).

15

## Preparation 4



3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-*d*]pyrimidine-6-carboxylic acid

20

Step (1): Thiophene-2,5-dicarboxylic acid diethyl ester

To a solution of 2,5-thiophene dicarboxylic acid (5.0 g, 29 mmol) in methanol (100 mL) was added sulfuric acid (1.0 mL), and the reaction was



-84-

refluxed for 72 hours. The mixture was then concentrated under reduced pressure. The crude residue was diluted with ethyl acetate (250 mL), and the mixture was washed with water (3 × 100 mL). The organic phase was dried (MgSO<sub>4</sub>) and concentrated to yield 6.52 g (98%) of thiophene-2,5-dicarboxylic acid diethyl ester as an orange oil.

Step (2): 3-Nitro-thiophene-2,5-dicarboxylic acid diethyl ester

To a chloroform solution (40 mL) of the product of Step (1) (6.52 g, 28.6 mmol) and trifluoroacetic anhydride (20 mL) was slowly added copper (II) nitrate hemipentahydrate (7.31 g, 31.5 mmol), and the reaction mixture was heated to 60°C over 4 hours. The reaction mixture was poured into ice (200 g), and was extracted with chloroform (2 × 150 mL). The chloroform layers were combined, dried (MgSO<sub>4</sub>), filtered, and concentrated. The resulting orange oil residue was purified by flash chromatography on silica gel (eluting with cyclohexane:ethyl acetate, 4:1) to yield 4.61 g (60%) of 3-nitro-thiophene-2,5-dicarboxylic acid diethyl ester as a yellow solid.

Step (3): 3-Amino-thiophene-2,5-dicarboxylic acid diethyl ester

A solution of the product of Step (2) (4.61 g, 16.9 mmol) in ethanol (20 mL) was hydrogenated over 10% Pd-C (460 mg, 10 wt %) in a Parr shaker at 200 psi over 48 hours at 60°C. The catalyst was then filtered off, and the filtrate was concentrated under vacuum, and the resulting residue was purified by flash chromatography on silica gel (cyclohexane:ethyl acetate, 4:1) to yield 3.20 g (78%) of 3-amino-thiophene-2,5-dicarboxylic acid diethyl ester as a white solid.

Step (4): 3-(3-Benzyl-ureido)-thiophene-2,5-dicarboxylic acid diethyl ester

A pyridine solution (10 mL) of the product of Step (3) (2.06 mmol, 500 mg), benzylisocyanate (2.06 mmol, 255 µL), and 4-(dimethylamino)pyridine (0.41 mmol, 50 mg) was heated to 90°C for 48 hours. The reaction mixture was then concentrated under reduced pressure, and the residue was purified by flash chromatography on silica gel (4:1:5 cyclohexane:ethyl acetate:toluene) to yield 599 mg (77%) of 3-(3-benzyl-ureido)-thiophene-2,5-dicarboxylic acid diethyl ester as a white solid.


Step (5): 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidine-6-carboxylic acid

-85-

To a solution of the product of Step (4) (1.57 mmol, 590 mg) in ethanol (15 mL) was added sodium ethoxide (3.14 mmol, 214 mg), and resulting solution was refluxed for 4 hours. The reaction mixture was then allowed to reach room temperature, and lithium hydroxide (3.9 mmol, 94 mg) was added. The reaction mixture was stirred for 17 hours and concentrated under reduced pressure to afford a crude product. The crude product was dissolved in 1.0M hydrochloric acid (10 mL). The resulting white precipitate was collected, washed with water (3 × 10 mL), cold acetonitrile (3 × 5 mL), and dried under vacuum to yield 336 mg (71%) of 3-benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidine-6-carboxylic acid as a white solid.

## EXAMPLE 1

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester




A dichloromethane (30 mL) solution of 3-benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (0.8 g, 2.65 mmol) from Preparation 3, 1-cyclohexyl-3-(2-morpholinoethyl)carbodiimide metho-*p*-toluenesulfonate (CMC, 1.35 g, 3.18 mmol), and benzyl alcohol (0.32 g, 2.91 mmol) is refluxed for 3 hours. The solution is then diluted with dichloromethane (100 mL) and washed with water (3 × 100 mL). The organic layer is concentrated and purified by chromatography over a silica gel column using 2:1 Hexane:Ethyl Acetate to yield 120 mg of white solid as product (12%). MP: 195-197°C; <sup>1</sup>H NMR (CDCl<sub>3</sub>), δ 5.18 (s, 2H), 5.33 (s, 2H), 7.26-7.49 (m, 10H), 8.03 (s, 1H), 10.84 (s, 1H). MS (APCI-), *m/z* 303 (M<sup>+</sup>). Calcd for C<sub>21</sub>H<sub>16</sub>N<sub>2</sub>O<sub>4</sub>S: C, 64.27; H, 4.11; N, 7.14.

-86-

Found: C, 64.24; H, 3.80; N, 7.04.

## EXAMPLE 2

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid pyridin-4-ylmethyl ester




5

The procedure of Example 1 was repeated, except that benzyl alcohol is replaced with 4-pyridyl methyl alcohol to provide 3-benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*] pyrimidine-6-carboxylic acid pyridin-4-ylmethyl ester as a white powder. (32%). MP: 248-250°C; <sup>1</sup>H NMR (DMSO), δ 5.00 (s, 2H), 5.36 (s, 2H), 7.22-7.34 (m, 5H), 7.41 (d, J = 5.7 Hz, 2H), 7.91 (s, 1H), 8.57 (d, J = 5.7 Hz, 2H), 12.62 (broad s, 1H). MS (APCI-), *m/z* 394 (M<sup>+</sup>).

10

## EXAMPLE 3

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl amide



15


The procedure of Example 1 was repeated, except that benzyl alcohol is replaced with benylamine, to provide 3-benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl amide as a white solid (20%). MP: >255°C; <sup>1</sup>H NMR (CDCl<sub>3</sub>), δ 4.53 (s, 2H), 4.90 (s, 1H), 5.17 (s, 2H), 7.16-7.41 (m, 10H), 7.77 (s, 1H). MS (APCI-), *m/z* 392 (M<sup>+</sup>).

20

-87-

## EXAMPLE 4


3-Benzy-2,4,dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6 carboxylic acid  
4-((E)-styryl-benzyl ester



5 The procedure of Example 1 was repeated, except that benzyl alcohol is replaced with [4-((E)-styryl-phenyl]-methanol, to give 3-benzy-2,4,dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-((E)-styryl-benzyl ester as a white solid. MP: 247-249°C; <sup>1</sup>H NMR (d<sub>8</sub>-THF), δ 10.85 (bd s, 1H), 7.91 (s, 1H), 7.58-7.19 (m, 16H), 5.31 (s, 2H), 5.08 (s, 2H). MS m/z 495.3 (m+1), m/z  
10 493.3 (m-1).

## EXAMPLE 5

5-Methyl-2,4-dioxo-3-phenylethyl-1,2,3,4-tetrahydro-thieno[2,3-*d*] pyrimidine-6-carboxylic acid benzyl ester



15 To a stirred solution of the 5-amino-3-methyl-thiophene-2,4-dicarboxylic acid 2-benzyl ester 4-ethyl ester in dioxane (0.5 g, 1.57 mmol) was added NaH (0.042 g, 1.72 mmol). The mixture was further stirred until no more hydrogen gas was evolved and then 2-isocyanato-ethyl-benzene (0.23 g, 1.57 mmol) was added slowly. The resulting mixture was refluxed under nitrogen until the reaction was  
20 complete by MS and TLC. The dioxane was removed by rotary evaporation. The reaction mixture was then purified by flash column chromatography eluting with

-88-

4:1 (Hex:EtOAc), 2:1 (Hex:EtOAc), and 1:1 (Hex:EtOAc) sequentially. The fractions containing the product were collected and concentrated to yield a white solid which was triterated with 4:1 (Hex:EtOAc). 5-Methyl-2,4-dioxo-3-phenylethyl-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester was collected by filtration and dried in a vacuum oven overnight.

Calcd for  $C_{23}H_{20}N_2O_4$ :

C, 65.70; H, 4.79; N, 6.66.


Found: C, 64.90; H, 4.82; N, 6.42.

MP: 207-209°C;  $^1H$  NMR ( $d_1$ - $CDCl_3$ ),  $\delta$  9.35 (s, 1H), 7.52-7.21 (m, 10H),

5.33 (s, 2H), 4.19 (t, 2H,  $J = 8$  Hz), 2.95 (t, 2H,  $J = 8$  Hz), 1.55 (s, 3H). MS  $m/z$  467.3 ( $m+1$ ),  $m/z$  465.2 ( $m-1$ ).

#### EXAMPLE 6

3-(4-Acetyl-phenyl)-5-methyl-2,4 dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;




The procedure of Example 5 was repeated, except that 2-isocyanato-ethylbenzene is replaced with 4-isocyanatoacetophenone to give 3-(4-acetyl-phenyl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester as an off white solid.  $^1H$  NMR ( $d_1$ - $CDCl_3$ ),  $\delta$  8.84 (s, 1H), 8.11 (d, 2H,  $J = 9$  Hz) 7.41-7.25 (m, 7H), 5.34 (s, 2H), 2.84 (s, 3H), 2.64 (s, 3H). MS  $m/z$  435.2 ( $m+1$ ),  $m/z$  434.2 ( $m-1$ ).

#### EXAMPLE 7

5-Methyl-2,4-dioxo-3-p-tolyl-1,2,3,4-tetrahydro-thieno[2,3-*d*]-6-carboxylic acid benzyl ester

-89-




When in the procedure of Example 5, 2-isocyanato-ethyl-benzene is replaced with 4-tolyl isocyanate, 5-methyl-2,4-dioxo-3-tolyl-1,2,3,4-tetrahydro-thieno[2,3-*d*]-6-carboxylic acid benzyl ester is obtained as a white solid.

5 MP 267-269°C;  $^1\text{H}$  NMR ( $\text{d}_1\text{-CDCl}_3$ ),  $\delta$  8.79 (s, 1H), 7.41-6.99 (m, 9H), 5.33 (s, 2H), 2.84 (s, 3H), 2.40 (s, 3H). MS  $m/z$  407.2 ( $m+1$ ),  $m/z$  405.3 ( $m-1$ ).

#### EXAMPLE 8

5-Methyl-3-(4-nitro-phenyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]-6-carboxylic acid benzyl ester



10


The procedure of Example 5 was repeated, except that 2-isocyanato-ethyl-benzene is replaced with 4-nitrophenyl isocyanate to give 5-methyl-3-(4-nitro-phenyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]-6-carboxylic acid benzyl ester as a yellow solid.  $^1\text{H}$  NMR ( $\text{d}_6\text{-DMSO}$ ),  $\delta$  9.64 (s, 1H), 8.31 (d, 2H,  $J = 9$  Hz), 7.62 (d, 2H,  $J = 9$  Hz), 7.44-7.35 (m, 5H), 5.30 (s, 2H), 2.70 (s, 3H). MS  $m/z$  436.1 ( $m-1$ ).

15

#### EXAMPLE 9

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester

-90-



To a solution of 3-benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]-pyrimidine-6-carboxylic acid benzyl ester (300 mg, 0.765 mmol) in DMF was added NaH (46 mg, 1.5 mmol). After 5 minutes, MeI (0.15 mL, 2.3 mmol) was added, and the reaction mixture was stirred at room temperature for 30 minutes. After removal of all volatiles, the residue was purified using flash chromatography to give the desired product as a white solid (204 mg, 66%).  $R_f = 0.51$

(2:1 hexane/EtOAc). MP: 143-145°C.


Calcd for  $C_{22}H_{18}N_2O_4S$ :

C, 65.01; H, 4.46; N, 6.89.

Found: C, 64.61; H, 4.31; N, 6.74.

#### EXAMPLE 10

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1,3-benzodioxol-5-ylmethyl ester




The procedure of Example 1 was repeated, except that benzyl alcohol is replaced with benzo[1,3]dioxol-5-yl-methanol to give 3-benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1,3-benzodioxol-5-ylmethyl ester as a white solid.  $^1H$  NMR (dg-THF),  $\delta$  10.86 (s, 1H), 7.89 (s, 1H), 6.80-7.49 (m, 8H), 5.96 (s, 2H), 5.21 (s, 2H), 5.09 (s, 2H). MS (APCI-),  $m/z$  393.2 ( $M^+ + 1$ ).



-91-

## EXAMPLE 11

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl amide



5 A dichloromethane (30 mL) solution of 3-benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (367 mg, 1.16 mmol), CMC (392 g, 0.92 mmol), and benzylamine (149 mg, 1.39 mmol) is refluxed for 3 hours. The solution is then diluted with dichloromethane (100 mL) and washed with water (3 × 100 mL). The organic layer is concentrated and  
 10 purified by chromatography over a silica gel column using 1:1 Hexane:Ethyl Acetate to yield 200 mg of white solid as product. <sup>1</sup>H NMR (d<sub>8</sub>-THF), δ 9.23 (t, 1H), 8.11 (s, 1H), 7.20-7.38 (m, 10H), 5.04 (s, 2H), 4.43 (s, 2H), 3.46 (s, 3H). MS (APCI-), *m/z* 406.1 (M<sup>+</sup>+1).

## EXAMPLES 12-14

15 By following the general procedures of Examples 1 through 11, the following invention compounds were prepared:

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-phenylethyl ester;


20 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid furan-3-ylmethyl ester; and

3-Benzyl-2, 4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid furfuryl-(5-carboxaldehyde) ester (also known as 3-benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 5-formyl-furan-2-ylmethyl ester).

-92-

## EXAMPLE 15


3-(3-Methoxycarbonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester



5 To a solution of 1-methoyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester (0.2 g, 0.63 mmol) in anhydrous DMF was added cesium carbonate (0.31 g, 0.945 mmol) and 3-bromomethyl-benzoic acid methyl ester (0.145 g, 0.63 mmol). The reaction was stirred at room temperature for overnight. Poured into water (150 mL) and extracted with EtOAc.  
10 The organic layer washed with water and brine, dried over  $\text{MgSO}_4$  and then filtered. The filtrate was concentrated *in vacuo*. Triterating the residue with 4:1 Hexane/EtOAc yielded a white solid as the desired product (40%). MS (APCI+),  $m/z$  465.1( $\text{M}^+$ )

## EXAMPLE 16

15 3-(3-Methoxycarbonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester




The procedure of Example 15 was repeated, except 3-bromomethyl-benzoic acid methyl ester is replaced by 1-chloromethyl-4-methylsulfanyl-benzene, to give 3-(3-methoxycarbonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester as an off white  
20 solid (50%). MS (APCI+),  $m/z$  453 ( $\text{M}^+$ ).

-93-

## EXAMPLE 17


3-Benzofuran-5-ylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester



5           The procedure of Example 15 was repeated, except 3-bromomethyl-benzoic acid methyl ester is replaced by 5-bromomethyl-benzofuran. Instead of trituration, the crude product was chromatographed using 8:1 Hexane/EtOAc to 4:1 Hexane/EtOAc to give 3-benzofuran-5-ylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester as a white solid  
10 (57%). MS (APCI+),  $m/z$  447 (M+).

## EXAMPLE 18

1-Methyl-3-(4-methyl-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester




15           The procedure of Example 15 was repeated, except 3-bromomethyl-benzoic acid methyl ester is replaced by 1-ethyl-4-methyl-benzene, to give 1-methyl-3-(4-methyl-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester as an off white solid (50%). MS (APCI+),  $m/z$  421 (M+).

20

## EXAMPLE 19

3-(4-Acetylamino-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester


-94-



The procedure of Example 15 was repeated, except 3-bromomethylbenzoic acid methyl ester is replaced by *N*-(4-chloromethyl-phenyl)-acetamide, to give 3-(4-Acetyl-amino-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester as an off white solid (57%). MS (APCI+), *m/z* 464 (M+).

## EXAMPLE 20

1-Methyl-2,4-dioxo-3-(4-vinyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester




The procedure of Example 15 was repeated, except 3-bromomethylbenzoic acid methyl ester is replaced by 1 ethyl-4-vinyl-benzene. Instead of trituration, the crude product was chromatographed using 8:1 Hexand/EtOAc to 4:1 Hexand/EtOAc to give 1-methyl-2,4-dioxo-3-(4-vinyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester as a white solid (73%). MS (APCI+), *m/z* 433 (M+).

## EXAMPLE 21

1-Methyl-2,4-dioxo-3-(4-sulfamoyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester


-95-



The procedure of Example 15 was repeated, except 3-bromomethylbenzoic acid methyl ester is replaced by 4-bromomethyl-benzenesulfonamide. Instead of trituration, the crude product was chromatographed using 2:1  
 5 Hexand/EtOAc to 100% EtOAc to give 1-methyl-2,4-dioxo-3-(4-sulfamoylbenzyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester as a white solid (60%). MS (APCI+), *m/z* 486 (M+).

## EXAMPLE 22

3-(4-Bromo-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-  
 10 carboxylic acid pyridin-4-ylmethyl ester




The procedure of Example 15 was repeated, except 3-bromomethylbenzoic acid methyl ester is replaced by 4-ethylbenzoic acid methyl ester, to give  
 15 3-(4-bromo-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid pyridin-4-ylmethyl ester as an off white solid (82%). MS (APCI+), *m/z* 465 (M+).

## EXAMPLE 23

1-Methyl-2,4-dioxo-3-phenethyl-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-  
 carboxylic acid benzyl ester


-96-



The procedure of Example 15 was repeated, except 3-bromomethyl-benzoic acid methyl ester is replaced by (2-bromo-ethyl)-benzene, to give 1-methyl-2,4-dioxo-3-phenethyl-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester as an off white solid (50%). MS (APCI+),  $m/z$  421 (M+).

## EXAMPLE 24

1-Methyl-2,4-dioxo-3-[4-(2H-tetrazol-5-yl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester




To a solution of 3-(4-cyano-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (0.615 g, 1.42 mmol) in 10 mL of dioxane was added tributyltin azide (0.71 g, 2.14 mmol). The reaction solution was refluxed overnight. After removing the solvent *in vacuo*, the residue was dissolved in ether and HCl gas was bubbled in for 1 hour. The precipitant was filtered, dissolved in chloroform and chromatographed using EtOAc and THF. The fractions were collected and concentrated. The residue was triturated with 4:1 Hexand/EtOAc, to yield the 1-methyl-2,4-dioxo-3-[4-(2H-tetrazol-5-yl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester as a white solid (20%). MS (APCI),  $m/z$  473 (M-).

-97-

## EXAMPLE 25


3-(4-Fluoro-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid pyridin-4-ylmethyl ester



5 The procedure of Example 2 was repeated, except the 3-benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid was replaced by 3-(4-fluoro-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid made using 4-fluorobenzyl in place of benzyl during the synthesis outlined in preparation 1-3, to give 3-(4-fluoro-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid pyridin-4-ylmethyl ester as  
10 a pink solid. MS (APCI+),  $m/z$  412 ( $M^+$ ).

## EXAMPLE 26

3-(4-*tert*-butoxycarbonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester




15 The procedure of Example 15 was repeated, except 3-bromomethylbenzoic acid methyl ester is replaced by 4-bromomethylbenzoic acid *tert*-butyl ester, to 3-(4-*tert*-butoxycarbonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester as a white solid  
20 (70%). MS (APCI+),  $m/z$  493 ( $M^+$ ).

## EXAMPLE 27

3-(4-*tert*-butoxycarbonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid



-98-




5 To a solution of 3-(4-*tert*-butoxycarbonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester (0.5 g, 0.98 mmol) in 40 mL of 10:1 THF/water, was added 0.24 g of LiOH. Reaction was stirred at room temperature for 5 hours. THF was removed in reduced pressure, and 50 mL of water was added along with 150 mL of EtOAc. The solution is then acidified by HCl and shaken. The organic layer was washed by water and brine, and concentrated to yield 3-(4-*tert*-butoxycarbonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid as an off white solid (66%). MS (APCI<sup>+</sup>), *m/z* 417 (M<sup>+</sup>).

10

## EXAMPLE 28

4-[6-(4-Fluoro-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-benzoic acid



15 To a solution of 3-(4-*tert*-butoxycarbonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (0.2 g, 0.48 mmol) and Mukiyama reagent (0.147 g, 0.57 mmol) in 6 mL of CH<sub>2</sub>Cl<sub>2</sub> was added Et<sub>3</sub>N (0.116 g, 1.14 mmol) and 4-fluorobenzyl amine (0.065 g, 0.52 mmol). The reaction solution was stirred at room temperature for overnight. The reaction solution was then chromatographed using 4:1 Hexane/EtOAc. The isolated product was then concentrated and dissolved in 5 mL of TFA. After stirring at room temperature for 30 minutes, the solution was concentrated and triturated using 4:1 Hexane/EtOAc to yield 4-[6-(4-fluoro-benzylcarbamoyl)-1-methyl-2,4-


20

-99-

dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-benzoic acid as a white solid (77%). MS (APCI+),  $m/z$  468 ( $M^+$ ).

## EXAMPLE 29


4-[6-(4-Dimethylamino-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-benzoic acid; compound with trifluoro-acetic acid



The procedure of Example 28 was repeated, 4-fluorobenzyl amine is replaced by (4-ethyl-phenyl)-dimethyl-amine, to give 4-[6-(4-dimethylamino-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-benzoic acid; compound with trifluoro-acetic acid as an off white solid (15%). MS (APCI+),  $m/z$  549 ( $M^+$ ).

## EXAMPLE 30


4-[6-(2-Ethoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-3-ylmethyl]-benzoic acid



The procedure of Example 28 was repeated, 4-fluorobenzyl amine is replaced by 1-ethoxy-2-ethyl-benzene, to give 4-[6-(2-ethoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-3-ylmethyl]-benzoic acid as an off white solid (20%). MS (APCI+),  $m/z$  494 ( $M^+$ ).


-100-

## EXAMPLE 31

1-Methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid

1-Methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester (4.45 g, 14.1 mmol) was put in 100 mL of HBr in Acetic acid. The solution was stirred at room temperature for overnight. The precipitant was filtered and washed with excess water to yield 1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid as a white solid (2.89 g). MS (APCI+),  $m/z$  227 (M+).

## EXAMPLE 32


1-Methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide

To a suspension of 1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (1.25 g, 5.53 mmol) in 50 mL of 2:1 CH<sub>2</sub>Cl<sub>2</sub>/THF was added HOBt (0.821 g, 6.08 mmol), 4-methyl morpholine (2.79 g, 27.6 mmol), 4-methoxy benzyl amine (0.91 g, 6.63 mmol) and EDAC (1.27 g, 6.631 mmol) in that order. The reaction is stirred at room temperature for overnight, and then was acidified by 5% HCl. The reaction was diluted with 100 mL of CH<sub>2</sub>Cl<sub>2</sub> and was shaken. The precipitant was filtered and washed with 100 mL of 5% HCl and 100 mL of 5% NaHCO<sub>3</sub> to yield 1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide as a white solid (79%). MS (APCI+),  $m/z$  346 (M+).

-101-

## EXAMPLE 33

1-Methyl-2,4-dioxo-3-[4-(1H-tetrazol-5-yl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide




5 To a solution of 1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (0.58 g, 2.07 mmol) in DMF was added cesium carbonate (0.68 g, 2.08 mmol) and 5-(4-bromomethyl-phenyl)-2-phenyl-2*H*-tetrazole (1.0 g, 2.08 mmol). The solution was stirred overnight at room temperature. 170 mL of water was then added, causing precipitation. The  
10 precipitant was filtered and then stirred in excess TFA at room temperature for overnight, concentrated and washed with Hexane and ether to give 3-(3-methoxycarbonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester as an off white solid (61%). MS (APCI+), *m/z* 504 (M+).

15

## EXAMPLE 34

1-Methyl-3-[4-(morpholine-4-sulfonyl)-benzyl]-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide



20


To a solution of 1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide (0.3 g, 0.87 mmol) in 50 mL of DMF was added cesium carbonate (0.283 g, 0.87 mmol) and 4-(4-bromomethyl-benzenesulfonyl)-morpholine (0.287 g, 0.87 mmol). The reaction was then stirred at room temperature overnight. The solution was then poured into

-102-

500 mL of water and extracted with EtOAc. The organic layer was washed with water and brine, dried over  $\text{MgSO}_4$  and concentrated. The residue was triturated with 4:1 Hexane/EtOAc to yield 1-methyl-3-[4-(morpholine-4-sulfonyl)-benzyl]-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide as a white solid (66%). MS (APCI+),  $m/z$  585 ( $\text{M}^+$ ).

## EXAMPLE 35


1-Methyl-3-[4-(morpholine-4-carbonyl)-benzyl]-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide



The procedure of Example 34 was repeated, except 4-(4-bromomethyl-benzenesulfonyl)-morpholine is replaced by 1-(4-bromomethyl-phenyl)-1-morpholin-4-yl-methanone, to give 1-methyl-3-[4-(morpholine-4-carbonyl)-benzyl]-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide as an off white solid (25%). MS (APCI+),  $m/z$  459 ( $\text{M}^+$ ).

## EXAMPLE 36

3-But-2-ynyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide




The procedure of Example 34 was repeated, except 4-(4-bromomethyl-benzenesulfonyl)-morpholine is replaced by 1-bromo-but-2-yne, to give 3-but-2-ynyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic

-103-

acid 3-methoxy-benzylamide as an off white solid (97%). MS (APCI+),  $m/z$  398 (M+).

## EXAMPLE 37


1-Methyl-2,4-dioxo-3-[3-(1*H*-tetrazol-5-yl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide



The procedure of Example 33 was repeated, except 5-(4-bromomethyl-phenyl)-2-phenyl-2*H*-tetrazole is replaced by except 5-(3-bromomethyl-phenyl)-2-phenyl-2*H*-tetrazole, to give 1-methyl-2,4-dioxo-3-[3-(1*H*-tetrazol-5-yl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide as an off white solid (70%). MS (APCI+),  $m/z$  504 (M+).

## EXAMPLE 38

3-(4-Cyano-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide




The procedure of Example 34 was repeated, except 4-(4-bromomethyl-benzenesulfonyl)-morpholine is replaced by 4-bromomethyl benzonitril, to give 3-(4-cyano-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide as an off white solid (70%). MS (APCI+),  $m/z$  431 (M-).

-104-

## EXAMPLE 39

{4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-phenyl}-acetic acid




5 The procedure of Example 33 was repeated, except 5-(4-bromomethyl-phenyl)-2-phenyl-2*H*-tetrazole is replaced by (4-bromomethyl-phenyl)-acetic acid *tert*-butyl ester, to give {4-[6-(3-methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-phenyl}-acetic acid as a white solid (70%). MS (APCI+), *m/z* 494 (M+).

10

## EXAMPLE 40

3-[2-(2,4-Dichloro-benzenesulfonyl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide




15 The procedure of Example 34 was repeated, except 4-(4-bromomethyl-benzenesulfonyl)-morpholine is replaced by 2,4-dichloro-1-(2-chloro-ethanesulfonyl)-benzene, to 3-[2-(2,4-dichloro-benzenesulfonyl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide as a white solid. MS (APCI+), *m/z* 582 (M+)



-105-

## EXAMPLE 41

3-(4-Methanesulfonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide




5           The procedure of Example 34 was repeated, except 4-(4-bromomethyl-benzenesulfonyl)-morpholine is replaced by 1-chloromethyl-4-methanesulfonyl-benzene, to give 3-(4-methanesulfonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide as a white solid. MS (APCI+), *m/z* 514 (M<sup>+</sup>)

10

## EXAMPLE 42

1-Methyl-2,4-dioxo-3-(4-sulfamoyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide



15


The procedure of Example 34 was repeated, except 4-(4-bromomethyl-benzenesulfonyl)-morpholine is replaced by 4-bromomethyl-benzenesulfonamide, to give 1-methyl-2,4-dioxo-3-(4-sulfamoyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide as a white solid. MS (APCI+), *m/z* 515 (M<sup>+</sup>)

## EXAMPLE 43

20

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide


-106-



The procedure of Example 34 was repeated, except 4-(4-bromomethyl-benzenesulfonyl)-morpholine is replaced by benzylbromide, and the amide starting material was a 2-methoxy-pyridine-4-yl methyl amide, to give 3-benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide as a white solid (30%). <sup>1</sup>H NMR (DMSO), δ 3.47 (s, 3H), 3.81 (s, 3H), 4.41 (d, *J* = 7.0 Hz, 2H), 5.03 (s, 2H), 6.66 (s, 1H), 6.88 (d, *J* = 4.9 Hz, 1H), 7.21-7.36 (m, 5H), 8.08 (d, *J* = 7.0 Hz, 2H), 8.14 (s, 1H), 9.27 (t, *J* = 7.0 Hz, 1H).

## EXAMPLE 44

1-Methyl-3-(4-methylsulfamoyl-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide




The procedure of Example 34 was repeated, except 4-(4-bromomethyl-benzenesulfonyl)-morpholine is replaced by 4-bromomethyl-*N*-methyl-benzenesulfonamide, to give 1-methyl-3-(4-methylsulfamoyl-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide as a white solid. <sup>1</sup>H NMR (DMSO), δ 2.37 (d, *J* = 5.0 Hz, 3H), 3.47 (s, 3H), 3.72 (s, 3H), 4.41 (d, *J* = 5.9 Hz, 2H), 5.12 (s, 2H), 6.80-6.87 (m, 3H), 7.24 (t, *J* = 8.0 Hz, 1H), 7.40-7.51 (m, 3H), 7.69 (d, *J* = 8.0 Hz, 2H), 8.13 (s, 1H), 9.21 (t, *J* = 5.7 Hz, 1H).

-107-

### EXAMPLE 45


**3-(4-Isopropylsulfamoyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide**



The procedure of Example 34 was repeated, except 4-(4-bromomethyl-benzenesulfonyl)-morpholine is replaced by 4-bromomethyl-*N*-isopropyl-benzenesulfonamide, to give 3-(4-isopropylsulfamoyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide as a white solid. <sup>1</sup>H NMR (DMSO), δ 0.92 (d, *J* = 6.6 Hz, 6H), 3.48 (s, 3H), 3.72 (s, 3H), 4.41 (d, *J* = 5.8 Hz, 2H), 5.12 (s, 2H), 6.80-6.87 (m, 3H), 7.24 (t, *J* = 8.1 Hz, 1H), 7.46-7.55 (m, 3H), 7.71 (d, *J* = 8.0 Hz, 2H), 8.13 (s, 1H), 9.21 (t, *J* = 5.7 Hz, 1H).

### EXAMPLE 46

15 1-Methyl-2,4-dioxo-3-[4-(pyrrolidine-1-sulfonyl)-benzyl]-1,2,3,4-tetrahydro-  
thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide




The procedure of Example 34 was repeated, except 4-(4-bromomethyl-benzenesulfonyl)-morpholine is replaced by 1-(4-bromomethyl-benzenesulfonyl)-pyrrolidine, to give 1-methyl-2,4-dioxo-3-[4-(pyrrolidine-1-sulfonyl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide as a white solid. <sup>1</sup>H NMR (DMSO), δ 1.64 (m, 4H), 3.11 (m, 4H), 3.49 (s, 3H), 3.73 (s, 3H), 4.42 (d, *J* = 5.8 Hz, 2H), 5.14 (s, 2H), 6.83-6.88 (m,

-108-

3H), 7.24 (m, 1H), 7.53 (d,  $J = 8.1$ , 2H), 7.73 (d,  $J = 8.0$  Hz, 2H), 8.13 (s, 1H), 9.21 (t,  $J = 5.7$  Hz, 1H).

## EXAMPLE 47


1-Methyl-3-[4-(4-methyl-piperidine-1-sulfonyl)-benzyl]-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide



The procedure of Example 34 was repeated, except 4-(4-bromomethyl-benzenesulfonyl)-morpholine is replaced by 1-(4-bromomethyl-benzenesulfonyl)-4-methyl-piperidine, to give 1-methyl-3-[4-(4-methyl-piperidine-1-sulfonyl)-benzyl]-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide as a white solid.  $^1\text{H}$  NMR (DMSO),  $\delta$  0.83 (d,  $J = 5.4$  Hz, 3H), 1.15 (m, 2H), 1.28 (s, 1H), 1.62 (d,  $J = 12.7$  Hz, 2H), 2.16 (t,  $J = 12.3$  Hz, 2H), 3.49 (s, 3H), 3.58 (d,  $J = 10.5$  Hz, 2H), 3.73 (s, 3H), 4.43 (d,  $J = 5.1$  Hz, 2H), 5.15 (s, 2H), 6.81-6.87 (m, 3H), 7.24 (m, 1H), 7.53 (d,  $J = 7.1$ , 2H), 7.66 (d,  $J = 6.8$  Hz, 2H), 8.14 (s, 1H), 9.23 (t,  $J = 5.7$  Hz, 1H).

## EXAMPLE 48

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzofuran-2-ylmethyl ester




-109-

To a solution of 3-benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (0.2 g, 0.63 mmol) and Mukiyama reagent (0.194 g, 0.76 mmol) in 6 mL of CH<sub>2</sub>Cl<sub>2</sub> was added Et<sub>3</sub>N (0.154 g, 1.52 mmol) and benzofuran-2-yl-methanol (0.103 g, 0.696 mmol). The reaction solution was stirred at room temperature for overnight. The reaction solution was then chromatographed using 4:1 Hexand/EtOAc, to yield 3-benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzofuran-2-ylmethyl ester as a white solid (135 mg, 48%). MS (APCI+), *m/z* 447 (M<sup>+</sup>).

## EXAMPLE 49

3-(4-Bromo-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid pyridin-4-ylmethyl ester




The procedure of Example 2 was repeated, except the 3-benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid was replaced by 3-(4-bromo-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid made using 4-bromo in place of benzyl during the synthesis outlined in preparation 1-3, to give 3-(4-bromo-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid pyridin-4-ylmethyl ester as an off white solid. MS (APCI+), *m/z* 472 (M<sup>+</sup>).

## EXAMPLE 50

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-methoxy-benzyl ester



-110-



The procedure of Example 1 was repeated, except that benzyl alcohol is replaced by 4-methoxy benzyl alcohol to provide 3-benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-methoxy-benzyl ester as a white powder (30 mg, 10%). MS (APCI+),  $m/z$  423 ( $M^+$ ).

## EXAMPLE 51

4-{1-Methyl-2,4-dioxo-6-[(pyridin-4-ylmethyl)-carbamoyl]-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl}-benzoic acid; compound with trifluoro-acetic acid




The procedure of Example 28 was repeated, except that 4-fluorobenzyl amine is replaced by (4-methylamino) pyridine, to give 4-{1-methyl-2,4-dioxo-6-[(pyridin-4-ylmethyl)-carbamoyl]-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl}-benzoic acid; compound with trifluoro-acetic acid as an off white solid (82%). MS (APCI+),  $m/z$  451 ( $M^+$ ).

## EXAMPLE 52

4-[6-(4-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-benzoic acid


-111-



The procedure of Example 28 was repeated, except that 4-fluorobenzyl amine is replaced by 4-methoxy benzyl amine, to give 4-[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-benzoic acid as an off white solid (38%). MS (APCI+), *m/z* 480 (M+).

## EXAMPLE 53

4-[6-(3,4-Dimethoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-benzoic acid *tert*-butyl ester




To a solution of 3-(4-*tert*-butoxycarbonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (0.15 g, 0.36 mmol) and Mukiyama reagent (0.11 g, 0.43 mmol) in 6 mL of CH<sub>2</sub>Cl<sub>2</sub> was added Et<sub>3</sub>N (0.87 g, 87 mmol) and 3,4-dimethoxy benzyl amine (0.067 g, 0.39 mmol). The reaction solution was stirred at room temperature for overnight. The reaction solution was then chromatographed using 4:1 Hexane/EtOAc, to yield 4-[6-(3,4-dimethoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-benzoic acid *tert*-butyl ester as a white solid (78%). MS (APCI+), *m/z* 567 (M+).

## EXAMPLE 54

4-[6-(3,4-Dimethoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-benzoic acid




-112-



4-[6-(3,4-Dimethoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-benzoic acid *tert*-butyl ester (0.1 g, 0.176 mmol) was dissolved in 5 mL of TFA. The solution was stirred at room temperature for 30 minutes then concentrated. The residue was triturated with 4:1 Hexane/EtOAc to yield 4-[6-(3,4-dimethoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-benzoic acid as a white solid (65 mg, 73%). MS (APCI+), *m/z* 510 (*M*<sup>+</sup>).

## EXAMPLE 55

4-[6-(4-Bromo-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-benzoic acid




The procedure of Example 28 was repeated, except that 4-fluorobenzyl amine is replaced by 4-bromobenzyl amine, to give 4-[6-(4-bromobenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-benzoic acid as an off white solid (55%). MS (APCI+), *m/z* 530 (*M*<sup>+</sup>).

## EXAMPLE 56

4-[6-(4-Bromo-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-benzoic acid *tert*-butyl ester


-113-



The procedure of Example 53 was repeated, except that 3,4-dimethoxy benzyl amine is replaced by 4-bromobenzyl amine, to give 4-[6-(4-bromo-  
benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-  
ylmethyl]-benzoic acid *tert*-butyl ester as an off white solid (71%). MS (APCI-),  
*m/z* 584 (M-).

## EXAMPLE 57

4-[6-(3,5-Bis-trifluoromethyl-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-  
2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-benzoic acid




The procedure of Example 28 was repeated, except that 4-fluorobenzyl amine is replaced by 3,5-*bis*-trifluoromethyl benzyl amine, to give 4-[6-(3,5-*bis*-  
trifluoromethyl-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-  
thieno[2,3-*d*]pyrimidin-3-ylmethyl]-benzoic acid as an off white solid (65%). MS  
(APCI+), *m/z* 586 (M+).

## EXAMPLE 58

4-[6-(4-Chloro-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-  
*d*]pyrimidin-3-ylmethyl]-benzoic acid


-114-



The procedure of Example 28 was repeated, 4-fluorobenzyl amine is replaced by 4-chlorobenzyl amine, to give 4-[6-(4-chloro-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-benzoic acid as an off white solid (39%). MS (APCI+), *m/z* 484 (M+).

## EXAMPLE 59


4-[1-Methyl-2,4-dioxo-6-(4-sulfamoyl-benzylcarbamoyl)-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-benzoic acid



The procedure of Example 28 was repeated, except that 4-fluorobenzyl amine is replaced by 4-aminoethyl-benzenesulfonamide, to give 4-[1-methyl-2,4-dioxo-6-(4-sulfamoyl-benzylcarbamoyl)-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-benzoic acid as an off white solid (41%). MS (APCI+), *m/z* 529 (M+).

## EXAMPLE 60

3-(4-Fluoro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide




-115-

The procedure of Example 34 was repeated, except that 4-(4-bromomethyl-benzenesulfonyl)-morpholine is replaced by 1-bromomethyl-4-fluoro-benzene, and 1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide is replaced by 1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide, to give 3-(4-fluoro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide as an off white solid (65%). MS (APCI+), *m/z* 454 (M+).

## EXAMPLE 61


3-(4-Iodo-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide



The procedure of Example 34 was repeated, except that 4-(4-bromomethyl-benzenesulfonyl)-morpholine is replaced by 1-bromomethyl-4-iodo-benzene, to give 3-(4-iodo-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide as an off white solid (27%). MS (APCI+), *m/z* 562 (M+).

## EXAMPLE 62

3-(4-Dimethylsulfamoyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide




-116-

The procedure of Example 34 was repeated, except that 4-(4-bromomethyl-benzenesulfonyl)-morpholine is replaced by 4-bromomethyl-*N,N*-dimethyl-benzenesulfonamide, and 1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide is replaced by  
 5 1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide, to give 3-(4-dimethylsulfamoyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide as an off white solid (67%). MS (APCI+), *m/z* 543 (M+).

## EXAMPLE 63

10 3-(3-Methoxy-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide




The procedure of Example 34 was repeated, except that 4-(4-bromomethyl-benzenesulfonyl)-morpholine is replaced by 3-methoxy  
 15 benzylbromide, and 1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide is replaced by 1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide, to give 3-(3-methoxy-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide as  
 20 an off white solid (83%). MS (APCI+), *m/z* 5466 (M+).

## EXAMPLE 64

3-(4-Cyano-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide


-117-



The procedure of Example 34 was repeated, except that 4-(4-bromomethyl-benzenesulfonyl)-morpholine is replaced by 4-cyanobenzyl bromide, and 1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide is replaced by 1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide, to give 3-(4-cyano-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide as an off white solid (97%). MS (APCI+), *m/z* 461 (M+).

#### EXAMPLE 65

3-(4-Acetylamino-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide




The procedure of Example 34 was repeated, except that 4-(4-bromomethyl-benzenesulfonyl)-morpholine is replaced by *N*-(4-chloromethyl-phenyl)-acetamide, to give 3-(4-acetylamino-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide as an off white solid (42%). MS (APCI+), *m/z* 493 (M+).

#### EXAMPLE 65a

5-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-furan-2-carboxylic acid ethyl ester


-118-



The procedure of Example 34 was repeated, except that 4-(4-bromomethyl-benzenesulfonyl)-morpholine is replaced by 5-chloromethyl-furan-2-carboxylic acid ethyl ester, to give 5-[6-(3-methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-furan-2-carboxylic acid ethyl ester as an off white solid (41%). MS (APCI+),  $m/z$  498 ( $M^+$ ).

## EXAMPLE 66

3-(4-Cyano-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzyl ester




The procedure of preparation 2 was repeated, except that 3-benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid ethyl ester is replaced by [1-(4-cyano-benzyl)-2,6-dioxo-1,2,3,6-tetrahydro-pyrimidine-4-sulfanyl-acetic acid 3-methoxy-benzyl ester, to yield 3-(4-cyano-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzyl ester as an off white solid (91%).  $^1\text{H}$  NMR (DMSO),  $\delta$  3.74 (s, 3H), 5.07 (s, 2H), 5.28 (s, 2H), 6.91 (d,  $J = 8.2$  Hz, 1H), 6.99 (d,  $J = 3.0$  Hz, 2H), 7.30 (t,  $J = 8.0$  Hz, 1H), 7.47 (d,  $J = 7.7$  Hz, 2H), 7.75 (d,  $J = 8.0$  Hz, 2H), 7.83 (s, 1H), 12.68 (s, 1H).



-119-

## EXAMPLE 67


2,4-Dioxo-3-[4-(2H-tetrazol-5-yl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzyl ester



5 The procedure of Example 24 was repeated, except that 3-(4-cyano-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzyl ester is replaced by 3-(4-cyano-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester, to give 2,4-dioxo-3-[4-(2H-tetrazol-5-yl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzyl ester as an off white solid (7%). MS (APCI+), *m/z* 491 (M<sup>+</sup>).

## EXAMPLE 68

4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-benzoic acid 2-dimethylamino-ethyl ester




15 To a solution of 4-[6-(3-methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-benzoic acid (100 mg, 0.289 mmol) in 50 mL of 2:1 CH<sub>2</sub>Cl<sub>2</sub>/THF, was added HOBt (43 mg, 0.32 mmol), 4-methyl morpholine (146 g, 1.44 mmol), 2-dimethylamino-ethanol

-120-

(28 mg, 0.318 mmol) and EDAC (66.5 mg, 0.347 mmol) in that order. The reaction is stirred at room temperature for overnight, and directly chromatographed with 10:1 CH<sub>2</sub>Cl<sub>2</sub>/MeOH. The crude product was then triturated with 4:1 Hexane/EtOAc to yield 4-[6-(3-methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-benzoic acid 2-dimethylamino-ethyl ester as a white powder (89%). MS (APCI+), *m/z* 551 (M<sup>+</sup>).

## EXAMPLE 69


3-Cylcohexylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid-3-methoxy-benzylamide



The procedure of Example 34 was repeated, except that 4-(4-bromomethyl-benzenesulfonyl)-morpholine is replaced by bromomethyl-cyclohexane, to give 3-cylcohexylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide as a white solid (62%). MS (APCI+), *m/z* 442 (M<sup>+</sup>).

## EXAMPLE 70

3-cylcohexylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid-4-methoxy-benzylamide



-121-

The procedure of Example 69 was repeated, except that 1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide is replaced by 1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide, to give 3-cylcohexylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide as a white solid (80%). MS (APCI+), *m/z* 442 (M+).

## EXAMPLE 71

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid furan-3-ylmethyl ester

The title compound was prepared according to the procedure of Example 1; MS (M+1) 383.2.

## EXAMPLE 72

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid pentafluorophenylmethyl ester

The title compound was prepared according to the procedure of Example 28; MS (M+1) 497.4.

## EXAMPLE 73

3-Benzyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester

The title compound was prepared according to the procedure of Example 9; mp 147-148°C.

## EXAMPLE 74

3-Benzyl-1-cyclopropylmethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester

The title compound was prepared according to the procedure of Example 9; MS (M+1) 447.1.

-122-

## EXAMPLE 75

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (pyridin-4-ylmethyl)-amide

5 The title compound was prepared according to the procedure of Example 28; MS (M+1) 407.1.

## EXAMPLE 76

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-bromo-benzyl ester

10 The title compound was prepared according to the procedure of Example 1; MS (M+1) 485.2.

## EXAMPLE 77

4-[6-(3-Difluoromethoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid

15 The title compound was prepared according to the procedure of Example 28; MS (M+1) 516.1.

## EXAMPLE 78

4-[6-(3-Difluoromethoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid tert-butyl ester

20 The title compound was prepared according to the procedure of Example 15; MS (M-C<sub>4</sub>H<sub>9</sub>) 516.1.

## EXAMPLE 79

4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid

25 The title compound was prepared according to the procedure of Example 28; MS (M+1) 480.1.

## EXAMPLE 80

4-[6-(4-Methanesulfonyl-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid tert-butyl ester

-123-

The title compound was prepared according to the procedure of Example 15; <sup>1</sup>H-NMR (CDCl<sub>3</sub>, d): 7.90 (m, 3H), 7.75 (d, 2H), 7.40 (m, 4H), 5.19 (s, 2H), 4.63 (d, 2H), 3.59 (s, 3H), 3.02 (s, 3H), 1.58 (s, 9H).

## EXAMPLE 81

5 4-[6-(4-Methanesulfonyl-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid

The title compound was prepared according to the procedure of Example 28; MS (M+1) 528.1.

## EXAMPLE 82

10 4-[1-Methyl-2,4-dioxo-6-(2-pyridin-4-yl-ethylcarbamoyl)-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid

The title compound was prepared according to the procedure of Example 28; MS (M+1) 465.1.

## EXAMPLE 83

15 1-Methyl-2,4-dioxo-3-(4-trifluoromethoxy-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide

The title compound was prepared according to the procedure of Example 15; MS (M+1) 520.1.

## EXAMPLE 84

20 4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid methyl ester

The title compound was prepared according to the procedure of Example 15; MS (M+1) 494.2.

## EXAMPLE 85

25 3-(2,3-Dihydro-benzofuran-6-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide

The title compound was prepared according to the procedure of Example 28; MS (M+1) 478.2.

-124-

## EXAMPLE 86

1-Methyl-3-(2-methyl-thiazol-5-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide

The title compound was prepared according to the procedure of Example 15; MS (M+1) 457.2.


## EXAMPLE 87

1-Methyl-2,4-dioxo-3-[4-(1H-tetrazol-5-yl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-fluoro-benzylamide

The title compound was prepared according to the procedure of Example 24; MS (M+1) 492.2.

## EXAMPLE 88

3-Benzyl-2-methoxy-4-oxo-3,4-dihydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester



To a solution of 3-benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester (550 mg, 1.27 mmol) was added  $\text{Me}_3\text{O}^+\text{BF}_3^-$  (376 mg, 2.54 mmol). The resulting yellow suspension was stirred at room temperature for 3 days, and MeOH was added to quench the reaction. After removal of volatile solvents *in vacuo*, the residue was purified using flash chromatography to give the desired product as a brownish oil. M+1 407.2.

## EXAMPLE 89

4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid 2,2-dimethyl-propionyloxymethyl ester

-125-

The title compound was prepared according to the procedure of Example 68; MS (M-CH<sub>3</sub>) 479.2.

## EXAMPLE 90

4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-cyclohexanecarboxylic acid

The title compound was prepared according to the procedure of Example 28; MS (M+1) 486.2.

## EXAMPLE 91

4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-cyclohexanecarboxylic acid methyl ester

The title compound was prepared according to the procedure of Example 15; MS (M+1) 500.1.

## EXAMPLE 92


1-{4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-phenyl}-cyclopropanecarboxylic acid methyl ester

The title compound was prepared according to the procedure of Example 15; MS (M+1) 534.2.

## EXAMPLE 93

1-{4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-phenyl}-cyclopropanecarboxylic acid *tert*-butyl ester

Step (1):




To a 0°C solution of the starting carboxylic acid (2.63 g, 14.9 mmol) in cyclohexane (100 mL) was added BF<sub>3</sub> etherate (0.18 mL, catalytic). White precipitate was observed. After the reaction was stirred for 1.5 hours, the reaction



-126-

was then filtered, and the filtrate was purified using a flash chromatography to give the desired ester as a colorless oil. 3.13 g, 90% yield.

Step (2):



5 The t-butyl ester (3.13 g, 13.5 mmol), NBS (2.88 g, 16.2 mmol), and a catalytic amount of AIBN (0.2 g) were dissolved in CCl<sub>4</sub> (100 mL). The solution was refluxed for 2 hours and cooled to room temperature. After filtration of the white precipitate, the filtrate was filtered, and the filtrate was purified using a flash chromatography to give the desired ester as an oil. 4.01 g, 96% yield. MS, 267.0, 269.0; <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ, 7.35 (m, 4H), 4.49 (s, 2H), 3.62 (s, 3H), 1.60 (m, 2H), 1.18 (m, 2H), 1.00-1.60 (m, 4H).

Step (3):

The title compound was prepared according to the procedure of Example 28; <sup>1</sup>H-NMR (CDCl<sub>3</sub>): δ 7.67 (s, 1H), 7.40 (d, 1H), 7.22 (2H), 6.85 (d, 3H), 6.40 (t, 1H), 5.18 (s, 2H), 4.59 (d, 2H), 3.80 (s, 3H), 3.58 (s, 3H), 1.40 (s, 9H).

#### EXAMPLE 94

1-{4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-phenyl}-cyclopropanecarboxylic acid

20 The title compound was prepared according to the procedure of Example 28; MS (M+1) 520.

#### EXAMPLE 95

25 2-{4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-phenoxy}-2-methyl-propionic acid tert-butyl ester

The title compound was prepared according to the procedure of Example 15; <sup>1</sup>H-NMR (CDCl<sub>3</sub>, d) 7.66 (s, 1H), 7.37 (d, 2H), 7.80 (m, 4H), 6.40

-127-

(t, 1H), 5.08 (s, 2H), 4.57 (d, 2H), 3.80 (s, 3H), 3.55 (s, 3H), 1.52 (s, 6H), 1.43 (s, 9H).


## EXAMPLE 96

2-{4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-phenoxy}-2-methyl-propionic acid

The title compound was prepared according to the procedure of Example 28; MS (M+1) 538.2.

## EXAMPLE 97

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-furo[2,3-d]pyrimidine-6-carboxylic acid benzyl ester



To a solution of the starting furano-pyrimidine-dione (265 mmg, 1.03 mmol) in THF at -78°C was added LiN(TMS)<sub>2</sub> (1.3 mmol). After 5 minutes, benzyl chloroformate (0.17 mL, 264 mg, 1.55 mmol) was added dropwise, and the reaction was warmed up to room temperature and quenched by aq. NH<sub>4</sub>Cl. Then extracted with EtOAc. The organic layer was washed with water and brine, dried over MgSO<sub>4</sub>. After removal of volatile solvents *in vacuo*, the residue was purified using flash chromatography to give the desired product as a brownish oil. M+1 257.1.

## EXAMPLE 98

3-(3-Methoxy-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

To a 0.1 M solution of 1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester in dimethylformamide was added

-128-

60% NaH in mineral oil (1.5 mol equivalents). After stirring for 20 minutes, 1 mL (0.1 mmol) of the reaction mixture was transferred to a 8 mL screw cap vial. To this was added a solution of 1-chloromethyl-3-methoxy-benzene (0.047 g, 0.3 mmol) in dimethylformamide (1 mL). The vial was capped, and the reaction mixture was shaken for 24 hours at room temperature. The reaction mixture was filtered, and the solvent was removed under vacuum. Purification was carried out via reverse-phase HPLC (3% n-propanol in acetonitrile and 3% n-propanol in water as the eluent; C-18 column). 0.023 g (50% yield). MS-APCI: (M + 1) = 437.486.

The procedure of Example 98 was used to prepare the compounds of Examples 99 to 145.

## EXAMPLE 99

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 407.4602 (The compound of Example 99 is the same as the compound of Example 147.)

## EXAMPLE 100

3-Biphenyl-4-ylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 483.5578

## EXAMPLE 101

3-(4-Methanesulfonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 485.551

## EXAMPLE 102

3-(4-Methanesulfonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 485.551

-129-

## EXAMPLE 103

1-Methyl-3-(4-methyl-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 421.487

5

## EXAMPLE 104

1-Methyl-2,4-dioxo-3-phenethyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 421.487

## EXAMPLE 105

10

3-(4-Amino-6-phenylamino-1,3,5-triazin-2-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 516.552

## EXAMPLE 106

15

1-Methyl-2,4-dioxo-3-(4-trifluoromethyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 475.457

## EXAMPLE 107

20

3-(6-Cyano-hexyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 426.507

## EXAMPLE 108

3-[2-(2,5-Dimethoxy-phenyl)-2-oxo-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 495.522

25

## EXAMPLE 109

3-(3-Iodo-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

-130-

MS-APCI (M+1) 533.352

## EXAMPLE 110

1-Methyl-2,4-dioxo-3-(3-trifluoromethyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

5 MS-APCI (M+1) 475.457

## EXAMPLE 111

3-(2,4-Bis-trifluoromethyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 543.454

## 10 EXAMPLE 112

3-[2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 490.506

## EXAMPLE 113

15 

3-[2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 490.506

## EXAMPLE 114

20 

3-(2-Carboxy-allyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 401.4094

## EXAMPLE 115

3-(2-Carboxy-allyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

25 MS-APCI (M+1) 401.4094

-131-

## EXAMPLE 116

3-(3-Amino-propyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 374.431

5

## EXAMPLE 117

3-(1,3-Dioxo-1,3-dihydro-isoindol-2-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 476.479

## EXAMPLE 118

10

3-(4-Fluoro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 425.45

## EXAMPLE 119

15

1-Methyl-3-oxiranylmethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 373.399

## EXAMPLE 120

20

1-Methyl-3-(2-methyl-butyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 387.47

## EXAMPLE 121

1-Methyl-2,4-dioxo-3-(4-phenoxy-butyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 465.54

25

## EXAMPLE 122

3-(2-Cyano-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

-132-

MS-APCI (M+1) 432.47

## EXAMPLE 123

1-Methyl-2,4-dioxo-3-(3-phenoxy-propyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

5 MS-APCI (M+1) 451.513

## EXAMPLE 124

3-Hex-5-enyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 399.481

10 EXAMPLE 125

1-Methyl-2,4-dioxo-3-pyridin-3-ylmethyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 408.448

## EXAMPLE 126

15 3-[2-Hydroxy-3-(naphthalen-1-yloxy)-propyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 517.572

## EXAMPLE 127

20 1,3-Dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 331.363

## EXAMPLE 128

3-Cyclobutylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

25 MS-APCI (M+1) 385.454



-133-

## • EXAMPLE 129

3-Allyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 357.4

5

## EXAMPLE 130

1-Methyl-2,4-dioxo-3-prop-2-ynyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 355.385

## EXAMPLE 131

10

3-But-2-ynyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 369.411

## EXAMPLE 132

15

1-Methyl-2,4-dioxo-3-(2-phenoxy-ethyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 437.486

## EXAMPLE 133

20

1-Methyl-2,4-dioxo-3-(2-phenoxy-ethyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 437.486

## EXAMPLE 134

3-(3-Hydroxy-2-methyl-propyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 389.442

25

## EXAMPLE 135

3-Isobutyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

-134-

MS-APCI (M+1) 373.443

## EXAMPLE 136

3-(6-Chloro-pyridin-3-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-  
thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

5 MS-APCI (M+1) 442.8934

## EXAMPLE 137

3-(2-Benzenesulfonylmethyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-  
thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 561.649

10

## EXAMPLE 138

1-Methyl-3-naphthalen-1-ylmethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-  
d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 457.52

## EXAMPLE 139

15

1-Methyl-2,4-dioxo-3-(2-trifluoromethyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-  
d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 475.457

## EXAMPLE 140

20

3-(3-Chloro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-  
d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 441.905

## EXAMPLE 141

3-(4-Methoxycarbonyl-butyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-  
d]pyrimidine-6-carboxylic acid benzyl ester

25

MS-APCI (M+1) 431.479

-135-

## EXAMPLE 142

3-Ethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 345.389

5

## EXAMPLE 143

1-Methyl-2,4-dioxo-3-(3-phenyl-propyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 435.514

## EXAMPLE 144

10

3-[2-(4-Chloro-benzenesulfonyl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 519.996

## EXAMPLE 145

15

3-(2-Acetoxy-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 403.425

## EXAMPLE 146

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-phenoxyethyl ester

20

In a 8 mL screw cap vial was added a mixture of 3-benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid, (0.032 g, 0.1 mmol), triethylamine (0.024 g, 0.24 mmol), and 2-chloro-1-methylpyridinium iodide (0.031 g, 0.12 mmol) in dichloromethane (2 mL), followed by 2-phenoxy ethanol (0.015 g, 0.11 mmol) in dichloromethane (1 mL). The vial was capped, and the reaction mixture was shaken for 24 hours at room temperature. The solvent was removed under vacuum. Purification was carried out via reverse-phase HPLC (3% n-propanol in acetonitrile and 3% n-propanol in water as the eluent; C-18 column). 0.023 g (50% yield). MS-APCI (M + 1) = 437.486.

25

-136-

The procedure of Example 146 was used to prepare the compounds of Examples 147 to 215.

## EXAMPLE 147

5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

MS-APCI (M+1) 407.4602 (The compound of Example 147 is the same as the compound of Example 99.)

## EXAMPLE 148

10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl amide

MS-APCI (M+1) 406.4761

## EXAMPLE 149

15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2,6-dichloro-benzyl ester

MS-APCI (M+1) 476.35

## EXAMPLE 150

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid butyl ester

MS-APCI (M+1) 373.443

20

## EXAMPLE 151

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2,3-dihydro-1,4-benzodioxin-2-ylmethyl ester

MS-APCI (M+1) 465.496

## EXAMPLE 152

25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-diethylamino-1-methyl-ethyl ester

MS-APCI (M+1) 430.538

-137-

## EXAMPLE 153

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-fluoro-benzyl ester

MS-APCI (M+1) 425.45

5

## EXAMPLE 154

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-isopropyl-benzyl ester

MS-APCI (M+1) 449.541

## EXAMPLE 155

10

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-p-tolyl-ethyl ester

MS-APCI (M+1) 435.514

## EXAMPLE 156

15

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-trifluoromethyl-benzyl ester

MS-APCI (M+1) 475.457

## EXAMPLE 157

20

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid cyclobutylmethyl ester

MS-APCI (M+1) 385.454

## EXAMPLE 158

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2,6-difluoro-benzyl ester

MS-APCI (M+1) 443.44

25

## EXAMPLE 159

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-(2-hydroxy-phenyl)-ethyl ester

-138-

MS-APCI (M+1) 437.486

## EXAMPLE 160

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-(2-hydroxy-phenyl)-ethyl ester

5

MS-APCI (M+1) 437.486

## EXAMPLE 161

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 1-methyl-piperidin-4-yl ester

MS-APCI (M+1) 414.496

10

## EXAMPLE 162

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 1-methyl-piperidin-4-yl ester

MS-APCI (M+1) 414.496

## EXAMPLE 163

15

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid pyridin-3-ylmethyl ester

MS-APCI (M+1) 408.448

## EXAMPLE 164

20

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-pyridin-3-yl-propyl ester

MS-APCI (M+1) 436.502

## EXAMPLE 165

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-dimethylamino-1-methyl-ethyl ester

25

MS-APCI (M+1) 402.485

-139-

## EXAMPLE 166

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzyl ester

MS-APCI (M+1) 437.486

5

## EXAMPLE 167

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid tetrahydro-pyran-4-yl ester

MS-APCI (M+1) 401.453

## EXAMPLE 168

10

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2,2,2-trifluoro-1-trifluoromethyl-ethyl ester

MS-APCI (M+1) 487.357

## EXAMPLE 169

15

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-trifluoromethyl-benzyl ester

MS-APCI (M+1) 475.457

## EXAMPLE 170

20

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-benzyloxy-ethyl ester

MS-APCI (M+1) 451.513

## EXAMPLE 171

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2,2,2-trichloro-ethyl ester

MS-APCI (M+1) 448.725

25

## EXAMPLE 172

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid phenethyl ester



-140-

MS-APCI (M+1) 421.487

## EXAMPLE 173

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-ethyl-oxetan-3-ylmethyl ester

5 MS-APCI (M+1) 415.48

## EXAMPLE 174

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-morpholin-4-yl-ethyl ester

MS-APCI (M+1) 430.495

10 EXAMPLE 175

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-pyrrolidin-1-yl-ethyl ester

MS-APCI (M+1) 414.496

## EXAMPLE 176

15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-pyrrolidin-1-yl-ethyl ester

MS-APCI (M+1) 414.96

## EXAMPLE 177

20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-(2-ethoxy-ethoxy)-ethyl ester

MS-APCI (M+1) 433.495

## EXAMPLE 178

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid tetrahydro-pyran-2-ylmethyl ester

25 MS-APCI (M+1) 415.48

-141-

## EXAMPLE 179

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-nitro-benzyl ester

MS-APCI (M+1) 452.457

5

## EXAMPLE 180

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid pentyl ester

MS-APCI (M+1) 387.47

## EXAMPLE 181

10

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-phenyl-propyl ester

MS-APCI (M+1) 435.514

## EXAMPLE 182

15

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-phenoxy-benzyl ester

MS-APCI (M+1) 499.557

## EXAMPLE 183

20

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3,5-dimethoxy-benzyl ester

MS-APCI (M+1) 467.512

## EXAMPLE 184

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methyl-butyl ester

MS-APCI (M+1) 387.47

25

## EXAMPLE 185

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-chloro-benzyl ester

-142-

MS-APCI (M+1) 441.905

## EXAMPLE 186

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 1-ethyl-piperidin-3-yl ester

5 MS-APCI (M+1) 428.522

## EXAMPLE 187

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-benzyloxy-benzyl ester

MS-APCI (M+1) 513.584

10 EXAMPLE 188

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid isobutyl ester

MS-APCI (M+1) 373.443

## EXAMPLE 189

15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-(4-methoxy-phenyl)-propyl ester

MS-APCI (M+1) 465.54

## EXAMPLE 190

20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-chloro-6-fluoro-benzyl ester

MS-APCI (M+1) 459.895

## EXAMPLE 191

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid tetrahydro-furan-3-yl ester

25 MS-APCI (M+1) 387.426

-143-

## EXAMPLE 192

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzyl ester

MS-APCI (M+1) 437.486

5

## EXAMPLE 193

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzyl ester

MS-APCI (M+1) 437.486

## EXAMPLE 194

10

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-pyridin-2-yl-propyl ester

MS-APCI (M+1) 436.502

## EXAMPLE 195

15

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-piperidin-2-yl-ethyl ester

MS-APCI (M+1) 428.522

## EXAMPLE 196

20

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 5-bromo-2-methoxy-benzyl ester

MS-APCI (M+1) 516.382

## EXAMPLE 197

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid cycloheptylmethyl ester

MS-APCI (M+1) 427.534

25

## EXAMPLE 198

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 1,2,3,4-tetrahydro-naphthalen-1-yl ester

-144-

MS-APCI (M+1) 447.525

## EXAMPLE 199

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid pyrrolidin-2-ylmethyl ester

5 MS-APCI (M+1) 400.469

## EXAMPLE 200

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-chloro-benzyl ester

MS-APCI (M+1) 441.905

10

## EXAMPLE 201

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 1,3-benzodioxol-5-ylmethyl ester

MS-APCI (M+1) 451.469

## EXAMPLE 202

15

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methylsulfanyl-benzyl ester

MS-APCI (M+1) 453.553

## EXAMPLE 203

20

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methylsulfanyl-benzyl ester

MS-APCI (M+1) 453.553

## EXAMPLE 204

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3,4-dichloro-benzyl ester

25

MS-APCI (M+1) 476.35

-145-

## EXAMPLE 205

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3,3-diphenyl-propyl ester

MS-APCI (M+1) 511.611

5

## EXAMPLE 206

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-pyridin-2-yl-ethyl ester

MS-APCI (M+1) 422.475

## EXAMPLE 207

10

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid furan-3-ylmethyl ester

MS-APCI (M+1) 397.421

## EXAMPLE 208

15

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid but-3-enyl ester

MS-APCI (M+1) 371.427

## EXAMPLE 209

20

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-cyano-ethyl ester

MS-APCI (M+1) 370.399

## EXAMPLE 210

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-ethoxy-ethyl ester

MS-APCI (M+1) 389.442

25

## EXAMPLE 211

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid cyano-phenyl-methyl ester

-146-

MS-APCI (M+1) 432.47

## EXAMPLE 212

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-trifluoromethyl-benzylamide

5 MS-APCI (M+1) 474.473

## EXAMPLE 213

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methyl-benzylamide

MS-APCI (M+1) 420.503

10 EXAMPLE 214

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid phenethyl-amide

MS-APCI (M+1) 420.503


## EXAMPLE 215

15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid cyclopropylamide

MS-APCI (M+1) 356.416

## EXAMPLE 216

20 1-Methyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide




1-Methyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (1.0589 g, 4.681 mmol) was suspended in 50 mL methylene chloride and 50 mL THF. To this solution, 4-methyl morpholine (2.6895 g, 26.59 mmol),

-147-

1-hydroxybenzotriazole monohydrate ("HOBT-H<sub>2</sub>O") (0.7685 g, 5.688 mmol), and 4-methoxybenzylamine (0.7848 g, 5.721 mmol) were added. Then 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride ("EDAC-HCl") (1.0795 g, 5.631 mmol) was added, and the reaction was stirred at room temperature overnight. The solvent was removed under vacuum, and ~20 mL 5% HCl was added, stirred for approximately 30 minutes, and the product was suction filtered. The filter cake was washed with 5% HCl, then 5% NaHCO<sub>3</sub>, water, and dried at 40°C under vacuum, to yield 1.4877 g white solid; mp 252-254°C.

## EXAMPLE 217

1-Methyl-2,4-dioxo-3-(4-sulfamoyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide




1-Methyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide (0.1484 g, 0.4297 mmol) was dissolved in 8 mL DMF, then cesium carbonate (0.2020 g, 0.62 mmol) was added and stirred at room temperature for 10 minutes. The 4-bromomethyl benzenesulfonamide (0.1084 g, 0.4334 mmol) was added and stirred at room temperature overnight. The solution was added dropwise to 70 mL of water, and the precipitate was suction filtered and dried under vacuum to give a white solid (0.1038 g). NMR (DMSO, ppm) 9.19 (1H, t, J = 5.9 Hz), 8.12 (1H, s), 7.75 (2H, d, J = 8.3 Hz), 7.47 (2H, d, J = 8.5 Hz), 7.32 (2H, br), 7.23 (2H, d, J = 8.5 Hz), 6.90 (2H, d, J = 8.5 Hz), 5.12 (2H, s), 4.38 (2H, d, J = 5.6 Hz), 3.73 (3H, s), 3.48 (3H, s).

## EXAMPLE 218

1-Methyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide




-148-



Made by the procedure of Example 216 using 3-methoxybenzyl amine; mp 279-281°C.

## EXAMPLE 219


- 5 1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide



- 10 Made by the procedure of Example 216 with 1-methyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid and 4-(aminomethyl)-2-methoxy-pyridine. NMR (DMSO) 11.58 (1H, br), 9.25 (1H, t, J = 6.1 Hz), 8.15-8.05 (2H, m), 6.9 (1H, m), 6.70 (1H, s), 4.42 (2H, d, J = 5.9 Hz), 3.83 (3H, s), 3.41 (3H, s). MS (APCI+) = 347.

## EXAMPLE 220

- 15 3-[4-(N-Hydroxycarbamimidoyl)-benzyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide



3-(4-Cyano-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide (3.03 g, 6.59 mmol) was suspended in 50 absolute ethanol, and hydroxylamine hydrochloride (2.17 g,


-149-

31.16 mmol) and solid potassium hydroxide (1.92 g, 34.15 mmol) were added. The solution was refluxed for 4 hours, cooled to room temperature, and the solid was filtered off, washed with cold water, and dried under vacuum to give a white solid (2.69 g). mp 226-228°C (dec.). MS (APCI+) = 494.

5

## EXAMPLE 221

1-Methyl-2,4-dioxo-3-[4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide



10

3-[4-(N-Hydroxycarbamimidoyl)-benzyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide (0.2897 g, 0.5870 mmol) was dissolved in 5 mL DMF and cooled in an ice bath, and pyridine (dissolved in 0.5 mL DMF) was added to this solution. Then ethylchloroformate (0.0742 g, 0.6837 mmol) dissolved in 0.5 mL DMF was added, and the reaction stirred at 0°C for 45 minutes. The reaction mixture was poured into 50 mL of water, the solid filtered off, and suction dried. This solid was suspended in 14 mL xylenes and refluxed 24 hours. The reaction was cooled to room temperature, the solid filtered off, washed with hexanes, and suction dried to give a white powder, 1-methyl-2,4-dioxo-3-[4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide (0.24 g). CHNS calculated: C, 57.80%; H, 4.07%; N, 13.48%; S, 6.17%. Found: C, 57.47%; H, 4.19%; N, 13.19%; S, 6.13%.


20

## EXAMPLE 222

1-Methyl-2,4-dioxo-3-[4-(5-thioxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide

25


-150-



3-[4-(N-Hydroxycarbamimidoyl)-benzyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide (0.2137 g, 0.4330 mmol) was suspended in 5 mL DMF, then thiocarbonyl diimidazole (0.1225 g, 0.6187 mmol) and 1,8-diazabicyclo[5.4.0]undec-7-ene ("DBU") (0.3427 g, 2.25 mmol) were added. After stirring at room temperature for 4 hours, the solution was poured into 60 mL water and acidified to pH 5 with 5% citric acid solution. The solid was filtered, resuspended in 5% citric acid solution, and sonicated. The solid was filtered and vacuum dried to give 1-methyl-2,4-dioxo-3-[4-(5-thioxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide (0.2511 g) as a tan powder. NMR (DMSO): 9.18 (1H, t, J = 5.9 Hz), 8.12, (1H, s), 7.81 (2H, d, J = 8.3 Hz), 7.48 (2H, d, J = 8.3 Hz), 7.23 (2H, d, J = 9.12 Hz), 6.90 (2H, d, J = 8.8 Hz), 5.13 (2H, s), 4.38 (2H, d, J = 5.9 Hz), 3.73 (3H, s), 3.49 (3H, s). MS (APCI+) = 536.

## EXAMPLE 223

3-Cyanomethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide




Made by the procedure of Example 217 with chloroacetonitrile; mp 180-183°C.

## EXAMPLE 224

3-Cyanomethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide


-151-



Made by the procedure of Example 217 with chloroacetonitrile; mp 159-163°C.

## EXAMPLE 225

5 (E)-4-[6-(4-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-yl]-but-2-enoic acid methyl ester




Made by the procedure of Example 217 with methyl 4-bromocrotonate; mp 169-171°C.

10

## EXAMPLE 226

(E)-4-[6-(4-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-yl]-but-2-enoic acid



15

(E)-4-[6-(4-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-yl]-but-2-enoic acid (0.053 g, 0.1195 mmol) was dissolved in 5 mL methanol and 5 mL water with potassium carbonate (0.0264 g, 0.191 mmol) and heated to reflux for 4 hours. The reaction was cooled to room temperature, and the solution concentrated to approximately 5 mL. The solution was acidified with 5% HCl, and the white precipitate was filtered and dried under vacuum. NMR (DMSO, ppm): 9.17 (1H, t, J = 6.1 Hz), 8.11 (1H, s), 7.23 (2H, d, J


20

-152-

= 8.5 Hz), 6.91 (2H, d), 6.8 (1H, m), 5.76 (1H, m), 4.62 (2H, m), 4.37 (2H, d, J = 5.9 Hz), 3.72 (3H, s), 3.48 (3H, s).

## EXAMPLE 227


3-(2-Benzenesulfonyl-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide



Made by the procedure of Example 217 with (2-chloro-ethanesulfonyl)-benzene; mp 118-121°C.

## EXAMPLE 228

2-Methoxy-4-[6-(4-methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid methyl ester




Made by the procedure of Example 217 with methyl 4-bromomethyl-2-methoxybenzoate; mp 201-203°C.

15

## EXAMPLE 229

3-(2-Methoxymethyl-1,1,3-trioxo-2,3-dihydro-1H-1,2-benzisothiazol-6-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide


-153-



Made by the procedure of Example 217 with 6-bromomethyl-(2-methoxymethyl-1,1,3-trioxo-2,3-dihydro-1H-1,2-benzisothiazole. NMR (DMSO) 9.22 (1H, m), 8.3-7.9 (4H, m), 7.24 (2H, d, J = 8.8Hz), 6.9 (2H, d, J = 8.5 Hz), 5.27 (2H, s), 5.15 (2H, s), 4.37 (2H, m), 3.73 (3H, s), 3.51 (3H, s), 3.35 (3H, s). MS (APCI-) = 583.

## EXAMPLE 230


1-Methyl-3-oct-2-ynyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide



Made by the procedure of Example 217 with 1-bromo-2-octyne. NMR (DMSO): 9.18 (1H, t, J = 6.1 Hz), 8.11 (1H, s), 7.24, (2H, d, J = 8.5), 6.90 (2H, d, J = 8.5), 4.58 (2H, s), 4.38 (2H, d, J = 5.9 Hz), 3.73 (3H, s), 3.49 (3H, s), 2.13 (2H, m), 1.45-1.2 (6H, m), 0.83 (3H, m). MS (APCI+) = 454.

## EXAMPLE 231

3-[2-(4-Chloro-benzenesulfonylamino)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide




Made by the procedure of Example 217 with 1-chloro-2-(4-chloro-benzenesulfonylamino)-ethane. NMR (DMSO): 9.16 (1H, t, J = 5.9Hz), 8.04 (1H,

-154-

s), 7.71 (2H, d), 7.60 (2H, d), 7.24 (2H, d), 6.90 (2H, d), 4.37 (2H, d), 3.91 (2H, t), 3.73 (3H, s), 3.44 (s), 3.06 (2H, t). MS (APCI+) = 563.

## EXAMPLE 231a



5            1-Methyl-2,4-dioxo-3-(4-sulfamoyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide (0.1031 g, 0.2002 mmol) was dissolved in 2 mL N,N-dimethylformamide ("DMF"), cooled in an ice bath, and sodium hydride (60% in oil, 0.019 g, 0.8041 mmol) was added, and stirred at 0° for 1 hour. Then n-butyl isocyanate (0.0273 g, 0.2752 mmol) was added and

10           stirred for 2 hours. The reaction mixture was added dropwise to 25 mL of water, and the pH was adjusted to 4 with 5% citric acid solution. The mixture was extracted twice with ethyl acetate, and once with chloroform. The combined organic extracts were washed with water, then brine, and dried over magnesium sulfate. The solution was filtered, and the solvent removed to give a solid that was


15           triturated with ethyl acetate. The solid was collected by filtration and suction dried to give a white solid (0.0691 g) NMR (DMSO): 10.35 (1H, s), 9.24 (1H, t), 8.15 (1H, s), 7.81 (2H, d), 7.50 (2H, d), 7.24 (1H, m), 6.9-6.8 (3H, m), 6.43 (1H, m), 5.14 (2H, s), 4.43 (2H, d), 3.73 (3H, s), 3.49 (3H, s), 2.9 (2H, m), 1.4-1.1 (4H, m), 0.8 (3H, m). CHNS (calculated): C, 54.80%; H, 5.09%; N, 11.41%; S, 10.45%.

20           Found: C, 54.29%; H, 5.06%; N, 11.40%; S, 10.69 %; water 0.64%.

## EXAMPLE 232

3-[2-(4-Bromo-phenoxy)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide

-155-




Made by the procedure of Example 217 with 1-methyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide and 1-bromo-2-(2-chloro-ethoxy) benzene; mp 184-185°C.

5

## EXAMPLE 233

3-[2-(4-Bromo-phenoxy)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide




10

Made by the procedure of Example 217 from 1-methyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide and 1-bromo-4-(2-chloro-ethoxy) benzene; mp 165-167°C.

## EXAMPLE 234

3-[2-(4-Fluoro-phenoxy)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide



15


Made by the procedure of Example 217 from 1-methyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide and 1-fluoro-4-(2-chloro-ethoxy) benzene; mp 170-171°C.



-156-

## EXAMPLE 235


3-(2-aminoethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide



5            3-Cyanomethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide (1.95 g) was dissolved in 95 mL tetrahydrofuran ("THF") with 5 mL triethylamine, and 0.45 Raney Ni catalyst added. The reaction was placed under a hydrogen atmosphere (50 psi) and shaken for 39 hours. The catalyst was filtered off, and the solvent removed to give  
10 a white solid. NMR (DMSO): 9.15 (1H, t, J = 5.6), 8.09 (1H, s), 7.23 (2H, d, J = 8.5 Hz), 6.90 (2H, d, J = 8.5 Hz), 4.37 (2H, d, J = 5.9 Hz), 3.88 (2H, t, J = 6.4 Hz), 3.73 (3H, s), 4.47 (3H, s), 2.7 (2H, t, J = 6.8 Hz). MS (APCI+) = 389.

## EXAMPLE 236

15            3-[2-(4-fluoro-phenoxy)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide




20            Made by the procedure of Example 217 from 1-methyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide and 1-fluoro-4-(2-chloro-ethoxy) benzene. NMR (DMSO): 9.21 (1H, t, J = 5.9 Hz), 8.13 (1H, s), 7.3-6.8 (8H, m), 4.5-4.1 (6H, m), 3.74 (3H, s), 3.49 (3H, s). MS (APCI+) = 484. CHNS calculated: C, 59.62%; H, 4.59%; N, 8.69%; S, 6.63%. F, 3.93%. Found: C, 59.71%; H, 4.61%; N, 8.62%; S, 6.69%; F, 4.03%.

-157-

## EXAMPLE 237


3-[2-(4-chloro-phenoxy)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide



- 5 Made by the procedure of Example 217 from 1-methyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide and 4-(2-bromo-ethoxy)-1-chlorobenzene; mp 109-112°C.

## EXAMPLE 238


- 10 4-[6-(4-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-2-methyl-benzoic acid methyl ester



Made by the procedure of Example 217 with 4-bromomethyl-2-methylbenzoic acid methyl ester; mp 179-181°C.

## EXAMPLE 239

- 15 4-[6-(4-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid methyl ester




Made by the procedure of Example 217 with 4-bromomethyl benzoic acid methyl ester; mp 235-237°C.

-158-

## EXAMPLE 240


2-Methoxy-4-[6-(3-methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid methyl ester



5 Made by the procedure of Example 217 with 4-bromomethyl-2-methoxybenzoic acid methyl ester; mp 200-203°C.

## EXAMPLE 241

4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-2-methylbenzoic acid methyl ester




10

Made by the procedure of Example 217 with 4-bromomethyl-2-methylbenzoic acid methyl ester; mp 175-177°C.

## EXAMPLE 242

15 1-Methyl-2,4-dioxo-3-(3-oxo-3-phenyl-propyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide




Made by the procedure of Example 217 with 3-chloro-1-phenyl-propan-1-one; mp. 208-211°C.

## EXAMPLE 243

20 1-Methyl-2,4-dioxo-3-(3-oxo-3-phenyl-propyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide


-159-



Made by the procedure of Example 217 with 3-chloro-1-phenyl-propan-1-one; mp 188-191°C.

## EXAMPLE 244

- 5 1-Methyl-2,4-dioxo-3-[2-(3-trifluoromethyl-benzenesulfonyl)-ethyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide




Made by the procedure of Example 217 with (2-chloro-ethanesulfanyl)-3-trifluoromethyl benzene; mp 203-205°C.

10

## EXAMPLE 245

- 1-Methyl-2,4-dioxo-3-[2-(3-trifluoromethyl-benzenesulfonyl)-ethyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide




Made by the procedure of Example 217 with (2-chloro-ethanesulfanyl)-3-trifluoromethyl benzene; mp 222-225°C.

15

## EXAMPLE 246

- 3-[2-(4-Chloro-benzenesulfonyl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide


-160-



Made by the procedure of Example 217 with 4-(2-chloro-ethanesulfanyl)-chlorobenzene; mp 186-190°C.

## EXAMPLE 247

- 5 3-[2-(4-Chloro-benzenesulfonyl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide




Made by the procedure of Example 217 with 4-(2-chloro-ethanesulfanyl)-chlorobenzene; mp 222-225°C.

10

## EXAMPLE 248

- 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid




15


1-Methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester (1.70 g, 5.387 mmol) was stirred with anhydrous HBr/acetic acid for 3 days at room temperature. An equal volume of water was added, and the solid was filtered off and dried under vacuum to give 1.06 g white solid. MS (APCI-) 225.

-161-

## EXAMPLE 249




## EXAMPLE 249a



5           4-[6-(4-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-  
thieno[2,3-d]pyrimidin-3-ylmethyl]-2-methyl-benzoic acid methyl ester (0.1543 g,  
0.304 mmol) was stirred with 5 mL anhydrous HBr/acetic acid for 2 days at room  
temperature. The solution was added dropwise to 50 mL water, and the solid  
filtered off. The solid was purified by column chromatography to give  
10   Example 249 [MS (APCI+) 374] and Example 249a [MS (APCI+) 388].

## EXAMPLE 250

4-[6-(3-hydroxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-  
thieno[2,3-d]pyrimidin-3-ylmethyl]-2-methyl-benzoic acid




15           4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-  
thieno[2,3-d]pyrimidin-3-ylmethyl]-2-methyl-benzoic acid methyl ester (0.2489 g,  
0.4903 mmol) was stirred with 5 mL anhydrous HBr/acetic acid for 3 days at  
room temperature. The solution was added dropwise to 50 mL of 5% hydrochloric  
acid and stirred 1 hour. The solid was filtered off and suction dried. The process

-162-

was repeated, and the resulting solid was purified by column chromatography to give 4-[6-(3-hydroxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-2-methyl-benzoic acid. MS (APCI+) 480.


## EXAMPLE 251



This was made analogously to Example 249. MS (APCI-) 374.

## EXAMPLE 252

3-(2-Aminoethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide



3-Cyanomethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide (4.3 g, 11.19 mmol) was reduced with Raney Nickel in THF under hydrogen. The catalyst was filtered off, and the solvent removed under vacuum to give the product as a white solid. MS (APCI+) 389.






## EXAMPLE 252a

In a 8 mL screw cap vial was added a solution of the compound of Example 216 (0.034 g, 0.1 mmol) in dimethylformamide (1 mL), a solution of 3-chloro-1-(Z)-phenyl-propan-1-one(0.039 g, 0.23 mmol) in dimethylformamide (575 mL) and anhydrous cesium carbonate(0.075 g, 0.023 mmol). The vial was capped, and the reaction mixture was shaken for 24 hours at room temperature. The reaction mixture was filtered, and the solvent was removed under vacuum.

-163-







Purification was carried out via reverse-phase HPLC (3% n-propanol in acetonitrile and 3% n-propanol in water as the eluent; C-18 column). 0.012 g (30% yield). MS-APCI (M+1) 478.1.

5 In a manner similar to the procedure of Example 252a, the following invention compounds were prepared:







Example No.	Structure	APCI MS (M+1)
253		450.5287
254		478.5387
255		484.6297
256		458.5919
257		441.5216









-164-

Example No.	Structure	APCI MS (M+1)
258		400.4689
259		500.5885
260		414.4957
261		482.5947
262		402.4847
263		400.4689






-165-

Example No.	Structure	APCI MS (M+1)
264		416.5115
265		412.4799
266		514.5927
267		414.4957
268		532.5828
269		528.6195






-166-

Example No.	Structure	APCI MS (M+1)
270		496.5288
271		512.9838
272		493.5536
273		545.4238
274		478.4991
275		466.5277







-167-

Example No.	Structure	APCI MS (M+1)
276		500.5019
277		665.7324
278		517.0398
279		450.5287
280		484.6297






-168-

Example No.	Structure	APCI MS (M+1)
281		458.5919
282		528.6195
283		441.5216
284		400.4689
285		500.5885




-169-

Example No.	Structure	APCI MS (M+1)
286		414.4957
287		482.5947
288		402.4847
289		400.4689
290		416.5115
291		412.4799

-170-

Example No.	Structure	APCI MS (M+1)
292		414.4957
293		528.6195
294		493.5536
295		545.4238
296		478.4991

-171-

Example No.	Structure	APCI MS (M+1)
297		466.5277
298		500.5019
299		665.7324

Also prepared by the methods exemplified above are the compounds of Examples 300 to 386.

#### EXAMPLE 300

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid methyl ester made by the procedure of Example 97; MS-APCI (M+1): 331.2.

#### EXAMPLE 301

3-(4-Bromo-benzyl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

To a solution of 5-amino-3-methyl-thiophene-2,4-dicarboxylic acid 2-benzyl ester 4-ethyl ester (0.5 g, 1.57 mmol) in dioxane (50 mL), was added sodium hydride (42 mg, 1.72 mmol). 1-bromo-4-isocyanatomethyl-benzene (0.332 g, 1.57 mmol) was added 5 minutes later. The reaction mixture was stirred



-172-

at room temperature for 1 hour. The reaction mixture was chromatographed using 2:1 hexane:ethyl acetate to yield 82 mg of title compound as a white solid (11%); MS-APCI (M<sup>+</sup>) 487.

## EXAMPLE 302

5 3-(4-Fluoro-benzyl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

The procedure of Example 74 was repeated, except 1-bromo-4-isocyanatomethyl-benzene was replaced by 1-fluoro-4-isocyanatomethyl-benzene to give 3-(4-fluoro-benzyl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester as a white solid (13%);  
10 MS-APCI (M<sup>+</sup>) 425.

## EXAMPLE 303

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid pyridin-4-ylmethyl ester

15 EXAMPLE 304

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzo[b]thiophen-2-ylmethyl ester

The procedure of Example 48 was repeated, except and benzofuran-2-yl-methanol was replaced by benzothiophene-2-yl-methanol to give 3-benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid  
20 benzo[b]thiophene-2-ylmethyl ester as a white solid (54%); <sup>1</sup>H NMR (CDCl<sub>3</sub>), δ 3.50 (s, 3H), 5.19 (s, 2H), 5.58 (s, 2H), 7.21-7.38 (m, 6H), 7.49 (d, J = 8.7 Hz, 2H), 7.74-7.82 (m, 2H), 8.11 (s, 1H).

## EXAMPLE 305

25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 1-methyl-1H-indol-5-ylmethyl ester

The procedure of Example 48 was repeated, except and benzofuran-2-yl-methanol was replaced by (1-methyl-1H-indol-5-yl)-methanol to give 3-benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid

-173-

1-methyl-1H-indo-5-ylmethyl ester as a white solid (59%);  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ),  $\delta$  3.51 (s, 3H), 3.80 (s, 3H), 5.17 (s, 2H), 5.43 (s, 2H), 6.50 (d,  $J = 3.2$  Hz, 1H), 7.08 (d,  $J = 3.1$  Hz, 1H), 7.22-7.34 (m, 5 H), 7.49 (m, 2H), 7.70 (s, 1H), 8.06 (s, 1H).

5

## EXAMPLE 306

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid thiophen-3-ylmethyl ester

The procedure of Example 1 was repeated, except that benzyl alcohol was replaced by thiophene-2-ylmethanol to provide 3-benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid thiophen-3-ylmethyl ester as a white powder (19%); MS-APCI ( $\text{M}^+$ ) 400.

10

## EXAMPLE 307

3-1,3-Benzodioxol-5-ylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

The procedure of Example 15 was repeated, except 3-bromomethylbenzoic acid methyl ester was replaced by 5-bromoethyl-benzo[1,3]dioxole. The crude product was chromatographed using 2:1 hexane/ethyl acetate to 100% ethyl acetate to give 3-1,3-benzodioxol-5-ylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester as a white solid (40%); MS-APCI ( $\text{M}^+$ ) 451.

15

20

## EXAMPLE 308

1-Methyl-2,4-dioxo-3-pyridin-4-ylmethyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

The procedure of Example 15 was repeated, except 3-bromomethylbenzoic acid methyl ester was replaced by 4-bromomethyl pyridine. The crude product was chromatographed using 2:1 hexane:ethyl acetate to 100% ethyl acetate to give 1-methyl-2,4-dioxo-3-pyridin-4-ylmethyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester as a white solid (49%); MS-APCI ( $\text{M}^+$ ) 408.

25

-174-

## EXAMPLE 309

3-(4-*tert*-Butyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

The procedure of Example 15 was repeated, except 3-bromomethyl-benzoic acid methyl ester was replaced by 1-bromomethyl-4-*tert*-butyl-benzene. The crude product was chromatographed using 2:1 hexane/ethyl acetate to 100% ethyl acetate to give 3-(4-*tert*-butyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester as a white solid (63%); MS-APCI (M<sup>+</sup>) 463.

## EXAMPLE 310

3-(3,4-Dichloro-benzyl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

The procedure of Example 74 was repeated, except 1-bromo-4-isocyanatomethyl-benzene was replaced by 1,2-dichloro-4-isocyanatomethyl-benzene to give 3-(3,4-dichloro-benzyl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester as a white solid (19%); MS-APCI (M<sup>+</sup>) 475.

## EXAMPLE 311

1-Methyl-2,4-dioxo-3-(4-trifluoromethoxy-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

The procedure of Example 15 was repeated, except 3-bromomethyl-benzoic acid methyl ester was replaced by 1-bromomethyl-4-trifluoromethoxy-benzene. The crude product was chromatographed using 2:1 hexane/ethyl acetate to 100% ethyl acetate to give 1-methyl-2,4-dioxo-3-(4-trifluoromethoxy-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester as a white solid (50%); MS-APCI (M<sup>+</sup>) 491.

## EXAMPLE 312

1-Methyl-3-naphthalen-2-ylmethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

-175-

The procedure of Example 15 was repeated, except 3-bromomethyl-benzoic acid methyl ester was replaced by 2-bromomethyl naphthalene. The crude product was chromatographed using 2:1 hexane/ethyl acetate to 100% ethyl acetate to give 1-methyl-3-naphthalen-1-ylmethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester as a white solid (72%);  
5 MS-APCI (M+) 457.

## EXAMPLE 313

3-(4-Cyano-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

10 The procedure of Example 15 was repeated, except 3-bromomethyl-benzoic acid methyl ester was replaced by 4-bromomethyl-benzonitrile. The crude product was chromatographed using 2:1 hexane/ethyl acetate to 100% ethyl acetate to give 3-(4-cyano-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester as a white solid (80%);  
15 MS-APCI (M+) 432.

## EXAMPLE 314

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzofuran-5-ylmethyl ester

20 The procedure of Example 1 was repeated, except that benzyl alcohol was replaced by benzofuran-5-yl-methanol to provide 3-benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzofuran-5-ylmethyl ester as a white powder (24%); MS-APCI (M+) 447.

## EXAMPLE 315

3-(3,5-Dimethoxy-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

25 The procedure of Example 15 was repeated, except 3-bromomethyl-benzoic acid methyl ester was replaced by 1-chloromethyl-3,5-dimethoxy-benzene. The crude product was chromatographed using 2:1 hexane/ethyl acetate to 100% ethyl acetate to give 3-(3,5-dimethoxy-benzyl)-1-methyl-2,4-dioxo-

-176-

1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester as a white solid (52%); MS-APCI (M<sup>+</sup>) 467.

## EXAMPLE 316

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

## EXAMPLE 317

3-(3,5-Dinitro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester

The procedure of Example 15 was repeated, except 3-bromomethyl-benzoic acid methyl ester was replaced by 1-chloromethyl-3,5-dinitro-benzene. The crude product was chromatographed using 2:1 hexane/ethyl acetate to 100% ethyl acetate to give 3-(3,5-dinitro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester as a white solid (10%); MS-APCI (M<sup>+</sup>) 501.

## EXAMPLE 318

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid

To a solution of 3-benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid ethyl ester (5.0 g, 14.5 mmol) in 90% THF/10% water, was added 5.0 g of LiOH. The solution was stirred at room temperature for 5 hours, then poured into 400 mL of 1:1 ethyl acetate/water, and acidified with hydrochloric acid until the pH is acidic. The organic layer was dried over magnesium sulfate and concentrated. The residue was triturated with 4:1 hexane/ethyl acetate to yield 2.8 g (62%) of the title compound as a white solid; MS-APCI (M<sup>+</sup>) 317.

## EXAMPLE 319

3-(4-Carboxy-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-ethoxy-benzyl ester


-177-

The procedure of Examples 53 and 54 were repeated, 3,4-dimethoxy benzyl amine was replaced by 2-ethoxy benzylamine, to give 4-[6-(2-ethoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid as a white solid (20%); MS-APCI (M+) 494.

5

## EXAMPLE 320

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid [2-(3,4-dimethoxy-phenyl)-ethyl]-amide



In a 8-mL screw cap vial was added a mixture of the compound of  
 10 Example 318, namely 3-benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid, (0.032 g, 0.1 mmol), triethylamine (0.024g, 0.24 mmol), and 2-chloro-1-methylpyridinium iodide (0.031 g, 0.12 mmol) in dichloromethane (2 mL) followed by 3,4-methoxyethyl amine, (0.020 g, 0.11 mmol) in dichloromethane (1 mL). The vial was capped, and the reaction  
 15 mixture was shaken for 24 hours at room temperature. The solvent was removed under vacuum. Purification was carried out via reverse-phase HPLC (3% n-propanol in acetonitrile and 3% n-propanol in water as the eluent; C-18 column). 0.023 g (50% yield). MS-APCI (M+1): 480.5.

In a manner similar to the procedure of Example 320, the compounds of  
 20 Examples 321 to 363 were prepared.

## EXAMPLE 321

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-amino-benzylamide  
 MS APCI (M+1): 421.491.

-178-

## EXAMPLE 322

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide

MS APCI (M+1): 454.948.

5

## EXAMPLE 323

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (biphenyl-2-ylmethyl)-amide

MS APCI (M+1): 482.5737.

## EXAMPLE 324

10

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3,4-dimethoxy-benzylamide

MS APCI (M+1): 466.5277.

## EXAMPLE 325

15

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (2-pyridin-4-yl-ethyl)-amide

MS APCI (M+1): 421.491.

## EXAMPLE 326

20

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-difluoromethoxy-benzylamide

MS APCI (M+1): 472.4821.

## EXAMPLE 327

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid [2-(3-ethoxy-phenyl)-ethyl]-amide

MS APCI (M+1): 464.5555.

25

## EXAMPLE 328

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-chloro-4-fluoro-benzylamide

-179-

MS APCI (M+1): 458.9113.

## EXAMPLE 329

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-  
carboxylic acid 2,4-dichloro-benzylamide

5 MS APCI (M+1): 475.3663.

## EXAMPLE 330

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-  
carboxylic acid (2-phenyl-propyl)-amide

MS APCI (M+1): 434.5297.

10

## EXAMPLE 331

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-  
carboxylic acid 3,4,5-trimethoxy-benzylamide

MS APCI (M+1): 496.5535.

## EXAMPLE 332

15

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-  
carboxylic acid 3-chloro-benzylamide

MS APCI (M+1): 440.9212.

## EXAMPLE 333

20

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-  
carboxylic acid 3,5-dimethoxy-benzylamide

MS APCI (M+1): 466.5277

## EXAMPLE 334

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-  
carboxylic acid 2,3-dimethoxy-benzylamide

25

MS APCI (M+1): 466.5277.



-180-

## EXAMPLE 335

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-trifluoromethyl-benzylamide

MS APCI (M+1): 474.4732.

5

## EXAMPLE 336

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-methoxy-benzylamide

MS APCI (M+1): 436.5019.

## EXAMPLE 337

10

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-methyl-benzylamide

MS APCI (M+1): 420.5029.

## EXAMPLE 338

15

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (4-phenyl-butyl)-amide

MS APCI (M+1): 448.5565.

## EXAMPLE 339

20

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (pyridin-3-ylmethyl)-amide

MS APCI (M+1): 407.4642.

## EXAMPLE 340

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide

MS APCI (M+1): 436.5019.

25

## EXAMPLE 341

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid ((S)-2,2-dimethyl-4-phenyl-1,3-dioxinan-5-yl)-amide

-181-

MS APCI (M+1): 405.5923.

## EXAMPLE 342

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid [2-(3-methoxy-phenyl)-ethyl]-amide

5 MS APCI (M+1): 450.5287.

## EXAMPLE 343

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide

MS APCI (M+1): 436.5019.

10

## EXAMPLE 344

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (thiophen-2-ylmethyl)-amide

MS APCI (M+1): 412.5043.

## EXAMPLE 345

15

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-chloro-benzylamide

MS APCI (M+1): 440.9212.

## EXAMPLE 346

20

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (5-methyl-furan-2-ylmethyl)-amide

MS APCI (M+1): 410.4641.

## EXAMPLE 347

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (2,2-diphenyl-ethyl)-amide

25

MS APCI (M+1): 496.6005.

-182-

## EXAMPLE 348

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid [2-(2-methoxy-phenyl)-ethyl]-amide

MS APCI (M+1): 450.5287.

5

## EXAMPLE 349

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid [2-(3-trifluoromethyl-phenyl)-ethyl]-amide

MS APCI (M+1): 488.5.

## EXAMPLE 350

10

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-bromo-benzylamide

MS APCI (M+1): 485.3722.

## EXAMPLE 351

15

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-amide

MS APCI (M+1): 459.5398.

## EXAMPLE 352

20

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3,5-dichloro-benzylamide

MS APCI (M+1): 475.3663.

## EXAMPLE 353

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid indan-1-ylamide

MS APCI (M+1): 432.5139.

25

## EXAMPLE 354

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (furan-2-ylmethyl)-amide

-183-

MS APCI (M+1): 396.4373.

## EXAMPLE 355

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid [2-(4-methoxy-phenyl)-ethyl]-amide

5 MS APCI (M+1): 450.5287.

## EXAMPLE 356

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2,4-dimethoxy-benzylamide

MS APCI (M+1): 466.5277.

10

## EXAMPLE 357

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-chloro-benzylamide

MS APCI (M+1): 440.9212.

## EXAMPLE 358

15

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (1-phenyl-ethyl)-amide

MS APCI (M+1): 420.5029.

## EXAMPLE 359

20

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3,4-dichloro-benzylamide

MS APCI (M+1): 475.3663.

## EXAMPLE 360

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-fluoro-3-trifluoromethyl-benzylamide

25

MS APCI (M+1): 492.4633.

-184-

## EXAMPLE 361

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (2-pyridin-2-yl-ethyl)-amide

MS APCI (M+1): 421.491.

5

## EXAMPLE 362

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid [2-(2,4-dimethyl-phenyl)-ethyl]-amide

MS APCI (M+1): 448.5565.

## EXAMPLE 363

10

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid [2-(2,4-dichloro-phenyl)-ethyl]-amide

MS APCI (M+1): 489.3931.

## EXAMPLE 364

15

1,3-Dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide

The procedure of Example 34 was repeated, except 4-(4-bromomethyl-benzenesulfonyl)-morpholine was replaced by 4-bromomethyl-benzenesulfonic acid methyl ester to give 1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide as a white solid (15%); MS APCI (M+) 360.

20

## EXAMPLE 365

3-Cyanomethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide

## EXAMPLE 366

25

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide

The procedure of Example 34 was repeated, except 4-(4-bromomethyl-benzenesulfonyl)-morpholine was replaced by benzyl bromide to give 3-benzyl-

-185-

1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid  
3-methoxy-benzylamide as a white solid (86%); MS APCI (M<sup>+</sup>) 494.


## EXAMPLE 367

3-(4-Cyclopropylsulfamoyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-  
thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide

The procedure of Example 34 was repeated, except 4-(4-bromomethyl-  
benzenesulfonyl)-morpholine was replaced by 1-bromomethyl-  
4-cyclopropylmethanesulfonyl-benzene, to 3-(4-cyclopropylsulfamoyl-benzyl)-  
1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid  
3-methoxy-benzylamide as a white solid (95%); <sup>1</sup>H NMR (DMSO), δ 0.37 (d,  
J = 2.9 Hz, 2H), 0.46 (d, J = 4.9 Hz, 2H), 2.04 (m, 1H), 3.49 (s, 3H), 3.73 (s, 3H),  
4.42 (d, J = 5.9 Hz, 2H), 5.14 (s, 2H), 7.02-6.89 (m, 3H), 7.25 (t, J = 8.1 Hz, 1H),  
7.52 (d, J = 8.1 Hz, 2H), 7.74 (d, J = 8.4 Hz, 2H), 7.91 (s, 1H), 8.1 (s, 1H),  
9.23 (t, J = 5.6 Hz, 1H).

## EXAMPLE 368

1-Methyl-3-(6-nitro-pyridin-3-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-  
d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide




Made by the procedure of Example 217 from 1-methyl-1,2,3,4-tetrahydro-  
thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide and 5-  
(bromomethyl)-2-nitropyridine; mp 213-215°C.

## EXAMPLE 369

1-Methyl-3-(6-nitro-pyridin-3-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-  
d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide

-186-




Made by the procedure of Example 217 from 1-methyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide and 5-(bromomethyl)-2-nitropyridine; mp 238-241°C.

5

## EXAMPLE 370

1-Methyl-3-(6-nitro-pyridin-3-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide




10

Made by the procedure of Example 217 from 1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide and 5-(bromomethyl)-2-nitropyridine; mp 200-207°C.

## EXAMPLE 371

3-Cyclohexylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide




15

Made by the procedure of Example 217 from 1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide and bromomethyl-cyclohexane; mp 167-210°C.

-187-

## EXAMPLE 372

3-{2-[(1H-Benzimidazole-5-carbonyl)-amino]-ethyl}-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide



5 In an 8-mL screw cap vial was added a mixture of the compound of  
Example 252, namely 3-(2-amino-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-  
thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzyl amide, (0.038 g,  
0.1 mmol), diisopropylethylamine (0.038 g, 0.30 mmol), O-(benzotriazol-1-yl)-  
1,1,3,3-tetramethyluronium hexafluorophosphate (0.114 g, 0.30), and 1-hydroxy-  
10 7-azabenzotriazole (0.053 g, 0.30 mmol) in dimethylformamide (2 mL) followed  
by 1 H-benzoimidazole-5-carboxylic acid, (0.045 g, 0.3 mmol) in  
dimethylformamide (1 mL). The vial was capped and the reaction mixture was  
shaken for 24 hours at room temperature. The solvent was removed under  
vacuum. Purification was carried out via reverse-phase HPLC (3% n-propanol in  
acetonitrile and 3% n-propanol in water as the eluent; C-18 column). 0.023 g  
15 (50% yield). MS APCI (M+1): 533.5.

In a manner similar to the procedure of Example 372, the compounds of  
Examples 373 to 383 were prepared.

## EXAMPLE 373

20 1-Methyl-2,4-dioxo-3-[2-(3-piperidin-1-yl-propionylamino)-ethyl]-1,2,3,4-  
tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide  
MS APCI (M+1): 528.6427.



-188-

## EXAMPLE 374

1-Methyl-2,4-dioxo-3-{2-[(6-pyrazol-1-yl-pyridine-3-carbonyl)-amino]-ethyl}-  
1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-  
benzylamide

5 MS APCI (M+1): 560.6045.

## EXAMPLE 375

3-[2-(4-Diethylamino-benzoylamino)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-  
tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide  
MS APCI (M+1): 564.6757.

10

## EXAMPLE 376

3-{2-[(6-Chloro-pyridine-3-carbonyl)-amino]-ethyl}-1-methyl-2,4-dioxo-1,2,3,4-  
tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide  
MS APCI (M+1): 528.9868.

## EXAMPLE 377

15

1-Methyl-2,4-dioxo-3-{2-[(1H-pyrrole-2-carbonyl)-amino]-ethyl}-1,2,3,4-  
tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide  
MS APCI (M+1): 482.5307.

## EXAMPLE 378

20

3-[2-(2-Dimethylamino-acetylamino)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-  
tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide  
MS APCI (M+1): 474.5513.

## EXAMPLE 379

25

1-Methyl-2,4-dioxo-3-{2-[(pyrazine-2-carbonyl)-amino]-ethyl}-1,2,3,4-  
tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide  
MS APCI (M+1): 495.5298.

-189-

## EXAMPLE 380

1-Methyl-3-[2-(2-methyl-2-methylamino-propionylamino)-ethyl]-2,4-dioxo-  
1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-  
benzylamide

5 MS APCI (M+1): 488.5781.

## EXAMPLE 381

1-Methyl-2,4-dioxo-3-{2-[(pyrrolidine-2-carbonyl)-amino]-ethyl}-1,2,3,4-  
tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide  
MS APCI (M+1): 486.5623.

10

## EXAMPLE 382

1-Methyl-2,4-dioxo-3-{2-[3-(5-phenyl-1H-pyrrol-2-yl)-propionylamino]-ethyl}-  
1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-  
benzylamide  
MS APCI (M+1): 586.6819.

15


## EXAMPLE 383

1-Methyl-2,4-dioxo-3-{2-[2-(pyridin-4-ylsulfanyl)-acetylamin]-ethyl}-1,2,3,4-  
tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide  
MS APCI (M+1): 540.6345.

## EXAMPLE 384

20

3-(6-Amino-pyridin-3-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-  
thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide




Made by catalytic hydrogenation of the compound of Example 368 with  
Raney nickel; mp 131-134°C (dec.).

-190-

## EXAMPLE 385


1-Methyl-2,4-dioxo-3-(3-phenyl-prop-2-ynyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide



5 Made by the procedure of Example 217 from 1-methyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide and (3-bromo-prop-1-ynyl)-benzene; mp 168-171°C.

## EXAMPLE 386

10 3-(6-Amino-pyridin-3-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide



Made by catalytic hydrogenation of the compound of Example 369 with Raney nickel; mp 240-241°C.

## EXAMPLE 387

15 1-Methyl-3-benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidine-6-carboxylic acid benzyl ester

Step (1): 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidine-6-carboxylic acid benzyl ester

20 To a solution of 3-benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidine-6-carboxylic acid (obtained by the method of Preparation 4) (0.26 mmol, 80 mg) in anhydrous DMF (4 mL) were added benzyl alcohol (0.29 mmol, 30  $\mu$ L), diisopropylethylamine (0.58 mmol, 101  $\mu$ L), and

-191-

O (7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate ("HATU") (0.29 mmol, 111 mg). The reaction mixture was stirred at room temperature for 17 hours, and then concentrated under reduced pressure to yield an orange oil. The orange oil was dissolved with 20 mL of dichloromethane. The organic phase was washed with water (2 × 10 mL), dried (MgSO<sub>4</sub>), filtered, and concentrated. The resulting orange oil was purified by flash chromatography on silica gel (98:2 dichloromethane/methanol) to yield 53.9 mg (52%) of 3-benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidine-6-carboxylic acid benzyl ester as a white solid.

Step (2): 1-Methyl-3-benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidine-6-carboxylic acid benzyl ester

To a solution of the product of Step (1) (89.2 μmol, 35 mg) in anhydrous DMF (3 mL) were added iodomethane (267.8 μmol, 17 μL) and potassium carbonate (133.8 μmol, 18.5 mg). The heterogeneous reaction mixture was then stirred at room temperature for 17 hours, filtered, and concentrated under reduced pressure to afford an orange oil. The orange oil was dissolved with diethyl ether (5 mL). The resulting white precipitate was collected, washed with diethyl ether (2 × 3 mL), and dried under vacuum to yield 28.8 mg (80%) of 1-methyl-3-benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidine-6-carboxylic acid benzyl ester as a white solid.

N.M.R: DMSO <sup>1</sup>H δ (ppm) : 3.55 (s, 3H), 5.10 (s, 2H), 5.40 (s, 2H), 7.20-7.50 (m, 10H), 8.25 (s, 1H); Purity (HPLC, Ultraviolet light detector at 214 nm): 98.0%.

#### EXAMPLE 388

1-Methyl-3-benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidine-6-carboxylic acid benzyl amide

Step (1): 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidine-6-carboxylic acid benzyl amide

To a solution of 3-benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidine-6-carboxylic acid (obtained by the method of Preparation 4) (0.12 mmol, 35 mg) in anhydrous DMF (3 mL) were added

-192-

benzylamine (0.115 mmol, 13  $\mu$ L), diisopropylethylamine (0.253 mmol, 44  $\mu$ L), and HATU (0.127 mmol, 49 mg). The reaction mixture was stirred at room temperature for 17 hours, and then concentrated under reduced pressure to yield a white solid. The white solid was dissolved with 4 mL of acetonitrile. The resulting precipitate was collected, washed with cold acetonitrile ( $2 \times 2$  mL), and dried under vacuum to yield 40.1 mg (88%) of 3-benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidine-6-carboxylic acid benzyl amide as a white solid.

Step (2): 1-Methyl-3-benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidine-6-carboxylic acid benzyl amide

To a solution of the product of Step (1) (76.7  $\mu$ mol, 30 mg) in anhydrous DMF (3 mL) were added iodomethane (230.1  $\mu$ mol, 15  $\mu$ L) and potassium carbonate (115.1  $\mu$ mol, 16 mg). The heterogeneous reaction mixture was then stirred at room temperature for 17 hours, filtered, and concentrated under reduced pressure to yield an orange oil. The orange oil was dissolved with diisopropyl ether (5 mL). The resulting white precipitate was collected, washed with diisopropyl ether ( $3 \times 5$  mL), and dried under vacuum to yield 28.2 mg (90%) of 1-methyl-3-benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidine-6-carboxylic acid benzyl amide as a beige solid.

N.M.R: DMSO  $^1\text{H}$   $\delta$  (ppm) : 3.50 (s, 3H), 4.50 (d, 2H), 5.08 (s, 2H), 7.20-7.40 (m, 10H), 8.00 (s, 1H), 9.40 (t, 1H); Purity (HPLC 214 nm): 95.4%.

#### EXAMPLE 389

1-Methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidine-6-carboxylic acid benzyl amide

Step (1): 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidine-6-carboxylic acid methyl ester

To a solution of 3-benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidine-6-carboxylic acid (obtained by the method of Preparation 4) (0.33 mmol, 100 mg) in anhydrous DMF (4 mL) were added iodomethane (0.99 mmol, 63  $\mu$ L) and potassium carbonate (0.99 mmol, 138 mg). The heterogeneous reaction mixture was then stirred at room temperature for 17 hours, filtered, and concentrated under reduced pressure to yield an orange solid. The

-193-

orange oil was dissolved with pentane (5 mL). The resulting precipitate was collected, washed with pentane ( $2 \times 5$  mL), and dried under vacuum to yield 93.2 mg (84%) of 3-benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidine-6-carboxylic acid methyl ester as a yellow solid.

5           Step (2): 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidine-6-carboxylic acid methyl ester

To a solution of the product of Step (1) (0.328 mmol, 108.3 mg) in benzene (12 mL) was added aluminum chloride (1.97 mmol, 262 mg), and the reaction mixture was allowed to warm to 45°C for 7 hours. The reaction mixture was then diluted with ethyl acetate (20 mL), and the organic phase was washed with water ( $3 \times 10$  mL), dried ( $\text{MgSO}_4$ ), and concentrated under reduced pressure to provide a brown solid. The brown solid was dissolved with diethyl ether. The resulting precipitate was collected, washed with diethyl ether ( $3 \times 5$  mL), and dried under vacuum to yield 42.3 mg (53%) of 1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidine-6-carboxylic acid methyl ester as a mauve-colored solid.

15           Step (3): 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidine-6-carboxylic acid

To a solution of the product of Step (2) (0.175 mmol, 42 mg) in methanol (2 mL) was added a solution of lithium hydroxide (0.437 mmol, 11 mg) in water (1 mL), and the resulting reaction mixture was stirred at room temperature for 17 hours. After concentration under reduced pressure, the crude product was dissolved in 1.0M hydrochloric acid (10 mL) and extracted with ethyl acetate ( $2 \times 15$  mL). The combined organic phases were washed with water ( $2 \times 15$  mL), dried ( $\text{MgSO}_4$ ), filtered, and concentrated under reduced pressure to yield 34.8 mg (88%) of 1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidine-6-carboxylic acid as a white solid.

25           Step (4): 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidine-6-carboxylic acid benzyl amide

30           To a solution of the product of Step (3) (0.152 mmol, 34.5 mg) in anhydrous DMF (3 mL) were added benzylamine (0.17 mmol, 19  $\mu\text{L}$ ), diisopropylethylamine (0.34 mmol, 59  $\mu\text{L}$ ), and HATU (0.17 mmol, 64 mg). The

-194-

reaction mixture was then stirred at room temperature for 17 hours and evaporated under reduced pressure to yield an orange oil. The orange oil was dissolved with 5 mL of ethanol. The resulting precipitate was collected, washed with cold ethanol (2 × 3 mL), pentane (2 × 3 mL), and dried under vacuum to yield 33.8 mg (70%) of 1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidine-6-carboxylic acid benzyl amide as a white solid.

N.M.R: DMSO  $^1\text{H}$   $\delta$  (ppm) : 3.42 (s, 3H), 4.50 (d, 2H), 7.25-7.40 (m, 5H), 7.95 (s, 1H), 9.35 (t, 1H); Purity (HPLC 214 nm): 96.5%.

The invention compounds of Formula I have been evaluated in standard assays for their ability to inhibit the catalytic activity of various MMP enzymes. The assays used to evaluate the biological activity of the invention compounds are well known and routinely used by those skilled in the study of MMP inhibitors and their use to treat clinical conditions.

The assays measure the amount by which a test compound reduces the hydrolysis of a thiopeptolide substrate caused by a matrix metalloproteinase enzyme. Such assays are described in detail by Ye et al., in *Biochemistry*, 1992;31(45):11231-11235, which is incorporated herein by reference.

Thiopeptolide substrates show virtually no decomposition or hydrolysis at or below neutral pH in the absence of a matrix metalloproteinase enzyme. A typical thiopeptolide substrate commonly utilized for assays is Ac-Pro-Leu-Gly-thioester;-Leu-Leu-Gly-OEt. A 100  $\mu\text{L}$  assay mixture will contain 50 mM of N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid buffer ("HEPES," pH 7.0) 10 mM  $\text{CaCl}_2$ , 100  $\mu\text{M}$  thiopeptolide substrate, and 1 mM 5,5'-dithio-bis-(2-nitrobenzoic acid) (DTNB). The thiopeptolide substrate concentration may be varied from, for example, 10 to 800  $\mu\text{M}$  to obtain  $K_m$  and  $K_{cat}$  values. The change in absorbance at 405 nm is monitored on a Thermo Max microplate reader (moleucular Devices, Menlo Park, CA) at room temperature (22°C). The calculation of the amount of hydrolysis of the thiopeptolide substrate is based on  $E_{412} = 13600 \text{ M}^{-1} \text{ cm}^{-1}$  for the DTNB-derived product 3-carboxy-4-nitrothiophenoxide. Assays are carried out with and without matrix metalloproteinase inhibitor compounds, and the amount of hydrolysis is compared for a determination of inhibitory activity of the test compounds.

-195-

Several representative compounds have been evaluated for their ability to inhibit various matrix metalloproteinase enzymes. The invention compounds are uniquely active in inhibiting MMP-13. Table I below presents inhibitory activity for compounds from various classes. In the table, MMP-13CD refers to the catalytic domain of collagenase-3. Test compounds were evaluated at various concentrations in order to determine their respective IC<sub>50</sub> values, the micromolar concentration of compound required to cause a 50% inhibition of the hydrolytic activity of the respective enzyme.



-196-  
Table I

Compound of Example No.	MMP-13CD IC <sub>50</sub> , (μM)
1	0.74
2	0.31
3	30.0
4	16.0
5	51.0
6	>100.0
7	10.0
8	15.0
9	0.007
10	0.068
11	0.47
12	>100.0
13	18.0
14	7.5
48	1.45
49	0.26
50	0.0875
51	0.0205
52	0.00395
53	30
54	4.5
55	0.011
56	30
57	5.6
58	0.0115
59	2
60	0.16
61	0.045

-197-

Table I (cont)

Compound of Example No.	MMP-13CD IC <sub>50</sub> , (μM)
62	0.0535
63	0.11
64	0.062
65	0.0535
65a	1.05
66	0.0275
67	0.00168
68	0.0635
69	0.057
70	0.1185
71	12.96
72	>100
73	>100
74	71.5
75	0.345
76	
77	0.00655
78	0.900
79	0.00205
80	25
81	3.899
82	3.700
83	0.140
84	0.02050
85	0.04750
86	1.3999
87	0.0185
88	3.149

-198-

Table I (cont)

Compound of Example No.	MMP-13CD IC <sub>50</sub> , (μM)
89	0.1135
90	0.00543
91	0.0496
92	0.0109
93	0.111
94	0.005349
95	0.10349
96	0.018499
97	>100
98	0.063
99	0.16
100	0.61
101	0.034
102	0.034
103	0.03
104	1.1
105	0.52
106	0.59
107	2.4
108	1.7
109	0.94
110	0.42
111	3.2
112	2.9
113	2.9
114	0.33
115	0.33
116	13
117	0.036

-199-

Table I (cont)

Compound of Example No.	MMP-13CD
	IC <sub>50</sub> , (μM)
118	0.015
119	0.51
120	0.13
121	0.25
122	4.5
123	7.8
124	0.11
125	0.09
126	13
127	3.9
128	0.19
129	0.16
130	0.097
131	0.019
132	0.074
133	0.074
134	1.5
135	0.086
136	0.051
137	8.3
138	0.66
139	0.25
140	0.017
141	0.15
142	0.39
143	0.28
144	0.003
145	1.3
146	47

-200-

Table I (cont)

Compound of Example No.	MMP-13CD
	IC <sub>50</sub> , (μM)
147	0.16
148	0.54
149	15
150	13
151	>100
152	9.9
153	0.004
154	32
155	62
156	0.18
157	>100
158	16
159	30
160	30
161	11
162	11
163	0.016
164	69
165	20
166	0.92
167	26
168	25
169	30
170	0.72
171	14
172	32
173	>100
174	>100
175	>100

-201-

Table I (cont)

Compound of Example No.	MMP-13CD IC <sub>50</sub> , (μM)
176	>100
177	>100
178	>100
179	0.25
180	30
181	>100
182	8.6
183	30
184	>100
185	0.014
186	4.5
187	>100
188	19
189	4.9
190	>100
191	2.3
192	0.0034
193	0.0034
194	88
195	>100
196	30
197	>100
198	>100
199	17
200	0.067
201	0.3
202	0.36
203	0.36
204	0.072

-202-

Table I (cont)

Compound of Example No.	MMP-13CD IC <sub>50</sub> , (μM)
205	19
206	15
207	0.2
208	0.1
209	>100
210	1.2
211	2.1
212	0.67
213	1.7
214	20
215	24
216	18
217	0.0785
218	18
219	17
220	0.061
221	0.0046
222	0.0042
223	N/A <sup>a</sup>
224	0.783
225	0.225
226	4.9
227	3.8
228	0.435
229	0.68
230	0.077
231	2.9
231a	0.00895
232	0.175

-203-

Table I (cont)

Compound of Example No.	MMP-13CD
	IC <sub>50</sub> , (μM)
233	0.069
234	0.15
235	18
236	0.0495
237	0.0925
238	0.0555
239	0.0585
240	0.18
241	0.0195
242	3
243	1.4
244	1.25
245	30
246	5.65
247	7.2
248	N/A
249	7.8
249a	0.64
250	0.00765
251	0.655
252	24
252a	N/A
253	0.81
254	1.5
255	14
256	27.5
257	1.5
258	0.27
259	30



-204-

Table I (cont)

Compound of Example No.	MMP-13CD
	IC <sub>50</sub> , (μM)
260	0.063
261	0.58
262	3.4
263	2.15
264	7.4
265	0.038
266	4
267	1.1
268	3.6
269	26
270	1.8
271	5.9
272	30
273	0.059
274	0.018
275	0.036
276	0.23
277	20
278	7.6
279	3.5
280	17
281	8.9
282	10
283	1.7
284	1.5
285	30
286	0.27
287	1.9
288	4.2

-205-

Table I (cont)

Compound of Example No.	MMP-13CD IC <sub>50</sub> , (μM)
289	2.7
290	15
291	0.12
292	10
293	>100
294	>100
295	0.23
296	0.0505
297	0.057
298	0.49
299	30
300	>100
301	>100
302	30
303	0.0036
304	3.1
305	46.6666
306	30
307	0.0052
308	0.00715
309	0.056
310	30
311	0.0845
312	0.0275
313	0.00645
314	0.0185
315	0.0205
316	NA
317	NA

-206-

Table I (cont)

Compound of Example No.	MMP-13CD IC <sub>50</sub> , (μM)
318	NA
319	8
320	>100
321	>100
322	>100
323	>100
324	>100
325	>100
326	-9999
327	2.8
328	2.7
329	30
330	>100
331	>100
332	1
333	>100
334	>100
335	0.25
336	30
337	>100
338	>100
339	0.38
340	0.12
341	14
342	>100
343	0.044
344	3.6
345	30
346	9.9

-207-

Table I (cont)

Compound of Example No.	MMP-13CD IC <sub>50</sub> , (μM)
347	16
348	30
349	>100
350	0.93
351	2
352	>100
353	>100
354	30
355	>100
356	10
357	0.32
358	>100
359	1
360	0.27
361	7.7
362	>100
363	30
364	NA
365	1.55
366	NA
367	0.00825
368	0.735
369	1.04
370	1.17
371	0.22
372	NA
373	NA
374	NA
375	NA

-208-

Table I (cont)

Compound of Example No.	MMP-13CD IC <sub>50</sub> , (μM)
376	NA
377	NA
378	NA
379	NA
380	NA
381	NA
382	NA
383	NA
384	0.66
385	0.007
386	NA

<sup>a</sup> NA means data not available

Selectivity of the invention compounds for inhibiting MMP-13 over certain other MMP enzymes is illustrated by a few randomly selected examples in Table II below.

In Table II, MMP-1FL refers to full-length interstitial collagenase; MMP-2FL refers to full length Gelatinase A; MMP-3CD refers to the catalytic domain of stromelysin-1; MMP-7FL refers to full-length matrilysin; MMP-9FL refers to full-length Gelatinase B; MMP-13CD refers to the catalytic domain of collagenase-3; and MMP-14CD refers to the catalytic domain of MMP-14. Test compounds were evaluated at various concentrations in order to determine their respective IC<sub>50</sub> values, the micromolar concentration of compound required to cause a 50% inhibition of the hydrolytic activity of the respective enzyme.

It should be appreciated that the assay buffer used with MMP-3CD is 50 mM N-morpholinoethanesulfonate ("MES") at pH 6.0 rather than the HEPES buffer at pH 7.0 described above.

-209-

Table II

IC<sub>50</sub> With Certain MMP Enzymes

Ex. No.	MMP-1FL	MMP-2FL	MMP-3CD	MMP-7FL	MMP-9FL	MMP-12CD	MMP-13CD	MMP-14CD
1	100	100	18	100	100	100	0.61	100
303	100	100	6	32	30	100	0.0036	100
20	100	100	100	100	100	100	0.0065	100
49	100	100	23	100	100	100	0.26	100
217	100	100	27	100	30	30	0.0785	100
63	30	30	18	30	30	30	0.11	30
228	30	30	15	10	30	30	0.435	30
39	100	100	16	100	100	10	0.0038	100
246	100	30	23	48	30	30	5.65	36
231a	100	50	13	46	91	30	0.0090	30
232	30	30	17	30	30	30	0.18	30
47	30	30	30	14	30	30	0.038	10
249a	100	30	100	30	30	100	0.64	30
369	10	30	10	30	30	30	1.04	30

The foregoing data in Tables I and II establish that the invention compounds of Formula I are potent inhibitors of MMP enzymes, and are especially useful due to their selective inhibition of MMP-13. Because of this potent and selective inhibitory activity, the invention compounds are especially useful to treat diseases mediated by the MMP enzymes, and particularly those mediated by MMP-13.

Administration of a compound of Formula 1, or a pharmaceutically acceptable salt thereof, to a mammal to treat the diseases mediated by MMP enzymes is preferably, although not necessarily, accomplished by administering the compound, or the salt thereof, in a pharmaceutical dosage form.

The compounds of the present invention can be prepared and administered in a wide variety of oral and parenteral dosage forms. Thus, the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Also, the compounds of the present invention can be

-210-

administered by inhalation, for example, intranasally. Additionally, the compounds of the present invention can be administered transdermally. It will be obvious to those skilled in the art that the following dosage forms may comprise as the active component, either a compound of Formula I or a corresponding pharmaceutically acceptable salt of a compound of Formula I. The active compound generally is present in a concentration of about 5% to about 95% by weight of the formulation.

For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.

In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component.

In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

The powders and tablets preferably contain from five or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component, with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.

For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture

-211-

is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions. For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.

Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing, and thickening agents as desired.

Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.

Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

The pharmaceutical preparation is preferably in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

The quantity of active component in a unit dose preparation may be varied or adjusted from 1 mg to 1000 mg, preferably 10 mg to 100 mg according to the particular application and the potency of the active component. The composition can, if desired, also contain other compatible therapeutic agents.

In therapeutic use as agents to inhibit a matrix metalloproteinase enzyme for the treatment of atherosclerotic plaque rupture, aortic aneurysm, heart failure, restenosis, periodontal disease, corneal ulceration, cancer metastasis, tumor



-212-

angiogenesis, arthritis, or other autoimmune or inflammatory disorders dependent upon breakdown of connective tissue, the compounds utilized in the pharmaceutical method of this invention are administered at a dose that is effective to inhibit the hydrolytic activity of one or more matrix metalloproteinase enzymes. The initial dosage of about 1 mg to about 100 mg per kilogram daily will be effective. A daily dose range of about 25 mg to about 75 mg per kilogram is preferred. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstance is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired. Typical dosages will be from about 0.1 to about 500 mg/kg, and ideally about 25 to about 250 mg/kg, such that it will be an amount which is effective to treat the particular disease being prevented or controlled.

The following examples illustrate typical formulations provided by the invention.

#### FORMULATION EXAMPLE 1

##### Tablet Formulation

Ingredient	Amount (mg)
Compound of Example 1	25
Lactose	50
Corn starch (for mix)	10
Corn starch (paste)	10
Magnesium stearate (1%)	5
Total	100

The fused pyrimidinone of Example 1, lactose, and corn starch (for mix) are blended to uniformity. The corn starch (for paste) is suspended in 200 mL of

-213-

water and heated with stirring to form a paste. The paste is used to granulate the mixed powders. The wet granules are passed through a No. 8 hand screen and dried at 80°C. The dry granules are lubricated with the 1% magnesium stearate and pressed into a tablet. Such tablets can be administered to a human from one to  
5 four times a day for treatment of atherosclerosis and arthritis.

## FORMULATION EXAMPLE 2

Preparation for Oral Solution

Ingredient	Amount
Compound of Example 210	400 mg
Sorbitol solution (70% N.F.)	40 mL
Sodium benzoate	20 mg
Saccharin	5 mg
Red dye	10 mg
Cherry flavor	20 mg
Distilled water q.s.	100 mL

The sorbitol solution is added to 40 mL of distilled water, and the fused pyrimidinone of Example 210 is dissolved therein. The saccharin, sodium  
10 benzoate, flavor, and dye are added and dissolved. The volume is adjusted to 100 mL with distilled water. Each milliliter of syrup contains 4 mg of invention compound.

## FORMULATION EXAMPLE 3

Parenteral Solution

15 In a solution of 700 mL of propylene glycol and 200 mL of water for injection is suspended 20 g of the compound of Example 14. After suspension is complete, the pH is adjusted to 6.5 with 1N sodium hydroxide, and the volume is made up to 1000 mL with water for injection. The formulation is sterilized, filled into 5.0 mL ampoules each containing 2.0 mL, and sealed under nitrogen.

20 As matrix metalloproteinase inhibitors, the compounds of Formula I are useful as agents for the treatment of multiple sclerosis. They are also useful as


-214-

agents for the treatment of atherosclerotic plaque rupture, restenosis, periodontal disease, corneal ulceration, treatment of burns, decubital ulcers, wound repair, heart failure, cancer metastasis, tumor angiogenesis, arthritis, and other inflammatory disorders dependent upon tissue invasion by leukocytes.

-215-  
CLAIMS

What is claimed is:


1. A compound of Formula I



I

- 5 or a pharmaceutically acceptable salt thereof;  
wherein:

W, together with the carbon atoms to which it is attached, form a  
5-membered ring diradical



10

A is  $\begin{array}{c} \text{O} \\ || \\ -\text{C}- \end{array}$  or  $\begin{array}{c} (\text{O})_{0-2} \\ || \\ -\text{S}- \end{array}$ ;

B is O or NR<sup>5</sup>; or

A and B are taken together to form -C≡C-;

15

X is O, S, SO, SO<sub>2</sub>, NR<sup>5</sup>, or CH<sub>2</sub>;

each Y independently is O or S;

-216-

$R^1$ ,  $R^4$ , and  $R^5$  independently are hydrogen,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  
 $C_2$ - $C_6$  alkynyl,  $(CH_2)_n$  cycloalkyl,  $(CH_2)_n$  heterocyclic,  
 $C_1$ - $C_6$  alkanoyl,  $(CH_2)_n$  aryl, or  $(CH_2)_n$  heteroaryl;

$R^2$  and  $R^3$  independently are hydrogen,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  
 $C_2$ - $C_6$  alkynyl, CN,  $NO_2$ ,  $NR^4R^5$ ,  $(CH_2)_n$  cycloalkyl,  $(CH_2)_n$   
 aryl, or  $(CH_2)_n$  heteroaryl;


$R^2$  may further be halo;

$n$  is an integer of from 0 to 5; and

$R^4$  and  $R^5$  when taken together with the nitrogen to which they are  
 attached complete a 3- to 8-membered ring containing carbon  
 atoms and optionally containing O, S, or N, and substituted or  
 unsubstituted;

with the proviso that  $R^1$  and  $R^3$  are not both selected from: hydrogen and  
 $C_1$ - $C_6$  alkyl.

2. A compound of Formula XI




XI

or a pharmaceutically salt thereof,

wherein:

W, together with the carbon atoms to which it is attached, form a  
 5-membered ring diradical



each Y independently is O or S;

X is S, O, or  $NR^5$ ;

-217-

$R^1$ ,  $R^4$ , and  $R^5$  independently are hydrogen,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $(CH_2)_n$  cycloalkyl,  $(CH_2)_n$  heterocyclic,  $C_1$ - $C_6$  alkanoyl,  $(CH_2)_n$  aryl, or  $(CH_2)_n$  heteroaryl;

$R^2$  is hydrogen, halo,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl, CN,  $NO_2$ ,  $NR^4R^5$ ,  $(CH_2)_n$  cycloalkyl,  $(CH_2)_n$  aryl, or  $(CH_2)_n$  heteroaryl;

$R^3$  is hydrogen, halo,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl, CN,  $NO_2$ ,  $NR^4R^5$ ,  $(CH_2)_q$  cycloalkyl,  $(CH_2)_q$  aryl, or  $(CH_2)_q$  heteroaryl;

$n$  is 0, 1, or 2;

$q$  is 2, 3, or 4; and

$R^4$  and  $R^5$  when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing O, S, or N, and substituted or unsubstituted;

with the proviso that  $R^1$  and  $R^3$  are not both selected from hydrogen and  $C_1$ - $C_6$  alkyl.


3. The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein Y is O, and X is S; or

The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein Y is O, and X is O; or

The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein Y is O, and X is  $NR^5$ , wherein  $R^5$  is hydrogen,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $(CH_2)_n$  cycloalkyl,  $(CH_2)_n$  heterocyclic,  $C_1$ - $C_6$  alkanoyl,  $(CH_2)_n$  aryl, or  $(CH_2)_n$  heteroaryl.

4. A compound of Formula II

-218-



II

or a pharmaceutically acceptable salt thereof,

wherein:

A is  $\begin{array}{c} \text{O} \\ \parallel \\ -\text{C}- \end{array}$  or  $\begin{array}{c} (\text{O})_{0-2} \\ \parallel \\ -\text{S}- \end{array}$ ;

B is O or NR<sup>5</sup>; or

A and B are taken together to form -C≡C-;

each Y independently is O or S;

R<sup>1</sup>, R<sup>4</sup>, and R<sup>5</sup> independently are hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, (CH<sub>2</sub>)<sub>n</sub> cycloalkyl, (CH<sub>2</sub>)<sub>n</sub> heterocyclic, C<sub>1</sub>-C<sub>6</sub> alkanoyl, (CH<sub>2</sub>)<sub>n</sub> aryl, or (CH<sub>2</sub>)<sub>n</sub> heteroaryl;

R<sup>2</sup> and R<sup>3</sup> independently are hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, CN, NO<sub>2</sub>, NR<sup>4</sup>R<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub> cycloalkyl, (CH<sub>2</sub>)<sub>n</sub> aryl, or (CH<sub>2</sub>)<sub>n</sub> heteroaryl;

R<sup>2</sup> may further be halo;

n is an integer of from 0 to 5; and

R<sup>4</sup> and R<sup>5</sup> when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing O, S, or N, and substituted or unsubstituted;

with the proviso that R<sup>1</sup> and R<sup>3</sup> are not both selected from: hydrogen and C<sub>1</sub>-C<sub>6</sub> alkyl.

5. The compound according to Claim 4, or a pharmaceutically acceptable salt thereof, wherein -A-B- is -C≡C-; or

-219-

The compound according to Claim 4, or a pharmaceutically acceptable salt



thereof, wherein A is -C- and B is NR<sup>5</sup>, wherein R<sup>5</sup> is hydrogen,

5

C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, (CH<sub>2</sub>)<sub>n</sub> cycloalkyl, (CH<sub>2</sub>)<sub>n</sub> heterocyclic, C<sub>1</sub>-C<sub>6</sub> alkanoyl, (CH<sub>2</sub>)<sub>n</sub> aryl, or (CH<sub>2</sub>)<sub>n</sub> heteroaryl; or


The compound according to Claim 4, or a pharmaceutically acceptable salt



10

thereof, wherein A is -C- and B is O.

6. A compound of Formula III



III

or a pharmaceutically acceptable salt thereof,

wherein:

15



A is -C- or -S-;

B is O or NR<sup>5</sup>; or

A and B are taken together to form -C≡C-;

20

R<sup>1</sup>, R<sup>4</sup>, and R<sup>5</sup> independently are hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, (CH<sub>2</sub>)<sub>n</sub> cycloalkyl, (CH<sub>2</sub>)<sub>n</sub> heterocyclic, C<sub>1</sub>-C<sub>6</sub> alkanoyl, (CH<sub>2</sub>)<sub>n</sub> aryl, or (CH<sub>2</sub>)<sub>n</sub> heteroaryl;

R<sup>2</sup> and R<sup>3</sup> independently are hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl,

C<sub>2</sub>-C<sub>6</sub> alkynyl, CN, NO<sub>2</sub>, NR<sup>4</sup>R<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub> cycloalkyl, (CH<sub>2</sub>)<sub>n</sub>

25

aryl, or (CH<sub>2</sub>)<sub>n</sub> heteroaryl;

R<sup>2</sup> may further be halo;

n is an integer of from 0 to 5; and




-220-

$R^4$  and  $R^5$  when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing O, S, or N, and substituted or unsubstituted;

5 with the proviso that  $R^1$  and  $R^3$  are not both selected from hydrogen and  $C_1$ - $C_6$  alkyl; or

a compound of Formula IV



or a pharmaceutically acceptable salt thereof,

10 wherein:

$$\begin{array}{c} \text{O} \quad (\text{O})_{0-2} \\ || \quad || \\ \text{A is } -\text{C}- \text{ or } -\text{S}-; \end{array}$$

B is O or  $\text{NR}^5$ ; or

15 A and B are taken together to form  $-\text{C}\equiv\text{C}-$ ;

$R^1$ ,  $R^4$ , and  $R^5$  independently are hydrogen,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $(\text{CH}_2)_n$  cycloalkyl,  $(\text{CH}_2)_n$  heterocyclic,  $C_1$ - $C_6$  alkanoyl,  $(\text{CH}_2)_n$  aryl, or  $(\text{CH}_2)_n$  heteroaryl;

$R^2$  and  $R^3$  independently are hydrogen,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,

20  $C_2$ - $C_6$  alkynyl, CN,  $\text{NO}_2$ ,  $\text{NR}^4\text{R}^5$ ,  $(\text{CH}_2)_n$  cycloalkyl,  $(\text{CH}_2)_n$  aryl, or  $(\text{CH}_2)_n$  heteroaryl;

$R^2$  may further be halo;

n is an integer of from 0 to 5; and


25  $R^4$  and  $R^5$  when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon

-221-

atoms and optionally containing O, S, or N, and substituted or unsubstituted;

with the proviso that  $R^1$  and  $R^3$  are not both selected from hydrogen and  $C_1$ - $C_6$  alkyl; or

5 a compound of Formula V



or a pharmaceutically acceptable salt thereof,  
wherein:

10 
$$\begin{array}{c} \text{O} \quad (\text{O})_{0-2} \\ \parallel \quad \parallel \\ \text{A is } -\text{C}- \text{ or } -\text{S}-; \end{array}$$

B is O or  $\text{NR}^5$ ; or

A and B are taken together to form  $-\text{C}\equiv\text{C}-$ ;

15  $R^1$ ,  $R^4$ , and  $R^5$  independently are hydrogen,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $(\text{CH}_2)_n$  cycloalkyl,  $(\text{CH}_2)_n$  heterocyclic,  $C_1$ - $C_6$  alkanoyl,  $(\text{CH}_2)_n$  aryl, or  $(\text{CH}_2)_n$  heteroaryl;

$R^2$  and  $R^3$  independently are hydrogen,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl, CN,  $\text{NO}_2$ ,  $\text{NR}^4\text{R}^5$ ,  $(\text{CH}_2)_n$  cycloalkyl,  $(\text{CH}_2)_n$  aryl, or  $(\text{CH}_2)_n$  heteroaryl;

20  $R^2$  may further be halo;

n is an integer of from 0 to 5; and

25  $R^4$  and  $R^5$  when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing O, S, or N, and substituted or unsubstituted;

-222-

with the proviso that R<sup>1</sup> and R<sup>3</sup> are not both selected from hydrogen and C<sub>1</sub>-C<sub>6</sub> alkyl.

7. The compound according to Claim 1, selected from:

- 5 4-{6-[3-(4-Methoxy-phenyl)-prop-1-ynyl]-1-methyl-2,4-dioxo-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidine-3-ylmethyl}-benzoic acid;
- 3-(4-Methanesulfonyl-benzyl)-6-[3-(4-methoxy-phenyl)-prop-1-ynyl]-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;
- 4-{6-[3-(3-Methoxy-phenyl)-prop-1-ynyl]-1-methyl-2,4-dioxo-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidine-3-ylmethyl}-benzoic acid;
- 10 3-(4-Methanesulfonyl-benzyl)-6-[3-(3-methoxy-phenyl)-prop-1-ynyl]-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;
- 4-[1-Methyl-2,4-dioxo-6-(3-pyridine-4-yl-prop-1-ynyl)-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidine-3-ylmethyl]-benzoic acid;
- 3-(4-Methanesulfonyl-benzyl)-1-6-(3-pyridin-4-yl-prop-1-ynyl)-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;
- 15 4-[1-Methyl-2,4-dioxo-6-(3-pyridine-3-yl-prop-1-ynyl)-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidine-3-ylmethyl]-benzoic acid;
- 3-(4-Methanesulfonyl-benzyl)-1-6-(3-pyridin-3-yl-prop-1-ynyl)-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;
- 20 4-{6-[3-(4-Fluoro-phenyl)-prop-1-ynyl]-1-methyl-2,4-dioxo-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidine-3-ylmethyl}-benzoic acid;
- 6-[3-(4-Fluoro-phenyl)-prop-1-ynyl]-3-(4-methanesulfonyl-benzyl)-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;
- 4-{6-[3-(3-Fluoro-phenyl)-prop-1-ynyl]-1-methyl-2,4-dioxo-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidine-3-ylmethyl}-benzoic acid;
- 25 6-[3-(3-Fluoro-phenyl)-prop-1-ynyl]-3-(4-methanesulfonyl-benzyl)-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;
- 4-{6-[3-(4-Chloro-phenyl)-prop-1-ynyl]-1-methyl-2,4-dioxo-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidine-3-ylmethyl}-benzoic acid;
- 30 6-[3-(4-Chloro-phenyl)-prop-1-ynyl]-3-(4-methanesulfonyl-benzyl)-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

-223-

- 4-{6-[3-(3-Chloro-phenyl)-prop-1-ynyl]-1-methyl-2,4-dioxo-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidine-3-ylmethyl}-benzoic acid;  
6-[3-(3-Chloro-phenyl)-prop-1-ynyl]-3-(4-methanesulfonyl-benzyl)-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;
- 5 4-{6-[3-(4-Bromo-phenyl)-prop-1-ynyl]-1-methyl-2,4-dioxo-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidine-3-ylmethyl}-benzoic acid;  
6-[3-(4-Bromo-phenyl)-prop-1-ynyl]-3-(4-methanesulfonyl-benzyl)-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;
- 10 4-{6-[3-(3-Bromo-phenyl)-prop-1-ynyl]-1-methyl-2,4-dioxo-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidine-3-ylmethyl}-benzoic acid;  
6-[3-(3-Bromo-phenyl)-prop-1-ynyl]-3-(4-methanesulfonyl-benzyl)-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;
- 15 4-{1-Methyl-6-[3-(4-nitro-phenyl)-prop-1-ynyl]-2,4-dioxo-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidine-3-ylmethyl}-benzoic acid;  
3-(4-Methanesulfonyl-benzyl)-1-methyl-6-[3-(4-nitro-phenyl)-prop-1-ynyl]-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;
- 20 4-{6-[3-(2-Methoxy-pyridin-4-yl)-prop-1-ynyl]-1-methyl-2,4-dioxo-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidine-3-ylmethyl}-benzoic acid;  
3-(4-Methanesulfonyl-benzyl)-6-[3-(2-methoxy-pyridin-4-yl)-prop-1-ynyl]-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;
- 25 4-{1-Methyl-6-[3-(4-methylsulfanyl-phenyl)-prop-1-ynyl]-2,4-dioxo-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidine-3-ylmethyl}-benzoic acid;  
3-(4-Methanesulfonyl-benzyl)-1-methyl-6-[3-(4-methylsulfanyl-phenyl)-prop-1-ynyl]-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;
- 30 4-{1-Methyl-6-[3-(3-methylsulfanyl-phenyl)-prop-1-ynyl]-2,4-dioxo-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidine-3-ylmethyl}-benzoic acid;  
3-(4-Methanesulfonyl-benzyl)-1-methyl-6-[3-(3-methylsulfanyl-phenyl)-prop-1-ynyl]-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;
- 4-[1-Methyl-2,4-dioxo-6-(3-*p*-tolyl-prop-1-ynyl)-1,4-dihydro-2*H*-thieno[2,3-*d*]pyrimidin-3-ylmethyl]benzoic acid;  
3-(4-Methanesulfonyl-benzyl)-1-methyl-6-(3-*p*-tolyl-prop-1-ynyl)-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

-224-

4-[1-Methyl-2,4-dioxo-6-(3-*m*-tolyl-prop-1-ynyl)-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]benzoic acid;

3-(4-Methanesulfonyl-benzyl)-1-methyl-6-(3-*m*-tolyl-prop-1-ynyl)-1H-thieno[2,3-*d*]pyrimidine-2,4-dione;

5 3-Benzyl-6-[3-(4-methoxy-phenyl)-prop-1-ynyl]-1-methyl-1H-thieno[2,3-*d*]pyrimidine-2,4-dione;

3-Benzyl-6-[3-(3-methoxy-phenyl)-prop-1-ynyl]-1-methyl-1H-thieno[2,3-*d*]pyrimidine-2,4-dione;

10 3-Benzyl-1-methyl-6-(3-pyridin-4-yl-prop-1-ynyl)-1H-thieno[2,3-*d*]pyrimidine-2,4-dione;

3-Benzyl-1-methyl-6-(3-pyridin-3-yl-prop-1-ynyl)-1H-thieno[2,3-*d*]pyrimidine-2,4-dione;

3-Benzyl-6-[3-(4-fluoro-phenyl)-prop-1-ynyl]-1-methyl-1H-thieno[2,3-*d*]pyrimidine-2,4-dione;

15 3-Benzyl-6-[3-(3-fluoro-phenyl)-prop-1-ynyl]-1-methyl-1H-thieno[2,3-*d*]pyrimidine-2,4-dione;

3-Benzyl-6-[3-(4-chloro-phenyl)-prop-1-ynyl]-1-methyl-1H-thieno[2,3-*d*]pyrimidine-2,4-dione;

20 3-Benzyl-6-[3-(3-chloro-phenyl)-prop-1-ynyl]-1-methyl-1H-thieno[2,3-*d*]pyrimidine-2,4-dione;

3-Benzyl-6-[3-(4-bromo-phenyl)-prop-1-ynyl]-1-methyl-1H-thieno[2,3-*d*]pyrimidine-2,4-dione;

3-Benzyl-6-[3-(3-bromo-phenyl)-prop-1-ynyl]-1-methyl-1H-thieno[2,3-*d*]pyrimidine-2,4-dione;

25 3-Benzyl-6-[3-(2-methoxy-pyridin-4-yl)-prop-1-ynyl]-1-methyl-1H-thieno[2,3-*d*]pyrimidine-2,4-dione;

3-Benzyl-1-methyl-6-[3-(4-methylsulfanyl-phenyl)-prop-1-ynyl]-1H-thieno[2,3-*d*]pyrimidine-2,4-dione;

30 3-Benzyl-1-methyl-6-[3-(3-methylsulfanyl-phenyl)-prop-1-ynyl]-1H-thieno[2,3-*d*]pyrimidine-2,4-dione;

3-Benzyl-1-methyl-6-(3-*p*-tolyl-prop-1-ynyl)-1H-thieno[2,3-*d*]pyrimidine-2,4-dione;

-225-

3-Benzyl-1-methyl-6-(3-*m*-tolyl-prop-1-ynyl)-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

3-(3-Fluoro-benzyl)-6-[3-(4-methoxy-phenyl)-prop-1-ynyl]-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

5 3-(3-Fluoro-benzyl)-6-[3-(3-methoxy-phenyl)-prop-1-ynyl]-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

3-(3-Fluoro-benzyl)-1-methyl-6-(3-pyridine-4-yl-prop-1-ynyl)-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

10 3-(3-Fluoro-benzyl)-1-methyl-6-(3-pyridine-3-yl-prop-1-ynyl)-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

3-(3-Fluoro-benzyl)-6-[3-(4-fluoro-phenyl)-prop-1-ynyl]-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

3-(3-Fluoro-benzyl)-6-[3-(3-fluoro-phenyl)-prop-1-ynyl]-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

15 6-[3-(4-Chloro-phenyl)-prop-1-ynyl]-3-(3-fluoro-benzyl)-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

6-[3-(3-Chloro-phenyl)-prop-1-ynyl]-3-(3-fluoro-benzyl)-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

20 6-[3-(4-Bromo-phenyl)-prop-1-ynyl]-3-(3-fluoro-benzyl)-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

6-[3-(3-Bromo-phenyl)-prop-1-ynyl]-3-(3-fluoro-benzyl)-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

3-(3-Fluoro-benzyl)-6-[3-(2-methoxy-pyridin-4-yl)-prop-1-ynyl]-1-methyl-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

25 3-(3-Fluoro-benzyl)-1-methyl-6-[3-(4-methylsulfanyl-phenyl)-prop-1-ynyl]-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

3-(3-Fluoro-benzyl)-1-methyl-6-[3-(3-methylsulfanyl-phenyl)-prop-1-ynyl]-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione;

30 3-(3-Fluoro-benzyl)-1-methyl-6-(3-*p*-tolyl-prop-1-ynyl)-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione; and

3-(3-Fluoro-benzyl)-1-methyl-6-(3-*m*-tolyl-prop-1-ynyl)-1*H*-thieno[2,3-*d*]pyrimidine-2,4-dione; or

The compound according to Claim 1, selected from:

-226-

- 3-(3-Methoxycarbonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 3-(3-Methoxycarbonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 5 3-Benzofuran-5-ylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 1-Methyl-3-(4-methyl-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 3-(4-Acetylamino-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 10 1-Methyl-2,4-dioxo-3-(4-vinyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 1-Methyl-2,4-dioxo-3-(4-sulfamoyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 15 3-(4-Bromo-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid pyridin-4-ylmethyl ester;
- 1-Methyl-2,4-dioxo-3-phenethyl-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 1-Methyl-2,4-dioxo-3-[4-(2H-tetrazol-5-yl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 20 3-(4-Fluoro-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid pyridin-4-ylmethyl ester;
- 3-(4-*tert*-Butyloxycarbonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 25 3-(4-*tert*-Butyloxycarbonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid;
- 4-[6-(4-Fluoro-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-benzoic acid;
- 4-[6-(4-Dimethylamino-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-benzoic acid, compound with trifluoro-acetic acid;
- 30 4-[6-(2-Ethoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-3-ylmethyl]-benzoic acid;

-227-

1-Methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid;

1-Methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

5 1-Methyl-2,4-dioxo-3-[4-(1H-tetrazol-5-yl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

10 1-Methyl-3-[4-(morpholine-4-sulfonyl)-benzyl]-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

1-Methyl-3-[4-(morpholine-4-carbonyl)-benzyl]-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

15 3-But-2-ynyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

1-Methyl-2,4-dioxo-3-[3-(1H-tetrazol-5-yl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

20 3-(4-Cyano-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

{4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-phenyl}-acetic acid;

25 3-[2-(2,4-Dichloro-benzenesulfonyl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

3-(4-Methanesulfonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

30 1-Methyl-2,4-dioxo-3-(4-sulfamoyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;



-228-

1-Methyl-3-(4-methylsulfamoyl-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxybenzylamide;

5 3-(4-Isopropylsulfamoyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxybenzylamide;

1-Methyl-2,4-dioxo-3-[4-(pyrrolidine-1-sulfonyl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxybenzylamide; and

10 1-Methyl-3-[4-(4-methyl-piperidine-1-sulfonyl)-benzyl]-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxybenzylamide; or

The compound according to Claim 1, selected from:

15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzofuran-2-ylmethyl ester;

3-(4-Bromo-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid pyridin-4-ylmethyl ester;

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-methoxy-benzyl ester;

20 4-{1-Methyl-2,4-dioxo-6-[(pyridin-4-ylmethyl)-carbamoyl]-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl}-benzoic acid, compound with trifluoro-acetic acid;

4-[6-(4-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-benzoic acid;

25 4-[6-(3,4-Dimethoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-benzoic acid *tert*-butyl ester;

4-[6-(3,4-Dimethoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-benzoic acid;

30 4-[6-(4-Bromo-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-benzoic acid;

4-[6-(4-Bromo-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-*d*]pyrimidin-3-ylmethyl]-benzoic acid *tert*-butyl ester;

-229-

- 4-[6-(3,5-Bis-trifluoromethyl-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid;
- 4-[6-(4-Chloro-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid;
- 5 4-[1-Methyl-2,4-dioxo-6-(4-sulfamoyl-benzylcarbamoyl)-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid;
- 3-(4-Fluoro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;
- 3-(4-Iodo-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 10 3-(4-Dimethylsulfamoyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;
- 3-(3-Methoxy-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;
- 15 3-(4-Cyano-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;
- 3-(4-Acetylamino-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 20 5-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-furan-2-carboxylic acid ethyl ester;
- 3-(4-Cyano-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzyl ester;
- 25 1-Methyl-2,4-dioxo-3-[4-(5-thioxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;
- 4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid
- 30 2-dimethylamino-ethyl ester;
- 3-Cyclohexylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

-230-

3-Cyclohexylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid furan-3-ylmethyl ester;

5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid pentafluorophenylmethyl ester;

3-Benzyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

10 3-Benzyl-1-cyclopropylmethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (pyridin-4-ylmethyl)-amide

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-bromo-benzyl ester;

15 4-[6-(3-Difluoromethoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid;

4-[6-(3-Difluoromethoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid tert-butyl ester;

20 4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid;

4-[6-(4-Methanesulfonyl-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid tert-butyl ester;

25 4-[6-(4-Methanesulfonyl-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid;

4-[1-Methyl-2,4-dioxo-6-(2-pyridin-4-yl-ethylcarbamoyl)-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid;

30 1-Methyl-2,4-dioxo-3-(4-trifluoromethoxy-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide

4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid methyl ester;

-231-

3-(2,3-Dihydro-benzofuran-6-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxybenzylamide

5 1-Methyl-3-(2-methyl-thiazol-5-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxybenzylamide

1-Methyl-2,4-dioxo-3-[4-(1H-tetrazol-5-yl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-fluorobenzylamide;

10 3-Benzyl-2-methoxy-4-oxo-3,4-dihydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid 2,2-dimethyl-propionyloxymethyl ester;

15 4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-cyclohexanecarboxylic acid;

20 4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-cyclohexanecarboxylic acid methyl ester;

1-{4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-phenyl}-cyclopropanecarboxylic acid methyl ester;

25 1-{4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-phenyl}-cyclopropanecarboxylic acid *tert*-butyl ester;

1-{4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-phenyl}-cyclopropanecarboxylic acid;

30 2-{4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-phenoxy}-2-methylpropionic acid *tert*-butyl ester;

-232-

2-{4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-phenoxy}-2-methyl-propionic acid;

5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-furo[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-(3-Methoxy-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-Biphenyl-4-ylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-(4-Methanesulfonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

15 3-(4-Methanesulfonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-3-(4-methyl-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-phenethyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

20 3-(4-Amino-6-phenylamino-1,3,5-triazin-2-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-(4-trifluoromethyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

25 3-(6-Cyano-hexyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-[2-(2,5-Dimethoxy-phenyl)-2-oxo-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

30 3-(3-Iodo-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-(3-trifluoromethyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

-233-

3-(2,4-Bis-trifluoromethyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-[2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-[2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-(2-Carboxy-allyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-(2-Carboxy-allyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-(3-Amino-propyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-(1,3-Dioxo-1,3-dihydro-isoindol-2-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-(4-Fluoro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-3-oxiranylmethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-3-((S)-2-methyl-butyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-(4-phenoxy-butyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-(2-Cyano-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-(3-phenoxy-propyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-Hex-5-enyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-pyridin-3-ylmethyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

-234-

- 3-[2-Hydroxy-3-(naphthalen-1-yloxy)-propyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;
- 1,3-Dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;
- 5 3-Cyclobutylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;
- 3-Allyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;
- 10 1-Methyl-2,4-dioxo-3-prop-2-ynyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;
- 3-But-2-ynyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;
- 1-Methyl-2,4-dioxo-3-(2-phenoxy-ethyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;
- 15 1-Methyl-2,4-dioxo-3-(2-phenoxy-ethyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;
- 3-((R)-3-Hydroxy-2-methyl-propyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;
- 3-Isobutyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;
- 20 3-(6-Chloro-pyridin-3-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;
- 3-(2-Benzenesulfonylmethyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;
- 25 1-Methyl-3-naphthalen-1-ylmethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;
- 1-Methyl-2,4-dioxo-3-(2-trifluoromethyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;
- 3-(3-Chloro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;
- 30 3-(4-Methoxycarbonyl-butyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;



-235-

- 3-Ethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-fluoro-benzyl ester;
- 5 3-[2-(4-Chloro-benzenesulfonyl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;
- 3-(2-Acetoxy-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;
- 10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-phenoxy-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzylamide;
- 15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2,6-dichloro-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid butyl ester;
- 20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2,3-dihydro-1,4-benzodioxin-2-ylmethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-diethylamino-1-methyl-ethyl ester;
- 25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-fluoro-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-isopropyl-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-*p*-tolyl-ethyl ester;
- 30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-trifluoromethyl-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid cyclobutylmethyl ester;



-236-

- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2,6-difluoro-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-(2-hydroxy-phenyl)-ethyl ester;
- 5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-(2-hydroxy-phenyl)-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 1-methyl-piperidin-4-yl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 1-methyl-piperidin-4-yl ester;
- 10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid pyridin-3-ylmethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-pyridin-3-yl-propyl ester;
- 15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-dimethylamino-1-methyl-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid tetrahydro-pyran-4-yl ester;
- 20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2,2,2-trifluoro-1-trifluoromethyl-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-trifluoromethyl-benzyl ester;
- 25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-benzyloxy-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2,2,2-trichloro-ethyl ester;
- 30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid phenethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-ethyl-oxetan-3-ylmethyl ester;

-237-

- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-morpholin-4-yl-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-pyrrolidin-1-yl-ethyl ester;
- 5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-pyrrolidin-1-yl-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-(2-ethoxy-ethoxy)-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid tetrahydro-pyran-2-ylmethyl ester;
- 10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-nitro-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid pentyl ester;
- 15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-phenyl-propyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-phenoxy-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3,5-dimethoxy-benzyl ester;
- 20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methyl-butyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-chloro-benzyl ester;
- 25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 1-ethyl-piperidin-3-yl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-benzyloxy-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid isobutyl ester;
- 30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-(4-methoxy-phenyl)-propyl ester;

-238-

- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-chloro-6-fluoro-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (S)-(tetrahydro-furan-3-yl) ester;
- 5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-pyridin-2-yl-propyl ester;
- 10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-piperidin-2-yl-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 5-bromo-2-methoxy-benzyl ester;
- 15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid cycloheptylmethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 1,2,3,4-tetrahydro-naphthalen-1-yl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (S)-1-pyrrolidin-2-ylmethyl ester;
- 20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-chloro-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 1,3-benzodioxol-5-ylmethyl ester;
- 25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methylsulfanyl-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methylsulfanyl-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3,4-dichloro-benzyl ester;
- 30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3,3-diphenyl-propyl ester;

-239-

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-pyridin-2-yl-ethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid furan-3-ylmethyl ester;

5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid but-3-enyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-cyano-ethyl ester;

10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-ethoxy-ethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid cyano-phenyl-methyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-trifluoromethyl-benzylamide;

15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methyl-benzylamide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid phenethyl-amide;

20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid cyclopropylamide;

1-Methyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

1-Methyl-2,4-dioxo-3-(4-sulfamoyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

25 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

1-Methyl-2,4-dioxo-3-(3-oxo-3-phenyl-propyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

30 3-[4-(N-Hydroxycarbamimidoyl)-benzyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

-240-

1-Methyl-2,4-dioxo-3-[4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

1-Methyl-2,4-dioxo-3-[4-(5-thioxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

4-(5-Isopropyl-2H-pyrazol-3-yl)-pyridine;

3-Cyanomethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

(E)-4-[6-(4-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-yl]-but-2-enoic acid methyl ester;

(E)-4-[6-(4-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-yl]-but-2-enoic acid;

3-(2-Benzenesulfonyl-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

2-Methoxy-4-[6-(4-methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid methyl ester;

3-(2-Methoxymethyl-1,1,3-trioxo-2,3-dihydro-1H-1,2-benzisothiazol-6-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

1-Methyl-3-oct-2-ynyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

3-[2-(4-Chloro-benzenesulfonylamino)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

3-[2-(4-Bromo-phenoxy)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

-241-

3-[2-(4-Bromo-phenoxy)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

5 3-[2-(4-Fluoro-phenoxy)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

3-[2-(4-Chloro-benzenesulfonyl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

10 3-[2-(4-Fluoro-phenoxy)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

1-Methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;

15 3-Cyclohexylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

4-[6-(4-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-2-methyl-benzoic acid methyl ester;

20 4-[6-(4-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid methyl ester;

2-Methoxy-4-[6-(3-methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-benzoic acid methyl ester;

25 4-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-2-methyl-benzoic acid methyl ester;

1-Methyl-2,4-dioxo-3-(3-oxo-3-phenyl-propyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

30 3-[2-(4-Chloro-phenoxy)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

-242-

1-Methyl-2,4-dioxo-3-[2-(3-trifluoromethyl-benzenesulfonyl)-ethyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

5 1-Methyl-2,4-dioxo-3-[2-(3-trifluoromethyl-benzenesulfonyl)-ethyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

3-[2-(4-Chloro-benzenesulfonyl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide; and

10 3-(2-Amino-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide; or

The compound according to Claim 1, selected from:

1-Methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid;

15 4-(6-Carbamoyl-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl)-2-methyl-benzoic acid;

4-(6-Carbamoyl-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl)-2-methyl-benzoic acid methyl ester;

20 4-[6-(3-Hydroxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-2-methyl-benzoic acid;

4-(6-Carbamoyl-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl)-2-hydroxy-benzoic acid;

3-(2-Amino-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide; and

25 4-(2,5-Di-pyridin-4-yl-thiophen-3-yl)-benzaldehyde; or

The compound according to Claim 1, selected from:

1-Methyl-2,4-dioxo-3-(1-phenyl-ethyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

30 1-Methyl-2,4-dioxo-3-(3-oxo-3-phenyl-propyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

3-((S)-3,7-Dimethyl-oct-6-enyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;



-243-

- 3-(2-Ethyl-hexyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;
- 3-(5-Cyano-pentyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;
- 5 3-(E)-But-2-enyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;
- 1-Methyl-3-(2-naphthalen-1-yl-ethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;
- 1-Methyl-2,4-dioxo-3-(E)-pent-2-enyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;
- 10 1-Methyl-2,4-dioxo-3-(2-phenylsulfanyl-ethyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;
- 3-sec-Butyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;
- 15 1-Methyl-3-(2-methyl-allyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;
- 3-(1-Ethyl-propyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;
- 1-Methyl-2,4-dioxo-3-pent-2-ynyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;
- 20 3-(2-Benzenesulfonyl-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;
- 1-Methyl-3-(3-methyl-but-2-enyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;
- 25 3-[2-(4-Fluoro-benzenesulfonyl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;
- 1-Methyl-2,4-dioxo-3-[2-(toluene-4-sulfonyl)-ethyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;
- 30



-244-

3-[3-(4-Fluoro-phenyl)-3-oxo-propyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

5 3-[3-(4-Chloro-phenyl)-3-oxo-propyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

3-(2-Benzoylamino-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

10 3-[2-(4-Bromo-phenoxy)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

3-Benzofurazan-5-ylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

15 1-Methyl-2,4-dioxo-3-(2-phenoxy-ethyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

{5-[6-(4-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-isoxazol-3-yl}-carbamic acid methyl ester;

20 3-Benzyloxycarbonylamino-5-[6-(4-methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-yl]-4-oxo-pentanoic acid *tert*-butyl ester;

3-[2-(4-Chloro-phenylsulfanyl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

25 1-Methyl-2,4-dioxo-3-(1-phenyl-ethyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

1-Methyl-2,4-dioxo-3-(E)-pent-2-enyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

30 3-(2-Ethyl-hexyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

1-Methyl-2,4-dioxo-3-(2-phenylmethanesulfonyl-ethyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

-245-

- 3-(5-Cyano-pentyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 3-(E)-But-2-enyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 5 1-Methyl-3-(2-naphthalen-1-yl-ethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 1-Methyl-2,4-dioxo-3-(E)-pent-2-enyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 10 1-Methyl-2,4-dioxo-3-(2-phenylsulfanyl-ethyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 3-sec-Butyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 1-Methyl-3-(2-methyl-allyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 15 3-(1-Ethyl-propyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 1-Methyl-2,4-dioxo-3-pent-2-ynyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 1-Methyl-3-(3-methyl-but-2-enyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 20 1-Methyl-2,4-dioxo-3-[2-(toluene-4-sulfonyl)-ethyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 3-(2-Benzoylamino-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 25 3-[2-(4-Bromo-phenoxy)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 3-Benzofurazan-5-ylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 30 1-Methyl-2,4-dioxo-3-(2-phenoxy-ethyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

-246-

{5-[6-(3-Methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-ylmethyl]-isoxazol-3-yl}-carbamic acid methyl ester; and

5 3-Benzylloxycarbonylamino-5-[6-(3-methoxy-benzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-thieno[2,3-d]pyrimidin-3-yl]-4-oxo-pentanoic acid *tert*-butyl ester; or

The compound according to Claim 1, selected from:

- 10 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 3-(4-Pyridyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 15 3-(4-Pyridyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (4-pyridyl) ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (4-pyridyl) ester;
- 20 3-(4-Pyridyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (4-pyridyl) ester;
- 3-(4-Pyridyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (4-pyridyl) ester;
- 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid piperoyl ester;
- 25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid piperoyl ester;
- 3-Piperoyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid piperoyl ester;
- 30 3-Piperoyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid piperoyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-furo[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

-247-

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-1*H*-pyrrolo[2,3-*d*]-pyrimidine-6-carboxylic acid benzyl ester;

3-Benzyl-1,7-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-1*H*-pyrrolo[2,3-*d*]-pyrimidine-6-carboxylic acid benzyl ester;

5 3-Benzyl-1,7-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-1*H*-pyrrolo[2,3-*d*]-pyrimidine-6-carboxylic acid benzofuran-6-ylmethyl ester;

3-Benzyl-1-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-1*H*-pyrrolo[2,3-*d*]-pyrimidine-6-carboxylic acid benzofuran-6-ylmethyl ester;

10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-furo[2,3-*d*]pyrimidine-6-carboxylic acid benzofuran-6-ylmethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzofuran-6-ylmethyl ester;

15 3-Benzyl-1,7-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-1*H*-pyrrolo[2,3-*d*]-pyrimidine-6-carboxylic acid benzothiophene-6-ylmethyl ester;

3-Benzyl-1-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-1*H*-pyrrolo[2,3-*d*]-pyrimidine-6-carboxylic acid benzothiophene-6-ylmethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-furo[2,3-*d*]pyrimidine-6-carboxylic acid benzothiophene-6-ylmethyl ester; and

20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzothiophene-6-ylmethyl ester; or

a compound according to Claim 1, or a pharmaceutically acceptable salt thereof, selected from:

25 3-(3-Methoxy-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(4-Chloro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(4-Cyano-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

30 3-(4-Fluoro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(3-Chloro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

-248-

1-Methyl-3-(2-methyl-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-3-(4-methyl-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

5 3-(4-Carboxy-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-(3-trifluoromethyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

10 3-Biphenyl-4-ylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-(2-trifluoromethyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(3-Cyano-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

15 3-(2-Cyano-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-(4-trifluoromethyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

20 3-[2-Hydroxy-3-(naphthalen-1-yloxy)-propyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(3-Chloro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-3-naphthalen-1-ylmethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

25 3-(6-Chloro-benzo[1,3]dioxol-5-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-(4-oxo-4-thiophen-2-yl-butyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

30 1-Methyl-2,4-dioxo-3-pyridin-4-ylmethyl-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-(4-*m*-tolylloxy-butyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

-249-

3-(3,5-Dimethyl-isoxazol-4-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-Dioxo-1,3-dihydro-isoindol-2-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

5 3-Dihydro-benzo[1,4]dioxin-2-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-pyridin-2-ylmethyl-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

10 3-[2-(2,5-Dimethoxy-phenyl)-2-oxo-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-Benzylloxymethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-(4-*m*-tolylloxy-butyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

15 1-Methyl-2,4-dioxo-3-(2-phenylmethanesulfonyl-ethyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(4-Amino-6-phenylamino-[1,3,5]triazin-2-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

20 3-[4-(4-Fluoro-phenyl)-4-oxo-butyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-[4-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-butyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

25 1-Methyl-2,4-dioxo-3-(4-phenoxy-butyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-(4-oxo-4-phenyl-butyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

30 1-Methyl-2,4-dioxo-3-(2-phenoxy-ethyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-{3-[4-(3-Chloro-phenyl)-piperazin-1-yl]-propyl}-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;



-250-

3-[1-Bromo-2-(1H-indol-3-yl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(2-Benzenesulfinyl-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

5 3-[3-(3-Fluoro-phenylcarbamoyl)-propyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-[2-(2-trifluoromethyl-phenylcarbamoyl)-ethyl]-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

10 3-[2-(4-Methoxy-phenyl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-[2-(4-Chloro-2-nitro-phenoxy)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

15 1-Methyl-3-(5-nitro-furan-2-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(1-Benzyl-1*H*-imidazol-2-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-[3-(Benzyl-methyl-amino)-propyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

20 3-(Bis-trifluoromethyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-[3-(2-Bromo-4-methyl-phenoxy)-propyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

25 3-Benzenesulfonylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-[2-(4-Chloro-benzenesulfonyl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-Benzo[1,3]dioxol-5-ylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

30 3-(3-Iodo-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-(4-trifluoromethoxy-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

-251-

3-(4-Acetoxy-butyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(4-Methanesulfonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

5 1-Methyl-2,4-dioxo-3-(4-[1,2,3]thiadiazol-4-yl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(5-Methoxycarbonyl-furan-2-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

10 3-(2-Carboxy-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-(3-pyrrol-1-yl-propyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(3-Carboxy-propyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

15 3-(2-Cyano-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(3-Ethoxycarbonyl-furan-2-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

20 3-(3-Amino-propyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(3-Cyano-propyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(2-Hydroxy-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

25 3-(2-Carboxy-hexyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-(2,2,2-trifluoro-ethyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

30 1-Methyl-2,4-dioxo-3-(2,2,2-trifluoro-ethyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxyl carboxylic acid benzyl ester;

Iodomethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;



-252-

3-(2-Fluoro-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

Methyl-2,4-dioxo-3-(tetrahydro-furan-2-ylmethyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

5 3-[1-(4-Carboxy-phenyl-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(Hex-5-enyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

10 3-(2-Ethyl-butyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-(2,2,2-trifluoro-ethyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxyl pyrimidine acid benzyl ester;

3-(Diethoxy-phosphorylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

15 3-But-2-ynyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

Bromo-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid;

20 1-Methyl-2,4-dioxo-3-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-propyl-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(2-Acetoxy-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid;

25 3-Butyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-Isobutyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

30 3-Ethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(3-Bromo-propyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

-253-

3-Cyclohexylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(2-Ethylamino-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

5 3-Cyclobutylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-((*R*)-3-Hydroxy-2-methyl-propyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

10 3-(4-Hydroxy-butyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(2-Ethoxy-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-Isobutyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

15 3-(2-Chloro-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-3-(3-methyl-but-2-enyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

20 3-Allyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(2,2-Dimethoxy-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-3-oxiranylmethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

25 1-Methyl-2,4-dioxo-3-propyl-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-Benzo[1,2,5]oxadiazol-5-ylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

30 3-(3-Hydroxy-2,2-dimethyl-propyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(2-Carboxy-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

-254-

3-Propyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic benzyl ester;

1-Methyl-2,4-dioxo-3-(4-sulfamoyl-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

5 1-Methyl-3-(4-methylsulfamoyl-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(4-Dimethylsulfamoyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

10 3-(4-Methanesulfonylamino-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-[4-(Methanesulfonyl-methyl-amino)-benzyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

15 3-(4-Acetylamino-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-[4-(Acetyl-methyl-amino)-benzyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(4-Dimethylamino-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

20 1-Methyl-3-(4-methylamino-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(4-Carbamoyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

25 3-(4-Dimethylcarbamoyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(4-Carboxy-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(4-Methoxycarbonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

30 3-{4-[Bis-(2-hydroxy-ethyl)-amino]-benzyl}-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(3,5-Dimethoxy-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

-255-

3-(4-*tert*-Butyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

1-Methyl-2,4-dioxo-3-(4-trifluoromethoxy-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

5 3-(4-Methanesulfonyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

2,4-Dioxo-3-[1,3,4]thiadiazol-2-ylmethyl-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

10 3-Isoxazol-3-ylmethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-Oxazol-2-ylmethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

2,4-Dioxo-3-thiazol-2-ylmethyl-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

15 3-(1*H*-Imidazol-2-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(1-Methyl-1*H*-imidazol-2-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

20 3-(1-Methyl-1*H*-pyrrol-2-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

2,4-Dioxo-3-(1*H*-pyrrol-2-ylmethyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

2,4-Dioxo-3-(1*H*-pyrrol-2-ylmethyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

25 2,4-Dioxo-3-thiophen-2-ylmethyl-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

2,4-Dioxo-3-[1,2,3,4]tetrazin-5-ylmethyl-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

30 2,4-Dioxo-3-[1,2,4,5]tetrazin-3-ylmethyl-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(1-Methyl-piperidin-4-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

-256-

2,4-Dioxo-3-pyrimidin-2-ylmethyl-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

2,4-Dioxo-3-(2*H*-pyran-2-ylmethyl)-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

5 3-(1*H*-Imidazo[4,5-*b*]pyridin-2-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(1*H*-Benzoimidazol-2-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

10 3-Benzo[*b*]thiophen-2-ylmethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

2,4-Dioxo-3-quinolin-2-ylmethyl-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(2*H*-Chromen-2-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

15 3-(1*H*-Benzoimidazol-2-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-(1-Methyl-1*H*-benzoimidazol-2-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

20 3-(1*H*-Indol-2-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid furan-3-ylmethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1-ethyl-propyl ester;

25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1,1-dioxo-tetrahydro-1<sup>6</sup>-thiophen-3-yl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-hydroxy-benzyl ester;

30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1-oxy-pyridin-4-ylmethyl ester;

-257-

- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid but-3-enyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-diethylamino-propyl ester;
- 5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1-cyano-1-phenyl-methyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-amino-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzyl ester;
- 10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1-oxy-pyridin-3-ylmethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-ethoxy-ethyl ester;
- 15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid thiophen-2-ylmethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2,6-dichloro-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid dimethylamino-methyl-ethyl ester;
- 20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2,2-diphenyl-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-pyridin-2-yl-ethyl ester;
- 25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-ethanesulfonyl-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid diethylamino-methyl-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid dimethylamino-methyl-propyl ester;
- 30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-(2-chloro-phenoxy)-ethyl ester;

-258-

- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-(2-ethoxy-ethoxy)-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-hydroxy-benzyl ester;
- 5 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-morpholin-4-yl-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-ethyl ester;
- 10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1-methyl-piperidin-4-yl ester;
- 15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-(4-hydroxy-phenyl)-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-cyano-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid hexyl ester;
- 20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-fluoro-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-hydroxy-6-methyl-pyridin-2-ylmethyl ester;
- 25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-benzyloxy-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-methoxy-benzyl ester;
- 30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-methoxy-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2,2,2-trifluoro-ethyl ester;



- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2,2,2-trichloro-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid pyridin-3-ylmethyl ester;
- 5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid pyridin-4-ylmethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-pyridin-3-yl-propyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid;
- 10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-phenoxy-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1,3-dimethyl-butyl ester;
- 15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-methyl-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1-phenyl-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1-benzyl-piperidin-4-yl ester;
- 20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid propyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid methyl ester;
- 25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-trifluoromethyl-benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-*p*-tolyl-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-trifluoromethyl-benzyl ester;
- 30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid tetrahydro-furan-2-ylmethyl ester;



-260-

- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid octahydro-inden-5-yl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-amino-benzyl ester;
- 5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-aziridin-1-yl-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methyl-but-2-enyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;
- 10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid trifluoro-trifluoromethyl-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid phenethyl ester;
- 15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-methoxy-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid biphenyl-4-ylmethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-chloro-6-fluoro-benzyl ester;
- 20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid tetrahydro-pyran-4-yl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-ethyl-oxetan-3-ylmethyl ester;
- 25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid butyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-(2-hydroxy-phenyl)-ethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-(4-fluoro-phenyl)-ethyl ester;
- 30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid cyclopropylmethyl ester;

-261-

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-ethyl-benzyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (S)-1-phenyl-ethyl ester;

5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2,6-difluoro-benzyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid cyclobutyl methyl ester;

10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-pyridin-4-yl-ethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-hydroxy-cyclopentyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1-pentafluorophenyl-ethyl ester;

15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-benzyloxycarbonylamino-ethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid ethyl ester;

20 2-{[1-(3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidin-6-yl)-methanoyl]-amino}-3-phenyl-propionic acid methyl ester;

(3-{[1-(3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidin-6-yl)-methanoyl]-amino}-propyl)-carbamic acid *tert*-butyl ester;

25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzofuran-5-ylmethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzofuran-2-ylmethyl ester;

30 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid thiophen-3-ylmethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3H-[1,2,3]oxathiazol-5-ylmethyl ester;

-262-

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3*H*-[1,2,3]oxathiazol-5-ylmethyl ester;

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid [1,4,2]dioxazol-3-ylmethyl ester;

5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid [1,4,2]dioxazol-3-ylmethyl ester;

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid furazan-3-ylmethyl ester;

10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid furazan-3-ylmethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid [1,2,4]oxadiazol-5-ylmethyl ester;

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid [1,2,4]oxadiazol-5-ylmethyl ester;

15 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3*H*-[1,2,3]triazol-4-ylmethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3*H*-[1,2,3]triazol-4-ylmethyl ester;

20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2*H*-[1,2,4]triazol-3-ylmethyl ester;

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2*H*-[1,2,4]triazol-3-ylmethyl ester;

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid isoxazol-5-ylmethyl ester;

25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid isoxazol-5-ylmethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid oxazol-2-ylmethyl ester;

30 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid oxazol-2-ylmethyl ester;

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid isothiazol-5-ylmethyl ester;

-263-

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid isothiazol-5-ylmethyl ester;

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid thiazol-2-ylmethyl ester;

5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid thiazol-2-ylmethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1*H*-imidazol-2-ylmethyl ester;

10 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2*H*-imidazol-2-ylmethyl ester;

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1*H*-pyrazol-3-ylmethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2*H*-pyrazol-3-ylmethyl ester;

15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1*H*-pyrrol-2-ylmethyl ester;

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2*H*-pyrrol-2-ylmethyl ester;

20 3-Furazan-3-ylmethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2*H*-chromen-2-ylmethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2*H*-thiochromen-2-ylmethyl ester;

25 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2*H*-thiochromen-2-ylmethyl ester;

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid [1,3,4]thiadiazol-2-ylmethyl ester;

30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid [1,3,4]thiadiazol-2-ylmethyl ester;

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1*H*-benzoimidazol-5-ylmethyl ester;

-264-

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1*H*-benzoimidazol-5-ylmethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1*H*-benzoimidazol-2-ylmethyl ester;

5 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1*H*-benzoimidazol-2-ylmethyl ester;

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1*H*-indol-2-ylmethyl ester;

10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1*H*-indol-2-ylmethyl ester;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1*H*-indol-5-ylmethyl ester;

3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 1*H*-indol-5-ylmethyl ester;

15 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2,3-dihydro-benzofuran-5-ylmethyl ester; and

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2,3-dihydro-benzofuran-5-ylmethyl ester;

or

20 The compound according to Claim 1, selected from:

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (2-pyridin-4-yl-ethyl)-amide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (2-morpholin-4-yl-ethyl)-amide;

25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-methyl-benzylamide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid *sec*-butylamide;

30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid cyclopentylamide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid cyclopropylamide;

-265-

- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid cyanomethyl-amide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid cyclohexylamide;
- 5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methyl-benzylamide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (3-ethoxy-propyl)-amide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-chloro-benzylamide;
- 10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-methyl-benzylamide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (2,2-diphenyl-ethyl)-amide;
- 15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (pyridin-3-ylmethyl)-amide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid cyclopropylmethyl-amide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (1-ethyl-pyrrolidin-2-ylmethyl)-amide;
- 20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (pyridin-2-ylmethyl)-amide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid [2-(3,4-dimethoxy-phenyl)-ethyl]-amide;
- 25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (furan-2-ylmethyl)-amide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-fluoro-benzylamide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (2-bromo-ethyl)-amide;
- 30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-sulfamoyl-benzylamide;



-266-

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid phenethyl-amide;

(S)-2-{[1-(3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidin-6-yl)-methanoyl]-amino}-propionic acid;

10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (1-phenyl-ethyl)-amide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 2-methoxy-benzylamide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid benzylamide;

15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 3-bromo-benzylamide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid [2-(4-sulfamoyl-phenyl)-ethyl]-amide;

20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid (3-imidazol-1-yl-propyl)-amide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid [2-(2-methoxy-phenyl)-ethyl]-amide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-trifluoromethyl-benzylamide;

25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid 4-amino-benzylamide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide; and

30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-*d*]pyrimidine-6-carboxylic acid ((R)-2-hydroxy-1-methyl-ethyl)-amide; or

a compound according to Claim 1, or a pharmaceutically acceptable salt thereof, selected from:

-267-

- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid methyl ester;
- 3-(4-Bromo-benzyl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;
- 5 3-(4-Fluoro-benzyl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid pyridin-4-ylmethyl ester;
- 10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzo[b]thiophen-2-ylmethyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 1-methyl-1H-indol-5-ylmethyl ester;
- 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid thiophen-3-ylmethyl ester;
- 15 3-1,3-Benzodioxol-5-ylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;
- 1-Methyl-2,4-dioxo-3-pyridin-4-ylmethyl-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;
- 3-(4-tert-Butyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;
- 20 3-(3,4-Dichloro-benzyl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;
- 1-Methyl-2,4-dioxo-3-(4-trifluoromethoxy-benzyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;
- 25 1-Methyl-3-naphthalen-2-ylmethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;
- 3-(4-Cyano-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzofuran-5-ylmethyl ester;
- 30 3-(3,5-Dimethoxy-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;



-268-

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

3-(3,5-Dinitro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester;

5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid; and

3-(4-Carboxy-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-ethoxy-benzyl ester; or

10 A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, selected from:

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid [2-(3,4-dimethoxy-phenyl)-ethyl]-amide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-amino-benzylamide;

15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (biphenyl-2-ylmethyl)-amide;

20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3,4-dimethoxy-benzylamide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (2-pyridin-4-yl-ethyl)-amide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-difluoromethoxy-benzylamide;

25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid [2-(3-ethoxy-phenyl)-ethyl]-amide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-chloro-4-fluoro-benzylamide;

30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2,4-dichloro-benzylamide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (2-phenyl-propyl)-amide;

-269-

- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3,4,5-trimethoxy-benzylamide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-chloro-benzylamide;
- 5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3,5-dimethoxy-benzylamide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2,3-dimethoxy-benzylamide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-trifluoromethyl-benzylamide;
- 10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-methoxy-benzylamide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-methyl-benzylamide;
- 15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (4-phenyl-butyl)-amide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (pyridin-3-ylmethyl)-amide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;
- 20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid ((S)-2,2-dimethyl-4-phenyl-1,3-dioxinan-5-yl)-amide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid [2-(3-methoxy-phenyl)-ethyl]-amide;
- 25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (thiophen-2-ylmethyl)-amide;
- 30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2-chloro-benzylamide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (5-methyl-furan-2-ylmethyl)-amide;

-270-

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (2,2-diphenyl-ethyl)-amide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid [2-(2-methoxy-phenyl)-ethyl]-amide;

5 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid [2-(3-trifluoromethyl-phenyl)-ethyl]-amide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-bromo-benzylamide;

10 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-amide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3,5-dichloro-benzylamide;

15 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid indan-1-ylamide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (furan-2-ylmethyl)-amide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid [2-(4-methoxy-phenyl)-ethyl]-amide;

20 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 2,4-dimethoxy-benzylamide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-chloro-benzylamide;

25 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (1-phenyl-ethyl)-amide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3,4-dichloro-benzylamide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-fluoro-3-trifluoromethyl-benzylamide;

30 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (2-pyridin-2-yl-ethyl)-amide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid [2-(2,4-dimethyl-phenyl)-ethyl]-amide;

-271-

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid [2-(2,4-dichloro-phenyl)-ethyl]-amide;

1,3-Dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

5 3-Cyanomethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

10 3-(4-Cyclopropylsulfamoyl-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

1-Methyl-3-(6-nitro-pyridin-3-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

15 1-Methyl-3-(6-nitro-pyridin-3-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

20 1-Methyl-3-(6-nitro-pyridin-3-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;

3-Cyclohexylmethyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;

25 3-{2-[(1H-Benzimidazole-5-carbonyl)-amino]-ethyl}-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

1-Methyl-2,4-dioxo-3-[2-(3-piperidin-1-yl-propionylamino)-ethyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

30 1-Methyl-2,4-dioxo-3-{2-[(6-pyrazol-1-yl-pyridine-3-carbonyl)-amino]-ethyl}-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

-272-

3-[2-(4-Diethylamino-benzoylamino)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

5 3-{2-[(6-Chloro-pyridine-3-carbonyl)-amino]-ethyl}-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

1-Methyl-2,4-dioxo-3-{2-[(1H-pyrrole-2-carbonyl)-amino]-ethyl}-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

10 3-[2-(2-Dimethylamino-acetylamino)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

15 1-Methyl-2,4-dioxo-3-{2-[(pyrazine-2-carbonyl)-amino]-ethyl}-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

1-Methyl-3-[2-(2-methyl-2-methylamino-propionylamino)-ethyl]-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

20 1-Methyl-2,4-dioxo-3-{2-[(pyrrolidine-2-carbonyl)-amino]-ethyl}-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

1-Methyl-2,4-dioxo-3-{2-[3-(5-phenyl-1H-pyrrol-2-yl)-propionylamino]-ethyl}-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

25 1-Methyl-2,4-dioxo-3-{2-[2-(pyridin-4-ylsulfanyl)-acetylamino]-ethyl}-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

30 3-(6-Amino-pyridin-3-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide;

1-Methyl-2,4-dioxo-3-(3-phenyl-prop-2-ynyl)-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide;

-273-

3-(6-Amino-pyridin-3-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxybenzylamide;

3-(6-Amino-pyridin-3-ylmethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid (pyridin-4-ylmethyl)-amide;

1-Methyl-2,4-dioxo-3-[2-(pyridin-2-ylamino)-ethyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxybenzylamide;

1-Methyl-2,4-dioxo-3-[2-(pyrimidin-2-ylamino)-ethyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 4-methoxybenzylamide; and

1-Methyl-2,4-dioxo-3-[2-(pyrimidin-2-ylamino)-ethyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxybenzylamide.

8. A pharmaceutical composition, comprising a compound of Claim 1, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier, diluent, or excipient.
9. A pharmaceutical composition, comprising a compound of Claim 2, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier, diluent, or excipient.
10. Use of compound of Formula I, or a pharmaceutically acceptable salt thereof, in the manufacture of medicament for the treatment of a disease mediated by an MMP-13 enzyme.
11. Use of compound of Formula II, III, VI, VII, or XI, or a pharmaceutically acceptable salt thereof, in the manufacture of medicament for the treatment of a disease mediated by an MMP-13 enzyme.

-274-

12. Use of compound of Formula I, or a pharmaceutically acceptable salt thereof, in the manufacture of medicament for the treatment of cancer; or

Use of compound of Formula I, or a pharmaceutically acceptable salt thereof, in the manufacture of medicament for the treatment of rheumatoid arthritis; or

5

Use of compound of Formula I, or a pharmaceutically acceptable salt thereof, in the manufacture of medicament for the treatment of osteoarthritis.



## INTERNATIONAL SEARCH REPORT

national Application No

PCT/IB 02/00204

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D495/04 A61K31/505 A61P29/00 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 915 093 A (OTSUKA PHARMA CO LTD) 12 May 1999 (1999-05-12) the whole document	1-12
A	US 5 747 486 A (SOHDA TAKASHI ET AL) 5 May 1998 (1998-05-05) the whole document	1-12
	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

15 May 2002

Date of mailing of the international search report

23/05/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl  
Fax: (+31-70) 340-3016

Authorized officer

Fritz, M



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 02/00204

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>CHEN J M ET AL: "STRUCTURE-BASED DESIGN OF A NOVEL, POTENT, AND SELECTIVE INHIBITOR FOR MMP-13 UTILIZING NMR SPECTROSCOPY AND COMPUTER-AIDED MOLECULAR DESIGN"</p> <p>JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US, vol. 122, 2000, pages 9648-9654, XP001010185 ISSN: 0002-7863 cited in the application the whole document</p> <p>-----</p>	1-12

# INTERNATIONAL SEARCH REPORT

Information on patent family members

national Application No

PCT/IB 02/00204

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0915093	A	12-05-1999	AU 716633 B2 02-03-2000
			AU 2977897 A 05-01-1998
			EP 0915093 A1 12-05-1999
			US 6166016 A 26-12-2000
			CA 2257222 A1 11-12-1997
			CN 1221419 A ,B 30-06-1999
			WO 9746560 A1 11-12-1997
US 5747486	A	05-05-1998	AU 699354 B2 03-12-1998
			AU 3815895 A 31-05-1996
			CA 2202985 A1 17-05-1996
			EP 0791000 A1 27-08-1997
			FI 971974 A 18-06-1997
			HU 77348 A2 30-03-1998
			WO 9614319 A1 17-05-1996
			JP 8225577 A 03-09-1996
			NO 972043 A 25-06-1997
			NZ 294933 A 28-05-1999